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Abstract 
As explained in the Introduction, Pacific Islands Countries (PICs) have some of the 
highest rates of Non-Communicable Diseases (NCDs) in the world, and also face severe 
fiscal constraints. The original research contained in this thesis by compilation aims to 
address knowledge gaps, and help PIC governments respond to the emerging NCD crisis. 
Chapter 2 investigates the health financing options available to governments in five PICs. 
The share of government expenditure going to health in these countries is already some 
of the highest in the world. Most options available to middle-income countries globally 
to increase the fiscal space for health are unavailable, or inappropriate, to PICs. 
Improving allocative and technical efficiency in existing government health expenditure 
is the most feasible option left for PICs.  
Chapters 3 and 4 use two case studies to better understand the budgetary pressures 
that, given the above fiscal constraints, NCDs will increasingly impose in the Pacific and 
to raise fundamental questions about the cost-effectiveness and sustainability of health 
financing in the Pacific. Chapter 3, as well as re-considering the fiscal options of Chapter 
2 in the context of Samoa, finds that dialysis treatment per patient in Samoa is twelve 
times the GDP per capita, user fees cover just 1.6% of the program, and two-thirds of 
patients die within two years. Chapter 4 investigates the cost to government of 
purchasing drugs to prevent and treat diabetes and hypertension in Vanuatu. 
Government pharmaceutical costs rise in large, step-wise, patterns as diabetes or 
hypertension progressively becomes more severe. About 20% of the population in 
Vanuatu has three or more risk factors for acquiring diabetes, but only 1.3% of the total 
population could be treated with insulin before the total Government drug budget for 
the country was fully spent.  
Chapter 5 finds that, contrary to general perceptions, the population of the PICs is 
“ageing” (i.e. the share of the population aged 60 years + is increasing). Current health 
systems are poorly designed to respond to their health needs. Ageing, combined with 
the high birth rates in many PICs, is likely to worsen the “dependency ratio” in countries, 
putting further strain on government budgets. This is exacerbated for those PICs with 
high levels of out-migration. 
 ix 
With limited financing options (Chapter 2), prohibitively expensive treatment protocols 
(Chapters 3 and 4), and an ageing population (Chapter 5), a strong case for any 
budgetary interventions is needed. Chapter 6 identifies, based on a literature survey and 
stakeholder views, how Ministries of Health can improve their capacity to negotiate 
better health financing from Ministries of Finance, and development partners. It 
identifies ten attributes of effective budget requests. 
The academic contribution of the thesis is to help fill the research gap relating to the 
effectiveness and sustainability of NCD and other health care costs in the Pacific. The 
policy contribution is to provide the analysis underpinning the Pacific’s response to the 
NCD crisis. The “NCD Road Map”, which I drafted and which Pacific governments have 
now approved, is summarized in the Conclusion.  
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Glossary  
Allocative 
efficiency and 
technical 
efficiency in the 
health sector.  
Allocative efficiency seeks to drive a higher level of health outcomes by 
reallocating scarce resources to programs and strategies where they are 
likely to have the biggest (or most equitable) impact. Technical efficiency 
seeks to get the maximum possible given output — number of hip 
replacements for example — for a given mix of doctors, nurses, and 
equipment and other inputs. The difference between allocative efficiency 
and technical efficiency has also been described as allocative efficiency is 
“doing the right things” while technical efficiency is “doing things right”. 
See Liu (2003) 1 for further details. 
Catastrophic 
health 
expenditure 
The WHO World Health Statistics Report (2016) states that out of pocket 
expenditures on health “are judged to be catastrophic when they exceed 
a given proportion (25%) of the total household budget or of the capacity 
to pay (40%)”.2(p19) See also “impoverishing” expenditure. 
DALYs Homedes (1996) 3(p8) defines a Disability Adjusted Life Years (DALYs) 
can be defined as “the only quantitative indicator of burden of 
disease that reflects the total amount of healthy life lost, to all 
causes, whether from premature mortality or from some degree of 
disability during a period of time. These disabilities can be physical 
or mental. The intended use of the DALY is to assist (i) in setting 
health service priorities; (ii) in identifying disadvantaged groups 
and targeting of health interventions; and (iii) in providing a 
comparable measure of output for intervention, program and 
sector evaluation and planning.” 
Demographic 
dividend 
Lee and Mason (2006) 4(p1) explain a demographic dividend as follows: 
“Industrial countries have largely completed what is called the 
demographic transition”— the transition from a largely rural agrarian 
society with high fertility and mortality rates to a predominantly urban 
industrial society with low fertility and mortality rates. At an early stage 
of this transition, fertility rates fall, leading to fewer young mouths to 
feed. 
During this period, the labour force temporarily grows more rapidly than 
the population dependent on it, freeing up resources for investment in 
economic development and family welfare. Other things being equal, per 
capita income grows more rapidly too. That is the first demographic 
dividend.  
But a second dividend is also possible. A population concentrated at older 
working ages and facing an extended period of retirement has a powerful 
incentive to accumulate assets—unless it is confident that its needs will 
be provided for by families or governments. Whether these additional 
assets are invested domestically or abroad, national income rises. 
In short, the first dividend yields a transitory bonus, and the second 
transforms that bonus into greater assets and sustainable development. 
These outcomes are not automatic but depend on the implementation 
of effective policies.” 
Employment 
Population 
Ratio 
The Employment Population Ratio (EPR) is the number of people 
employed in cash work, divided by the corresponding total population 15 
years and older, multiplied by 100. 5 
Fiscal space  Fiscal space can be defined as “room in a government´s budget that 
allows it to provide resources for a desired purpose without jeopardizing 
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the sustainability of its financial position or the stability of the economy.” 
See P Heller (2005) 6. 
Health System The World Health Organization states “A good health system delivers 
quality services to all people, when and where they need them. The exact 
configuration of services varies from country to country, but in all cases 
requires a robust financing mechanism; a well-trained and adequately 
paid workforce; reliable information on which to base decisions and 
policies; well-maintained facilities and logistics to deliver quality 
medicines and technologies.” Further details at 
http://www.who.int/topics/health_systems/en/ 
High Income 
country  
The World Bank advises 7 for the current 2018 fiscal year high-income 
economies are those with a GNI per capita of $12,236 or more in 2016.  
International 
dollars 
International dollars are a hypothetical construct designed to adjust for 
differences in costs in individual countries, and market based exchange 
rate differences. The World Bank states “an international dollar would 
buy in the cited country a comparable amount of goods and services a 
U.S. dollar would buy in the United States”. Further details at 
https://datahelpdesk.worldbank.org/knowledgebase/articles/114944-
what-is-an-international-dollar 
Impoverishing 
health 
expenditure  
The WHO states 2(p19) out of pocket expenditure on health “are labelled 
impoverishing when OOP payments push a household’s other spending 
below a minimum socially recognized living standard such as that 
identified by a poverty line. The poverty line should be defined according 
to national standards and also against an international poverty line, 
consistent with Sustainable Development Goals”. 
Low income 
country  
The World Bank advises 7 for the current 2018 fiscal year, low-income 
economies are defined as those with a GNI per capita of $1,005 or less in 
2016.  
Lower middle-
income country  
The World Bank advises 7 that lower middle-income economies are those 
with a GNI per capita between $1,006 and $3,955 in 2016.  
Low and 
Middle-income 
countries  
The World Bank definition means that countries with a GNI per capita less 
than $12,235 in 2016 are in the low and middle-income category. 7 
Market failure The Economist Dictionary defines market failure as “When a market left 
to itself does not allocate resources efficiently. Economists have 
identified four main sorts or causes of market failure. The abuse of 
market power which can occur whenever a single buyer or seller can 
exert significant influence over prices or output …..; externalities - when 
the market does not take into account the impact of an economic activity 
on outsiders. For example, the market may ignore the costs imposed on 
outsiders by a firm polluting the environment; public goods  
 such as national defence. How much defence would be provided if it 
were left to the market? Where there is incomplete or asymmetric 
information or uncertainty.” For further details see 
https://www.economist.com/economics-a-to-z/m#node-21529422 
Millennium 
Development 
Goals  
The Millennium Development Goals (MDGs) involved eight global targets 
to reduce extreme poverty and improve social development by 2015 that 
were adopted by the United Nations in September 2000. Details available 
at http://www.un.org/millenniumgoals/ 
The MDGs have been replaced by the Sustainable Development Goals 
(SDGs): see elsewhere in glossary for details. 
 xix 
Non-
communicable 
diseases 
The World Health Organization states that “Noncommunicable diseases 
(NCDs), also known as chronic diseases, tend to be of long duration and 
are the result of a combination of genetic, physiological, environmental 
and behaviours factors. The main types of NCDs are cardiovascular 
diseases (like heart attacks and stroke), cancers, chronic respiratory 
diseases (such as chronic obstructive pulmonary disease and asthma) and 
diabetes.” 8 
It should be noted that there is debate in the international literature 
9about changing the term Non-communicable diseases to “socially 
transmitted conditions” to better reflect the broader social determinants 
of heart disease, diabetes, cancers, and lung disease.  
Obesity  WHO defines obesity and overweight as follows: “Overweight and obesity 
are defined as abnormal or excessive fat accumulation that may impair 
health. Body mass index (BMI) is a simple index of weight-for-height that 
is commonly used to classify overweight and obesity in adults. It is 
defined as a person's weight in kilograms divided by the square of his 
height in meters (kg/m2). For adults, WHO defines overweight and 
obesity as follows: 
overweight is a BMI greater than or equal to 25; and 
obesity is a BMI greater than or equal to 30. 
BMI provides the most useful population-level measure of overweight 
and obesity as it is the same for both sexes and for all ages of adults. 
However, it should be considered a rough guide because it may not 
correspond to the same degree of fatness in different individuals.  
For children, age needs to be considered when defining overweight and 
obesity”. 10 Details for children are available at the WHO website. 10  
Overweight See obesity 
Pacific Island 
Countries  
In this thesis I focus on the fourteen middle-income and / or small island 
countries of the Pacific Island Forum. They are, in alphabetical order: 
Cook Islands; Federated States of Micronesia (FSM); Fiji; Kiribati; Marshall 
Islands; Nauru; Niue; Palau; Papua New Guinea (PNG); Samoa; Solomon 
Islands; Tonga; Tuvalu; and Vanuatu. Tokelau is an observer member of 
the Pacific Islands Forum.  
PEN  Package of Essential NCD Interventions. The WHO defines PEN as “a 
conceptual framework for strengthening equity and efficiency of primary 
health care in low-resource settings; it identifies core technologies, 
medicines and risk prediction tools; discusses protocols required for 
implementation of a set of essential NCD interventions; develops 
technical and operational outline for integration of essential NCD 
interventions into primary care and for evaluation of impact.” Further 
details are available at 
http://www.who.int/cardiovascular_diseases/publications/pen2010/en/ 
Primary 
prevention 
Primary prevention “aims to prevent disease or injury before it ever 
occurs. This is done by preventing exposures to hazards that cause 
disease or injury, altering unhealthy or unsafe behaviours that can lead to 
disease or injury, and increasing resistance to disease or injury should 
exposure occur”. Further details available at 
https://www.iwh.on.ca/wrmb/primary-secondary-and-tertiary-
prevention 
 
See also Secondary prevention.  
Public health 
expenditure.  
The World Bank definition 11 of public health expenditure, and the 
definition used in this thesis is as follows: “Public health expenditure 
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consists of recurrent and capital spending from government (central and 
local) budgets, external borrowings and grants (including donations from 
international agencies and nongovernmental organizations), and social 
(or compulsory) health insurance funds.”  
Purchasing 
Power Parity 
PPP stands for purchasing power parity. The formal definition according 
to the IMF is “The rate at which the currency of one country would have 
to be converted into that of another country to buy the same amount of 
goods and services in each country.” In general terms, PPP is an approach 
that takes into account the fact that while poorer countries tend to have 
a lower level of income per head, they may also have much lower costs 
and prices: $ US 10 in a poor country may well buy more food (although 
perhaps of a lower quality) than $US 10 in a rich country. PPP also aims to 
reduce the impact of commercial exchange rate variations. PPP 
approaches usually use purely notional “International dollars” – shown as 
$ I – to distinguish PPP estimates from $US.  
Further details at 
http://www.imf.org/external/pubs/ft/fandd/basics/ppp.htm 
Secondary 
prevention  
Secondary prevention “aims to reduce the impact of a disease or injury 
that has already occurred. This is done by detecting and treating disease 
or injury as soon as possible to halt or slow its progress, encouraging 
personal strategies to prevent reinjury or recurrence, and implementing 
programs to return people to their original health and function to 
prevent long-term problems”. Further details at 
https://www.iwh.on.ca/wrmb/primary-secondary-and-tertiary-
prevention 
 
See also Primary prevention.  
STEP wise 
approach  
STEPS is not an acronym. Instead, it is a term used to cover the WHO 
STEP wise approach to Surveillance of risk factors and diseases. Further 
details on STEPS is available at http://www.who.int/chp/steps/en/ 
Sustainable 
Development 
Goals  
The United Nations states “On September 25th 2015, countries adopted 
a set of goals to end poverty, protect the planet and ensure prosperity for 
all as part of a new sustainable development agenda. Each goal has 
specific targets to be achieved over the next 15 years.” Further details at  
http://www.un.org/sustainabledevelopment/sustainable-development-
goals/ 
Technical 
efficiency  
See allocative efficiency.  
Total Health 
Expenditure 
The World Bank definition of THE, and the definition used in this thesis is 
“Total health expenditure is the sum of public and private health 
expenditure. It covers the provision of health services (preventive and 
curative), family planning activities, nutrition activities, and emergency 
aid designated for health but does not include provision of water and 
sanitation.” Source: World Development Indicators: data.11  
Upper Middle-
Income country  
The World Bank states 7 that for the current 2018 fiscal year upper 
middle-income economies are those with a GNI per capita between 
$3,956 and $12,235 in 2016. 
Universal 
Health 
Coverage  
WHO states that “Universal health coverage (UHC) means that all people 
can use the promotive, preventive, curative, rehabilitative and palliative 
health services they need, of sufficient quality to be effective, while also 
ensuring that the use of these services does not expose the user to 
financial hardship.” Further details at  
 http://www.who.int/mediacentre/factsheets/fs395/en/ 
 xxi 
 
References from the Glossary 
1. Liu X. Policy tools for allocative efficiency of health services. Geneva: World Health 
Organization; 2003. 154 p. 
2. World Health Organization. World health statistics 2016: measuring health for the SDGs. 
Geneva: World Health Organization; 2016. 
3. Homedes N. The disability-adjusted life year (DALY) definition, measurement and 
potential use. Washington: World Bank; 1996.  
4. Lee R, Mason A. What is the demographic dividend? Finance Dev. 2006;43(3). 
5. United Nations Population Fund Pacific Sub-Regional Office. Population and development 
profiles: Pacific Island countries. Suva: United Nations Population Fund; 2014. 128 p. 
6. Heller P. Understanding fiscal space. Washington: International Monetary Fund; 2005. 
7. The World Bank. World Bank country and lending groups for the 2018 fiscal year 
[Internet]. [cited 6 August 2017]. Available from 
https://datahelpdesk.worldbank.org/knowledgebase/articles/906519. 
8. World Health Organization. Noncommunicable diseases [Internet]. 2017 [cited 1 August 
2017]. Available from: http://www.who.int/news-room/fact-sheets/detail/noncommunicable-
diseases. 
9. Allen LN, Feigl AB. Reframing non-communicable diseases as socially transmitted 
conditions. Lancet Glob Health. 2017;5(7): e644–e6. 
10. World Health Organization. Obesity and overweight [Internet]. 2016 [cited August 2017]. 
Available from: http://www.who.int/mediacentre/factsheets/fs311/en/. 
11. The World Bank. World development indicators [Internet]. 2017 [cited 20 April 2017]. 
Available from: 
http://databank.worldbank.org/data/reports.aspx?source=2&series=SH.XPD.PUBL&country=. 
 
Chapter 1 
22 
Chapter 1: Introduction  
Section 1: Introduction, context, and significance of the research. 
This Chapter explains the research purpose and structure of this thesis.  
Section 1 establishes the overall context and significance of the research. It also explains 
the distinctive nature and development challenges of the Pacific Island Countries (PICs).  
Section 2 summarises what is currently understood about the public health, and public 
financing, challenges facing the PICs. I show that the PICs have distinctive public health 
and health financing challenges including an unfinished agenda of communicable 
diseases and high fertility as well as disproportionately high rates of expensive to treat 
non-communicable diseases (NCDs) such as diabetes. The PICs also have an already   
high dependence on government expenditure for health care, leaving PIC governments 
little room to manoeuvre in terms of responding to growing health financing demands.  
Section 3 explains the existing research gap and the resulting research questions that 
drive this thesis. I argue that the most commonly used approaches to analysing health 
financing challenges and options in low and middle-income countries globally have only 
limited applicability and relevance in the PICs, due to those Pacific countries’ unique 
public health and public financing characteristics. I show these issues are poorly 
addressed in the current international literature on priority setting and resource 
allocation in the health sector. This is the general research gap that the thesis aims to 
address. There are, within this general research gap, three specific gaps the thesis 
attends to. Surprisingly little research has been undertaken on (i) the financial costs to 
PIC governments of the cost of treating NCDs and (ii) on the implications of ageing on 
health systems in the PICs (iii) how Ministries of Health can prepare more persuasive 
and evidence-based budget proposals when negotiating with Ministries of Finance and 
/ or development partners. Against this background, I identify five specific research 
questions driving this thesis that respond to those general and specific research gaps. 
As this is a thesis by compilation, Section 3 shows how each of those five specific 
research questions is answered in a corresponding peer-reviewed and published article. 
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Each article is in a separate chapter in this thesis. Each chapter builds logically on the 
research findings of the previous chapter.  
Section 4 explains the research method and approach, including ethical approvals.   
1:1 Why prioritising and allocating resources to improve health is a central issue in 
public policy. 
How countries organise their health care financing is a central issue in public policy 
globally. That is so for six reasons. First, good health has intrinsic value. The World Health 
Organization (WHO) (1) and others (2, 3) see health as a fundamental human right. 
Amartya Sen sees health as an essential condition for expanding human “capabilities” 
and hence personal freedom and dignity (4, 5) with health equity closely linked to social 
justice in society (6).  
Second, good health has complex, two-way, interactions with broader economic and 
social development (7-13). In brief, countries – and households – tend to spend more 
on health as they become richer. However, the arrows of causality point the other way 
as well. Healthier people are more able to learn, and be productive full- time workers, 
than those that are in serious ill health. The poor, and near poor, can suffer catastrophic 
or impoverishing1 out of pocket health expenditure: an estimated 150 million people 
globally suffer financial catastrophe annually as a result of paying out of pocket for 
health care (14). Research2 published in The Lancet in an article (not included in the 
thesis) of which I was a co-author finds that “increasing health expenditure by just $5 
per person per year up to 2035 in 74 countries with high (maternal and child mortality) 
burdens could yield up to nine times that value in economic and social benefits” (15 
p1333).  
                                                        
1 WHO states in World Health Statistics 2016) that out of pocket (OOP) payments “are judged to 
be catastrophic when they exceed a given proportion (25%) of the total household budget or of 
the capacity to pay (40%). They are labelled impoverishing when OOP payments push a 
household’s other spending below a minimum socially recognized living standard such as that 
identified by a poverty line. The poverty line should be defined according to national standards 
and also against an international poverty line, consistent with Sustainable Development Goals”.  
2 This publication has been cited 153 times since its publication in 2014. I am the 4th listed out of 
28 authors. 
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Third, there are special features of the health sector, including market failures,3 that can 
justify, to varying degrees, government intervention (16-19). Market failures include 
significant asymmetry of information and knowledge between both patients and health 
workers; monopolies and oligopolies that restrict competition in, for example, the 
pharmaceutical industry, and professional associations; and inequities in access and 
outcomes. There are also important externalities and regional and global public goods 
including reducing communicable diseases such as pandemic influenza and reducing 
drug resistant antibiotics where the private sector has little incentive to participate and 
government intervention may be required. Not surprisingly, health economics is now a 
distinct field within economics (20, 21) and researchers argue a strong case for “the 
visible hand” (22 p1) or at least government regulation and oversight in the health 
sector.  
Fourth, even when government expenditure on health is modest in per capita terms it 
can still be a significant part of total government expenditure, thereby affecting broader 
macroeconomic parameters. How much a government should spend on health care has 
been an issue in public policy for some time (23). Various minimum targets have been 
set over time (10, 24, 25). Latest research from WHO now concludes that there is “no 
magic number” (26 p1) for spending targets on health. Nevertheless, the needs for 
public expenditure on health can be large and substantive in national and global terms. 
WHO estimates that to achieve the Sustainable Development Goals (SDGs)4 for health 
in 67 LMICs5 would require new investments increasing from $134 billion per annum 
initially to $ 371 billion by 2030 (27). Importantly from a public policy perspective, those 
estimates assume health systems are already operating at efficient levels. The modelling 
concludes that $7 billion extra funding would be freed up in 2030 if low-income 
countries were able to improve efficiency of drug purchases and reduce expenditure 
                                                        
3 See glossary for definition of market failures. 
4 See glossary for a definition of the SDGs. 
5 The modelling included all low-income countries, the 20 most populous lower middle-income 
countries, and the 20 most populous upper middle-income countries. According to WHO, this 
covers 95% of the population in low and middle-income countries and 75% of the global 
population. Unfortunately – and not for the first time – that process has meant that no Pacific 
Island country was included in the estimates.  
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leakages. Much of that funding could be used to address the rise in NCDs: a particular 
challenge for the Pacific Island countries.  
Fifth, global trends suggest middle-income countries need to anticipate increasing 
absolute and relative levels of public expenditure being allocated to the health sector. 
Population growth, ageing, and political demands of a rising middle class will increase 
demand for health expenditure in middle income countries. Tandon (28 p17) notes that 
many middle-income countries can also expect to see an increase in the proportion of 
funding going to health, and not just the absolute amounts, as they develop, due to 
Wagner’s Law.6 Low and middle-income countries globally should also expect to 
increasingly finance public health expenditure through their own resources. The 
Institute for Health Metrics and Evaluation (IHME) estimates (29) that low and middle-
income countries were already spending, on average, nearly $20 ($19.80) for every 
dollar received in external aid in 2012. Development Assistance for Health (DAH) globally 
has generally plateaued since 2010 (30) and development partners globally focus their 
efforts increasingly on low income, rather than middle income, countries.  
The sixth reason why health and health expenditure are central to public policy is that 
public expenditure can be ineffective – even harmful – to public health. Good health can 
be achieved at low cost under a range of different political, economic and social systems 
(31-33). However, even when governments are committed to improving health 
outcomes Filmer, Hammer and Pritchett argue that “weak links in the chain” - including 
limited institutional capacity, health workers’ motivation, and crowding out of private 
health provision – can make health expenditure ineffective (34 p199, 35). WHO analysis 
(36) argued that up to 20-40 % of health expenditure globally was wasted.7 A recent 
series of articles in The Lancet highlight the waste – and harm to health – that occurs in 
both the underuse - and overuse - of health care (37-40).  
                                                        
6 Tandon says (page 17) that ’Wagner’s Law refers to the positive correlation between the size of 
government and national income….Not only do richer countries spend more in absolute levels, 
they also spend a higher proportion of their resources on health and education” (italics in the 
original) 
7 The leading causes of waste in health expenditure globally were purchasing practices for 
medicines (under-use of generics; use of substandard or counterfeit medicines; irrational 
prescribing policies); misaligned incentives (fee for service payments); management practices 
(medical errors, costly staffing mixes); poor investment decisions (hospital size; technology 
choices) 
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1.2 Pacific Island countries face some distinctive development challenges.  
The specific unit of analysis for this thesis are the fourteen-middle income and / or small 
countries8 of the Pacific Islands Forum. In alphabetical order the countries are: Cook 
Islands; Federated States of Micronesia (FSM); Fiji; Kiribati; Marshall Islands; Nauru; 
Niue; Palau; Papua New Guinea (PNG); Samoa; Solomon Islands; Tonga; Tuvalu; and 
Vanuatu.9 Map 1 on page 28 shows the location of these countries. Table 1 provides 
basic socio-economic data about these fourteen countries. While there are differences 
between, and within, the three subregional groupings of the Pacific – Melanesia, 
Polynesia and Micronesia10 – there are also some common challenges. Small populations 
– particularly when they are spread over large distances as happens in much of the 
Pacific – is one such challenge as it limits opportunities for economies of scale and 
specialisation in the health and other sectors. Table 1 shows that eleven of the fourteen 
countries have total populations of less than 250,000, with six countries having less than 
100,000, and Niue just 1,600.  
Achieving - and sustaining - economic growth is another distinctive challenge facing the 
PICs. With the exception of PNG, the real (adjusted for inflation) GDP growth in the 
Pacific has been below the global average of other middle-income countries, and “small 
states”11 over the decade to 2015 (47). Kiribati, FSM and Vanuatu have stayed at lower-
middle income level since 1990. Economic growth has also been volatile for many PICs 
reflecting, among other things, commodity cycles; natural disasters; and ethnic tensions. 
Five PICs12 have had their World Bank country classification at least temporarily 
                                                        
8 Palau is classified by the World Bank as a high-income country. However, as a country with a 
population of only 17,800 it shares many of the health and health financing challenges of the 
other 13 middle income countries that are members of the Pacific Islands Forum. 
9 Tokelau is an observer member of the PIF and, where information exists on Tokelau, it has been 
included in this thesis for completeness 
10 The Melanesia countries included in this thesis are Fiji; Papua New Guinea; Solomon Islands and 
Vanuatu. The Micronesia countries are Federated States of Micronesia; Kiribati; Marshall Islands; 
Nauru and Palau. The Polynesian countries are Cook Islands; Niue; Samoa; Tokelau; Tonga; and 
Tuvalu.  
11 The World Bank defines small states as having less than 1.5 million population.  
12 More specifically, Fiji had been classified as lower middle-income country (LMIC) in 1987; 
“graduated” to upper middle-income country (UMIC) in 2007 – 2009; regressed back to LMIC 
status over the period 2010 – 2012; returning to UMIC status from 2012 to 2016 (latest year 
available). Nauru was classified as a high-income country in 2015 when it joined the World Bank 
but regressed to UMIC status in 2016. PNG has been classified as LMIC over the period 1987-2000; 
regressed to Low Income status over the period 2001-2007; and “graduated” back to LMIC status 
Chapter 1 
27 
downgraded since 1990, at least for a period, with Solomon Islands moving categories 
several times (48). Papua New Guinea had periods of strong, resource-driven, economic 
growth but has not been able to translate this into substantial or sustained progress in 
human development, including in the health sector (49-54). 
The relatively high population growth in much of the Pacific means that per capita real 
GDP growth has also been lower than comparable countries. Recent research from the 
World Bank (47) finds that the average annual real GDP per capita growth over the 
period 2005 – 2015 was around 4% for middle income countries globally. PNG – 
supported by a (then) commodities boom – was the only one of eleven PICs13 to match 
that level or exceed the global average 3% per capita real GDP growth for “small states”. 
Per capita real GDP growth globally was less than 1% per annum over the decade to 
2015 in Samoa, Tonga and Vanuatu, and negative for Kiribati, FSM and Palau. Table 1 
shows that nearly half (46%) of the countries for which data is available had a GDP per 
capita growth rate less than 1% per annum, with the two most populous countries – 
PNG and Fiji – having GDP per capita growth rates less than 0.5% per annum in the latest 
year available. Even then, GDP per capita can overstate the situation in countries like 
PNG where the resources sector is largely foreign owned.14  
Furthermore, periods of rapid overall economic growth in the resource sector of an 
economy do not necessarily translate into broader economic growth or development. 
Recent research on PNG finds that “(government) expenditure after inflation has fallen 
by 36% from its 2014 peak and is also back at about 2006 levels. Core services have been 
squeezed out by the fall in revenue, the increase in salaries and interest, and the great 
                                                        
over the period 2008-2016. Solomon Islands has moved categories several times. Solomon Islands 
was classified as low income in 1987; LMIC in 1988; regressing to low income 1989-1991; back to 
LMIC 1992-1997; regressing again to low income 1998-2007; back to LMIC in 2008; regressing to 
low income in 2009; and back to LMIC from 2010-2016. Tonga was classified as LMIC 1987-2011; 
“graduated” to UMIC 2012-2014; regressed to LMIC in 2015; and returned to UMIC in 2016. 
Marshall Islands, Palau, and Samoa, are the only three countries to have “graduated” to higher 
income level groupings without regressing to a lower classification. Kiribati, and Vanuatu have 
stayed at LMIC status since 1987, as has FSM since 1991.  
13 The World Bank estimates covered its members at the time, so did not include Cook Islands, 
Nauru, or Niue. 
14 As a result, profits and incomes generated in PNG are repatriated to overseas owners, meaning 
that GDP overestimates national income.  
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boost to subnational spending (particularly funds under the discretion of Members of 
Parliament)” (55 p1). 
There is a significant body of knowledge in the peer-reviewed (56-59) and grey literature 
(60-64) that seek to explain the broader economic and development challenges facing 
middle-income PICs. Common themes include the challenges of having small, open, 
economies; vulnerability to cyclones and climate change; poor governance; political and 
cultural factors including land ownership characteristics; and small private sectors / 
limited employment opportunities.  
Distance and remoteness are widely perceived to be fundamental underlying 
constraints. Map 1 indicates the relatively remote geographical location of PICs. 
Research from the World Bank (65) takes purely geographical remoteness a step further 
by showing that PICs are also relatively remote from major economic markets, 
particularly when compared to Caribbean island countries of roughly similar population 
size. On average, PICs are located 12,000 kilometres away from the nearest markets, 
making them the most remote grouping among small islands globally (66). 
 
Map 1: Pacific Island countries, including the 14 middle income countries of this 
thesis, cover a vast expanse of territory 
Source: Pacific Community (67). 
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Most PICs are also aid-dependent, receiving significantly more external aid per capita 
than their comparators. Figure 1 below shows net ODA per capita is significantly higher 
in the Pacific than the global average for a wide range of comparator countries including 
“small states”; lower middle-income countries; and upper middle-income countries. 
This has policy implications for priority setting and resource allocation: see Section 2:2. 
 
Figure 1: Net ODA per capita in 2014 (current $). 
Source: The World Bank World Development Indicators (41). 
Section 2: Public health and public financing challenges in the PICs 
In this Section I summarise what is currently known about public health and public 
financing challenges facing the Pacific. I show that the PICs have distinctive health, and 
health financing, characteristics that set them apart from other comparable middle-
income countries globally.  
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2:1 A mixed, but generally disappointing, record of overall health outcomes and health 
systems. 
PICs have achieved some important health outcomes. For example, the Pacific has been 
polio free15 since 2000, and the PICs have eliminated maternal and neonatal tetanus 
(68). Hetzel and colleagues (69 p695) conclude there has been an “unprecedented” 
decline in malaria prevalence throughout PNG, faster than in Africa or other regions. 
Maternal and child mortality has reduced over time in most PICs but is still high by global 
standards in PNG (70). 
Nevertheless, the PICs have a generally disappointing record of health outcomes. Linhart 
et al find that life expectancy - a key indicator of health outcomes - has been plateauing 
for males in more than half (8/15) PICS and in almost half (7/15) for females over the 
last two decades: see Annex 1. The IHME estimates that, although improving, life 
expectancy for both males and females is well below projected outcomes given PNG’s 
economic and other characteristics.  
PICs made mixed - and sometimes surprisingly poor - progress under the Millennium 
Development Goals (MDGs) for health, arguably the most important universally 
accepted measure of development over the last decade and a half. Just over half (9/14) 
PIC countries16 achieved the MDG goal 4 of reducing child mortality by two thirds; only 
half (7/14) achieved MDG 5 goal of reducing maternal mortality17; and just less than 
half18 (6/14) achieved the overall MDG 6 target of combating HIV / AIDS, TB, malaria and 
other infectious diseases (70). That same report finds PNG failed to achieve any of the 
three health related MDG goals for maternal health, child health, or reducing 
communicable diseases (or, indeed, the other four non-health related MDG goals such 
as reducing poverty). 
                                                        
15 This statement was correct at the time of submitting this thesis to examiners on 2 March 2018. 
However, in July 2018 the WHO confirmed there had been an outbreak of vaccine derived poliovirus 
type 1 from a child in Lae, Papua New Guinea. Further details are available at 
http://www.who.int/csr/don/02-July-2018-polio-png/en/ 
16 In alphabetical order: Cook Islands; Federated States of Micronesia; Fiji; Republic of the 
Marshall Islands; Niue; Palau; Samoa; Tonga; and Tuvalu. Kiribati, Nauru had mixed results. PNG 
and Solomon Islands did not meet the goal.  
17 Cook Islands; Fiji; Republic of the Marshall Islands; Niue; Palau; Tonga and Tuvalu.  
18 Cook Islands, Nauru, Niue, Palau, Tonga and Vanuatu.  
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There is an unfinished agenda of health challenges in the Pacific normally associated 
with low income countries. For example, the Total Fertility Rate (TFR) – the number of 
children born per woman – varies within the Pacific but is generally higher than global 
averages for countries at that stage of development (71-73). Eight PICs, including four 
upper middle-income19 PICs, have higher TFRs than occurs on average in the UN’s forty- 
eight “least developed” countries, most of which are in Sub-Saharan Africa.20 Cultural 
and family preferences explain some of this high TFR in the Pacific. However, the latest 
UNFPA report (71 p104) shows that the Contraceptive Prevalence Rate is less than 50% 
for all fourteen PIC countries it tracks. Importantly from a public policy perspective one 
fifth or more of women aged 15-49 years have an unmet need for modern contraception 
in nine of the fourteen countries. Kennedy et al (74) note that the Pacific has some of 
the highest rates of unmet need for family planning in the world.  
The unfinished agenda also includes reducing communicable diseases, under-nutrition 
and environmental health. Despite progress in reducing malaria, and HIV AIDS in PNG, 
much of the Pacific have high rates of sexually transmitted infections, with UNICEF 
reporting chlamydia infection rates “among the highest in the world” (75 p26, 76). PNG 
has multi-drug resistant tuberculosis (77, 78). PNG also has the fourth highest rate of 
stunting in the world (79). Nearly half (49.5%) and nearly one third (32.8%) of children 
under 5 years of age in PNG and Solomon Islands respectively were stunted (short height 
for age: prima facie evidence of chronic under-nutrition) over the period 2005-2016 (80). 
About 6.9 million people in Pacific island countries cannot access improved sanitation 
and more than 4.8 million cannot access improved water supplies (81). Researchers have 
already recognised that the Pacific faces a double burden of disease – communicable 
diseases co-existing with NCDs (50, 82, 83). WHO argues there is now a triple burden in 
the Pacific: communicable disease, NCDs and the health impact of climate change (84).  
PICs do not perform particularly well in terms of overall health systems. Researchers in 
The Lancet (85) tracked death rates for 32 diseases “that can be avoided effectively 
treated with proper medical care” in each of the 195 countries over the period 1990-
2015. They concluded most countries improved both access and quality of health care 
                                                        
19 Samoa, Nauru, Tuvalu and Marshall Islands. 
20Among the 48 “least developed” countries, are four from the Pacific: Kiribati, Solomon Islands, 
Tuvalu, and Vanuatu. 
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for their citizens over that period but countries in Sub-Saharan Africa and Oceania (i.e. 
the Pacific) mainly saw the lowest level of progress.  (85). The article also found several 
countries in the Pacific had health systems that were well short of their potential 
effectiveness and efficiency. 
2:2 Six distinctive health and health financing challenges in the Pacific.  
There is some acknowledgement in the international literature that small island 
economies face particular challenges, including in terms of overall health services and 
outcomes. Hotchkiss (86) identifies several constraints facing small islands including the 
fact that small populations make specialised or expensive services unviable, difficulties 
in recruiting and retaining specialised staff. Taylor, in the aptly named article “The 
tyranny of size: challenges of health administration in Pacific Islands  States” notes that 
“Small health services are not just scaled-down versions of large health services; they 
are qualitatively different. They are of such a size, and isolated to such an extent, that 
their situation and difficulties are qualitatively, as well as quantitatively, different” (87 
p72). Haque et al, (58) analysing 118 countries globally, find that small populations, and 
a limited pool of human capital, largely explains why PICs have poorer public 
expenditure and financial management scores than larger countries of similar income. 
Apart from their small size, there are another six significant public health, and public 
financing, challenges that set the PICs apart from other middle-income countries, and 
even other small island states.  
First, PICs have much higher prevalence of NCDs, especially diabetes, than all other 
countries in the world. Figure 2 below shows that the Pacific has eight of the top ten  
countries21 in the world for the estimated prevalence of age-adjusted adult female 
diabetes. The prevalence is noticeably higher than the vast majority of 186 countries 
globally: in eight PICs, females aged 18 years and over have a prevalence of 20 % or 
more, whereas the majority of 186 countries globally have an equivalent prevalence of 
10% or less. (The pattern of male prevalence of diabetes in the Pacific is not particularly 
different). The combination of a high prevalence of diabetes among women, and high 
                                                        
21 In descending order: Nauru 28.4% prevalence; Niue 27.3%; Cook Islands 26.7%; Samoa 26.6%; 
Tonga 26.4%; Tuvalu 24.3%; Federated States of Micronesia 23.4%; Palau 21.6%; Egypt 19.8%; and 
Kuwait 19.6%. 
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fertility, is a particularly problematic public health issue, as diabetes in pregnancy raises 
health complications for both mother and then her child.22 
 
Figure 2: Female diabetes prevalence23 among 186 countries with Pacific Island 
countries shown in red bars. 
Source: World Health Organization (88). 
The rise of NCDs in the Pacific has been a relatively recent phenomenon but is often 
occurring at faster rates than other middle-income countries. Zimmet et al (89 p91) state 
that diabetes, hypertension, strokes, and coronary artery disease were “unknown or 
rare” in most countries of the Pacific in the 1960s (90, 91). Changing diets (92, 93) and 
lifestyles leading to obesity go part way to explaining the disproportionately large rise 
in diabetes in the Pacific (94) but Joffe and Zimmet also argue (95) Pacific populations 
may possess a “thrifty gene”.24 Hawley and McGarvey state that the prevalence of 
obesity and diabetes is “rising disproportionately faster in the Pacific region over the 
past three decades than in the rest of the world” (221 p28 italics added). The latest WHO 
                                                        
22 I am grateful to Dr Robert Condon who highlighted this point during my Ph D oral presentation 
at the ANU in August 2017. 
23 The definition used by WHO is raised fasting blood glucose > 7 mmol/L or on medication, age 
standardised, mid-point estimate, females aged 18 years + 
24 The “thrifty gene” hypothesis argues that a genetic metabolic capacity to store fat that was 
historically protective for those living in remote islands subject to food insecurity but which is now 
damaging health in an era of processed food abundance. 
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World Statistics Report (80 p60) finds that of 183 developed and developing countries 
world-wide in 2015, PNG has the highest probability (36.1%) of dying from any of the 
four major NCDs between age 30 and age 70, and that Fiji has the third highest 
probability (31.4%). Six other PICs for which information is available have probabilities 
higher than 20%: Kiribati (28.2%); Solomon Islands (26.4%); Micronesia Federated States 
(25.9%); Tonga (24.1%); Vanuatu (22.3%) and Samoa 22%.25  
Second, high levels of NCDs are associated with higher levels of premature death in PICs 
than in comparable countries. WHO estimates show that NCDs are associated with 
significantly higher rates of premature (less than 60 years of age) death in the PICs than 
other lower-middle 26income countries globally: see Figure 3. Gopalini and colleagues 
find that premature deaths from NCDs in the Federated States of Micronesia are higher 
than global levels (96). Not only are rates of premature death high, Tonga now officially 
attributes reduced life expectancy in the country largely to the rise of NCDs (97). Despite 
difficulties in estimating the prevalence of NCDs in the Pacific, it is clear that diabetes is 
also causing or is at least associated with morbidity including eye problems (retinopathy) 
and limb amputations (98).  
                                                        
25 These are all more than double the probability in Australia (8.9%), reflecting both the different 
prevalence and risk factors for NCDs in the PICs but also the increased access to effective medical 
care in Australia.  
26 WHO did not provide estimates for upper middle-income countries. 
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Figure 3: Premature deaths: proportion of all male NCD deaths < 60 years of age 
in 2010 
Source: World Health Organization (99). 
Third, PICs have some of the highest risk factors for acquiring NCDs in the world, feeding 
a pipeline of future NCDs unless urgent action is taken. WHO states that obesity is a 
major – but preventable – risk factor for most NCDs including cardiovascular disease, 
cancer and diabetes (100). Lin et al note that “obesity is the strongest and most 
prevalent risk factor for type 2 diabetes” (101 p534). The ten countries in the world with 
the highest levels of obesity are all in the Pacific27, with six of those countries having 
50% or more of the adult population obese (102). It is particularly concerning that young 
people in the Pacific have rates of obesity and overweight that are the highest in the 
world. Girls aged 5-19 years in Melanesia, Polynesia, and Micronesia, and boys the same 
age in Polynesia and Micronesia already had the highest Body Mass Index 28 (BMI) out 
of 200 countries in the world in 1975 (103). Even more concerning, that research found 
                                                        
27 In rank order, showing the percentage of the adult population that are obese (confidence 
intervals shown in the original data set): Nauru 61%; Cook Islands 55.9%; Palau 55.3%; Marshall 
Islands 52.9%; Tuvalu 51.6%; Niue 50%; Tonga 48.2%; Samoa 47.3%; Kiribati 46%; Federated 
States of Micronesia 45.8%. Kuwait is the eleventh ranked country in the world with an obesity 
prevalence of 37.9%. 
28 Body Mass Index compares a person’s weight to their height. The formula is BMI is calculated 
by dividing a person’s weight in kilograms divided by their height in meters squared. 
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that the increase in BMI between 1975 and 2016 was highest in the world for both girls 
and boys in some countries of Polynesia.  
Rates of tobacco use is also high by world standards among males in parts of the Pacific. 
This is important because tobacco use causes or exacerbates all four major NCDs (104, 
105). Beaglehole et al (106) argue that tobacco control is the most important priority for 
managing the rise of NCDs. Savedoff and Alwang argue that tobacco taxation is “the 
single best health policy in the world” (107 p1). Yet Kiribati has the highest prevalence 
(47.8%) of male smoking out of 195 countries globally and six PICs (Kiribati, Tonga, PNG, 
Samoa, Vanuatu and Solomon Islands) have male smoking rates higher than the global 
average (108). The IHME estimates that tobacco use is the single largest risk factor for 
death and disability in PNG (109). Hou, Xu, and I (110 pi) show tobacco consumption 
particularly affected the poorest in PNG: “tobacco consumption accounts for about 23% 
of total household food expenditure for households in the poorest quartile, compared 
about 15% for the entire sample”. 
Kessaram et al analyse other risk factors drawn from WHO STEPs data29 from the Pacific, 
showing high levels of other risk factors for NCDs in the Pacific including physical 
inactivity and alcohol use (111). Having a high level of risk factors for NCDs is particularly 
important and relevant in the Pacific given that WHO states that NCDs such as  chronic 
respiratory diseases globally are already often “under recognized, under diagnosed, 
under-treated and insufficiently prevented”(112 p1).  
The fourth factor that makes the PICs particularly distinctive is that governments finance 
much more of Total Health Expenditure (THE)30 than in countries of similar levels of 
socio-economic development. Figure 3 shows that governments fund more than 75% of 
THE in twelve of the fourteen PICs in 2014 (latest year available). In six of the fourteen 
countries government funds 90% or more of THE. All fourteen countries, except Fiji, 
spend significantly more than comparable countries at that level of development. In 
                                                        
29 STEPS is not an acronym. Instead, it is a term used to cover the WHO STEP wise approach to 
Surveillance of risk factors and diseases. Further details on STEPS is available 
at http://www.who.int/chp/steps/en/ 
30 Total Health Expenditure (THE) consists of government expenditure, private out of pocket 
expenditure, and expenditure through health insurance schemes. In most PICs, government 
finances – and itself directly delivers – health services. In PNG, government financed 81.3% of THE 
in 2014, but government has purchased the actual delivery of health services from churches. 
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Niue, FSM, PNG and Kiribati government expenditure on health as a percentage of THE 
is more than double the global average for lower middle-income countries. In four 
countries – Samoa, Tonga, Tuvalu and Vanuatu – the share of government expenditure 
in THE has increased over time since 1995 rising in Samoa from 73.6% in 1995 (earliest 
baseline date available) to 90% in 2014 (41). In the remaining ten PICs, the share of 
government expenditure as a percentage of THE has fallen only marginally or stayed the 
same.  
That governments in the Pacific shoulder such a high share of the total expenditure on 
health cannot be explained just by the small size of the economies of the Pacific. Figure  
4 shows that all PICs, with the exception of Fiji, still have significantly higher shares of 
government expenditure on health than the “small states” global average of 68.6%. 
Other factors, including the relatively low levels of formal employment (and hence 
private insurance) and relatively high levels of external aid financing are likely to be 
contributing factors to the high share of government expenditure in total health 
spending.  
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Figure 4: Government expenditure as percentage of Total Health Expenditure  
Source: The World Bank World Development Indicators (41). 
The corollary to high shares of government expenditure on health is that, unlike most 
middle-income countries, PICs then have some of the lowest levels of out of pocket 
expenditure on health care in the world. Figure 5 shows that the average level of out of 
pocket health expenditure in the PICS (13.2%) is less than one quarter of the average for 
lower middle-income countries globally (54.9%) and less than one half the average for 
upper middle-income countries globally (32.4%). This is important from the point of view 
of public policy because it means few if any Pacific Islanders currently experience direct 
financial distress as a result of health expenditure.31  
                                                        
31 Although citizens in remote parts of PNG and Solomon Islands may also simply not get access to 
essential care.  
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Figure 5: Out of pocket expenditure on health as % of Total Health Expenditure in 
2014 
Source: The World Bank World Development Indicators 2017 (41). 
The current low levels of direct out of pocket expenditure on health care will remain a 
policy challenge for the PICs. Governments wishing to keep direct out of pocket 
expenditure levels low for social and political reasons have few easy or palatable options 
for expanding health expenditure to meet increasing needs.  Private health insurance 
and / or social health insurance social health insurance32 are not realistic options. That 
is because the small total populations of the Pacific, and even smaller formal sector 
economy, makes the potential total health insurance pool too small to spread risks in a 
viable or financially sustainable way. Development partners are also most unlikely to fill 
any growing health financing gap: an expensive and potentially open-ended obligation 
for them and hard to sell politically in bilateral partner’s own constituencies, especially 
if PICs have been recently “graduating’’ to upper middle-income status: see footnote 12 
for an account of such movements. Any reduction in overall PIC government financing, 
                                                        
32 Social health insurance essentially involves taking a portion of formal sector workers’ salary and 
pooling it to cover a proportion of health care costs. While common and popular in some 
European OECD countries, social health insurance usually requires a political culture of ‘solidarity’ 
for it to be politically acceptable. Both private health insurance and social health insurance 
requires potentially significant actuarial, management, and administrative skills to minimise 
gaming of the system. 
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whether from domestic sources or aid funding, is also unlikely to be met by PIC citizens 
directly seeking private sector health providers as there are few such (qualified) 
providers especially in rural or remote areas.  
Conceptually, that then leaves only one option if people are to access health care at all: 
increasing user fees.33 Some user fees can be justified, including for purely cosmetic 
surgery or when applied to hospital emergency or outpatients services as a means of 
discouraging citizens from bypassing primary health care facilities with minor ailments. 
But the international literature is clear that user fees that require out of pocket 
expenditure for health care at the point of service is the most regressive and least 
attractive form of health financing in any country, especially if it leads to the non-use of 
health care by the poor (113-116). See also the discussion on what the international 
literature says on financial protection and direct out of pocket expenditure on health 
care in Section 3:1.  
In short, the current low levels of direct out of pocket expenditure on health care will 
remain a policy challenge for the PICs in the absence of alternative sources of revenue 
to meet the needs of growing, ageing populations with already high levels of expensive 
to treat NCDs. 
The fifth factor that makes PICs health financing particularly distinctive is that 
government expenditure on health is already a significant share of total government 
expenditure, unlike most other middle-income countries. Four of the ten middle-income 
countries in the world with the highest share of government overall expenditure being 
allocated to health are in the Pacific: Marshall Islands; Federated States of Micronesia; 
Palau and Vanuatu. Figure 6 shows that all ten of the twelve PICs for which information 
is available allocate more of their overall government budget to health than the average 
globally for lower middle-income countries (data on upper middle-income shares are 
not available). Figure 6 shows six PICs allocated 15% or more of government expenditure 
to health care. To put this in perspective, the WHO notes that “In 2012 only 14% of 
                                                        
33 Total health care comprises expenditure from either the government; through private or social 
health insurance; through development partners; or directly out of pocket either to private 
providers or via increased user fees for government services. It needs to be recognised that poor 
and marginalised people may also simply forego health care because they cannot afford transport 
or other indirect out of pocket expenses to access care, including the loss of a day’s income.  
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governments in low and lower-middle-income countries met the (15% Abuja target of 
government expenditure going to the health sector); indeed, only 29% of upper-middle-
income and high-income countries reached this level.” (26 p4) 
 
Figure 6: Public Health Expenditure as % of total government expenditure 
Source: The World Bank World Development Indicators (41). 
A sixth factor that makes health challenges in the PICs particularly distinctive is the level 
of aid dependence, a characteristic that has important implications for priority setting 
and resource allocation. Figure 1 showed that net ODA per capita is significantly higher 
in the Pacific than the global average for a wide range of comparator countries including 
“small states”; lower middle-income countries; and upper middle-income countries. 
High levels of external aid are particularly relevant to issues of priority setting and 
resource allocation because bilateral and multilateral development partners, while 
providing welcome additional resources, can also distort the public policy priorities of 
host governments, and because aid volatility can particularly disrupt country priority 
setting (117-125).  
It is the combination of these six distinctive features that puts the PICs in a particularly 
difficult and challenging policy space. PICs acknowledge that they are facing an NCD 
“crisis” that can undo previous development gains. In 2011 the Prime Ministers and 
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other leaders of the fourteen PICs formally acknowledged that the region is facing an 
“NCD crisis” (126). A subsequent joint meeting of all Forum Economic and Health 
Ministers declared that “NCDs impose increasingly large, yet often preventable financial 
costs on national budgets and the economy more broadly. Without decisive action, 
NCDs can undo the development gains of the last 20 years”  (127). Despite the 
importance of these issues, I show in Section 3 below that there is a research gap when 
it comes to the fourteen middle-income countries of the Pacific which I then address 
through this thesis.  
Section 3: The general, and the specific, research gaps that this thesis 
addresses.  
3.1. The general research gap.   
The general research gap exists because the international literature on how middle-
income countries should prioritise and allocate scarce resources in the health sector 
does not adequately take into account the particularly distinctive public health and 
health financing characteristics and challenges facing the PICs, as outlined in the 
previous section (2:2). This thesis therefore aims to “provide a corrective to the current 
research and debate” as described in page 1 of ANU’s guidelines for writing a Ph D thesis 
(128) at least in terms of how the literature applies to the Pacific.  
The evidence that this general research gap applies with respect to the PICs is as follows. 
There is a substantial body of literature on how, in general, low and middle-income 
countries might best prioritise public health interventions and allocate scarce resources 
to address public health challenges. How much a country should spend on health care is 
a vexed question (23, 26, 35, 129-132). Having said that, various high-profile studies (10, 
12, 133-135) argued that the level, and allocation, of public financing for health in low 
and middle-income countries is often below what is needed to provide a package of 
essential services. Numerous peer-reviewed and grey area publications stress that the 
demand for health services will always and everywhere exceed supply: priorities and 
trade-offs must therefore be set (136-140). The literature also makes clear that scarce 
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financial and other resources34 in the health sector must be allocated in ways that take 
account of relative costs and relative benefits, as well as equity and sustainability (136, 
138, 141-149). There are several guides to prioritising and resource allocation, including 
for particular diseases or specific health challenges (12, 22, 150-158).  
A particularly well-established approach is the WHO “building blocks” approach. In 
essence, the WHO argues there are six key components of a well-functioning health 
system: leadership and governance; service delivery; health financing; human resources 
for health; essential medical products and technologies; and health information systems 
(134, 159-161). This “building blocks” approach has been influential in shaping the way 
researchers analyse the totality of a health system in low and middle-income countries 
(162, 163). I also use the WHO “building blocks” approach in Chapter 5 of this thesis 
because the research aim was to analyse how ageing affects the whole health system in 
the PICs.  
Several researches use a political economy lens to analyse health systems (164-171). As 
just one example, Walt and Gilson argue that “much health policy wrongly focuses on 
the content of reform, and neglects the actors involved in policy reform ……the processes 
contingent on developing and implementing change and the and the context within 
which policy is developed” (172 p353, italics in the original). They therefore use broader 
political context, technical content, and processes as three sides of a “health policy 
triangle” to analyse health systems. Several researchers use various other frameworks 
and approaches to analyse overall health system strengthening in low and middle-
income countries (173-177).  
All of these approaches are helpful as far as they go, but they do not adequately capture 
the particularly distinctive characteristics of the Pacific. For example, there has been a 
particular focus in the literature on options to expand the “fiscal space for health” but 
                                                        
34 Money and finance are just one resource that decision-makers need to prioritise and allocate to 
their most productive uses. “Other resources” include the health workforce (and labour beyond 
the health workforce that indirectly affects public health including, for example, those workers 
involved in producing nutritious food and workers involved in expanding the water and sanitation 
infrastructure in a society). “Other resources” that need to be prioritised and allocated carefully 
can even extend to the time that managers have to focus on a problem. Skilled and experienced 
managers are an important resource anywhere, especially in the Pacific: it is a poor use of that 
resource if most of their time is spent on routine administrative tasks or in unproductive or 
unnecessary meetings.   
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few of these policy options apply to PICs. Expanding the “fiscal space for health” means, 
in essence, increasing financial resources to the health sector “without any prejudice to 
the sustainability of a government’s financial position” (178 p75). In 2010 Tandon and 
colleagues at the World Bank developed this into a framework “for assessing fiscal space 
for health from five potential sources: conducive macroeconomic conditions; 
reprioritization of health within the government budget; earmarked income and 
consumption taxes directed towards the health sector; better efficiency of existing 
health expenditure; and external aid” (145, 179 p4, 180). Tandon and colleagues state 
that this framework has now been applied in more than 50 low and middle-income 
countries, albeit with mixed results (179, 180).  
This framework is useful and relevant, particularly to larger middle-income countries 
with wider economic and institutional options. However, as Chapter 2 and Chapter 3 of 
this thesis shows, four of the five options available under the World Bank fiscal space 
analysis rarely apply in the Pacific. That is so particularly given low or at least volatile per 
capita income growth in the PICs; high levels of existing aid dependency; and existing 
high shares of government expenditure on health; and limited ability of hypothecated 
taxes to meet overall financing needs of the PICs.  
Much of the existing literature also focuses on the importance of generating additional 
revenue for health through taxes or Social Health Insurance (181-186). This has limited 
relevance in the Pacific where, for example, Vanuatu does not have any form of income 
tax on individuals or businesses. Even in Fiji, a PIC with a relatively large formal sector, 
Social Health Insurance was not found to be appropriate (187).  
The literature is also generally critical of applying user fees to generate revenue for the 
health sector, especially in low and middle-income countries, given their regressive 
nature (113, 188, 189). An argument could be made that, because PIC government 
subsidies to health care were likely to be pro-rich, then user-fees may have the twin 
benefit of raising revenue for the health sector and providing some measure of equity 
in health financing.35 I see this as true in principle. On the other hand, the costs of the 
most expensive dialysis and / or drug treatments – see Chapters 3 and 4 of this thesis – 
are so high compared to average per capita incomes in the PICs that there is little 
                                                        
35 Dr Peter McCawley made this observation during my oral presentation at the ANU.  
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headroom to raise user fees even among the richest percentile, or cover the majority of 
costs. 
The international literature encourages increased use of cost-effectiveness analysis, 
program budgeting, and strategic purchasing to buy health outputs and outcomes in 
middle-income countries globally (113, 144, 190-192). While sound in principle, this is 
often unrealistic in the PICs where there is limited data on actual cost of government 
health services; limited numbers of trained and qualified staff to undertake program 
budgeting; small markets in which to undertake strategic purchasing or outsourcing; and 
limited bureaucratic authority to shift resources between historically determined 
budget line items. I found one study being undertaken on cost-effectiveness of salt 
reduction as a means of reducing risk factors in the Pacific (193). On the other hand, 
Shroufi and colleagues (194) conducted a systematic review of cost-effective 
interventions for the prevention of cardiovascular disease in low and middle-income 
countries. Out of 9731 search results - which specifically included “Pacific Islands” in the 
search terms - they identified 16 eligible studies: none covered the Pacific as such.  
There is also a global focus in the literature on financial protection for individuals and 
households. PICs. Direct out of pocket payments for health care are regressive; can be a 
barrier to seeking essential care for the poor; and can lead to impoverishing or 
catastrophic36 health expenditures (116, 195, 196). Financial protection for those 
seeking health care is now a key component for achieving Universal Health Coverage 
and is specifically being tracked through indicator 3.8.2 of the Sustainable Development 
Goals (197). That focus on financial protection has, in turn, generated significant 
attention in terms of global guidelines for achieving financial protection in middle-
income countries (36, 114, 181, 183, 185, 198, 199) and in the peer-reviewed literature 
(200-202). However, once again, that growing literature is of little direct relevance to 
PICs. That is because, as Figure 5 shows, PICs have significantly lower shares of out of 
pocket expenditures than comparable countries globally, most having rates one third 
lower than lower-middle income countries globally. Indeed, WHO states (203) that 
Kiribati has the lowest annual out of pocket household expenditure on health in the 
world at just $ 0.20 in 2012 (latest year available).  
                                                        
36 See footnote 1 and glossary for definition of terms.  
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The literature gives attention to public private partnerships as part of the resource 
allocation menu for middle income countries (204-207) but, again, there is only limited 
coverage of that option in the Pacific (208). Irava and Prasad also found this option to 
be at a relatively undeveloped state, with limited opportunities for expansion, even in 
Fiji which as a larger formal private sector than most countries in the Pacific (209).  
There is much focus on the rise of NCDs in middle-income countries, but little specific 
attention to the Pacific where the prevalence of some NCDs are the highest in the world. 
There are several peer-reviewed (106, 210-217) and grey literature documents (218, 
219) providing guidance on the NCDs in middle-income countries. However, even 
though the PICs have some of the highest rates of NCDs, and risk factors for NCDs, there 
is little specific literature on how best to reduce NCDs and what the financial costs to 
government might be: see section 3.3 below. 
In summary, this thesis aims to provide a “corrective” to the widely used approaches 
and analytical frameworks by explaining how the PICs have particularly distinctive 
health, and health financing, challenges. 
3:2 The specific research gaps.  
Within this general research gap, I also identify three specific research gaps.  
First, there is little peer-reviewed, and / or up to date published data on actual health 
financing challenges and options in the Pacific, particularly in terms of the financial costs 
of treating the rapid rise of NCDs. This is despite the financial and economic costs of 
NCDs being a key part of a health and development “crisis” recognised by all PIC leaders.  
There is some research in the international literature about the dramatic rise of specific 
NCDs in the Pacific, some going back to the year 2000 and earlier (90, 94, 95, 111, 220-
225). There is less peer-reviewed literature on what public health interventions are 
specifically suited to the PICs, but there is some (91, 193, 227-232). However, there are 
also gaps. Mannava, Annear, and colleagues (233) reviewed the literature on NCDs and 
broader health systems in Asia and the Pacific published over the period 1990-2010. 
Despite the disproportionately high prevalence of NCDs in the PICs, with each country 
in the Pacific included in the search terms, none of the twenty-nine single country 
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studies analysed a Pacific Island country or the region as a whole. 37 A recent book (83) 
on the history of responses to NCDs and communicable diseases in “Asia and Pacific” 
had twelve chapters on Asian countries, two chapters on PNG, but no other specific 
research on other PICs, despite PICs having disproportionately high levels of NCDs such 
as diabetes. Snowdon notes the general need to increase evidence and data on NCDs in 
the Pacific (232). 
There is limited and / or dated research about health financing challenges in the Pacific. 
Deeble, (234) writing in 1990, argues for increased health expenditure in the Pacific. He 
recommends changes in government priorities; increased health user charges; and a 
greater role for community financing as a means of increasing resources for health. 
(Chapter 2 of this thesis explains why all but the first option is inappropriate for the 
Pacific). In 1990, Taylor, drawing on health expenditure data up to 1986, provided one 
of the more comprehensive overview summaries of health expenditure, as well as health 
status and health services, of six countries of the Pacific. 38 Gani estimates the possible 
reduction in infant mortality of a 10% increase in per capita health expenditure in the 
Pacific (235) however his analysis uses data from 1990–2002. WHO has produced 
country studies, including chapters on health financing, on Fiji (236), Tonga (237) and 
Solomon Islands (238). In addition to the World Bank publications included or referred 
to in this thesis, I have been the lead author of published World Bank studies on the 
health financing options facing Vanuatu (239); the economic costs of NCDs in the Pacific 
(240), and the Pacific NCD Roadmap (241). My co-author for the article published in 
Chapter 4 of this thesis recently published a short study on financing Universal Health 
Coverage in Fiji (242).  
There is even less published research on the direct financial costs to governments of 
preventing and controlling NCDs in the Pacific but what is available is now somewhat 
dated. In 2003 Beaver (219) estimated the costs of diabetes treatment in five PICs: Cook 
Islands, FSM, Fiji, the Marshall Islands and Tonga. She also shows how costs rise with co-
morbidities: the wholesale cost of medication for a non-insulin diabetes patient in Tonga 
was $Tonga 20 per year in 2001. However, “costs increased 35 fold to $Tonga  697 if the 
                                                        
37 There were ten published studies on India, six for Thailand and three for Sri Lanka. 
38 Fiji, Kiribati, Samoa, Solomon Islands, Tonga and Vanuatu.  
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patient was treated for hypertension, two episodes of foot infection and one episode of 
diabetes sepsis” (219 p92). Falconer (243) also estimated the costs of diabetes 
treatment in Vanuatu, but his 2010 publication uses data from around 2006 which 
makes it now somewhat dated. His study also did not extend to the direct costs of 
hypertension that was included in the study I led (see Chapter 4 of this thesis for details).  
There is some research on NCD costs in the Pacific that is based on modelling, rather 
than primary sources. The International Diabetes Federation (IDF) has used modelling 
to estimate the mean diabetes related expenditure per person for 220 countries and 
territories including for selected countries in the Pacific. However, these estimates 
should be treated with caution as they involve five different data sources39, each of 
which involve their own significant – even heroic – assumptions. Zhang and colleagues 
build on that approach to estimate that 41% of national health expenditure in Nauru 
was allocated to diabetes in 2010, the highest percentage out of 193 countries in the 
world and well above the estimated 12% global average. Tuvalu and Tonga had the 
fourth, and sixth, highest shares of national expenditure going to diabetes in the world 
at 19% and 18% respectively (244).  
There is some research on the broader economic costs of NCDs in the Pacific including 
lost productivity although, again, some is quite dated. Szmedra and Sharma (245) 
estimate that productivity and income losses of those in the formal sector suffering from 
NCDs amounted to 14% of the 2004 GDP in Nauru and 1.4% of the GDP in Fiji. Tin (246) 
finds that approximately 10% of people with diabetes in the Pacific retired from the 
workforce as a result of that illness. Ding and colleagues estimated the economic burden 
of physical inactivity in 142 countries finding, among other things, that 94% of the 
economic burden of physical inactivity in the Solomon Islands is borne by the public 
health system – the highest rate in the world. This is followed by Seychelles (92%), 
Micronesia (90.3%), Samoa (89.5%) and 87.3% in Vanuatu (247, 248). I was the co-
author of the chapter in the World Bank’s Pacific Possible report that estimated, through 
                                                        
39 Page 40 of the IDF report explains the modelling used 5 inputs: IDF’s own estimates of diabetes 
prevalence at the country level; UN population estimates; WHO annual health expenditures; WHO 
mortality rates; and the assumption that diabetes patients incur expenditure at twice the level of 
non-diabetes patients.  
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modelling, the possible economic impact of NCDs in eleven40 PICs. We concluded (47 
p95):  
In summary, four results stand out in terms of projected economic costs of NCD 
mortality analyses in the Pacific. First, the economic burden of NCDs is greater 
than expected for middle-income countries; second, although cardiovascular 
disease is the biggest contributor to the mortality burden in the Pacific, 
diabetes plays a far greater role in the Pacific countries compared to the global 
average; third, the economic burden is increasing with time, especially as 
incomes rise; and fourth, in the absence of these four NCDs, the labour force 
could be at least 9%, and up to 30%, larger across the 11 Pacific countries.  
The second specific research gap concerns little if any published research on the 
implications of ageing on the overall health systems of the Pacific. There is some 
research on the extent of ageing in the Pacific (249-250) and some analysis of the 
implications of ageing on the health workforce in the Pacific (251-253). However, to my 
knowledge, there is no published peer-reviewed analysis of the implications of ageing 
on the overall health system, or on key aspects of a health system such as leadership 
and governance.  Chapter 5 addresses that research gap.   
The third specific research gap exists because there is limited published research on how 
Ministries of Health can better present arguments for priority setting and resource 
allocation to Ministries of Finance and / or development partners. There are several 
“investment case” articles and grey literature that advocate additional financing for 
specific diseases or maternal and child health (15, 150-152, 254-256). There is also some 
guidance on integrating aid funding, particularly in the context of Sector Wide 
Approaches (154, 257-263). There is literature on the political economy of priority 
setting and resource allocation in the health sector of low and middle-income countries, 
some of which I have contributed to (264-273). However, there are few if any articles on 
how Ministries of Health can better present arguments at a broader systems level (137, 
141, 142) and none that I could find that specifically address the situation in the Pacific. 
Chapter 6 of this thesis addresses that gap. 
                                                        
40 This was a World Bank study. The Cook Islands and Niue are not members of the World Bank so 
were not included in the study.  
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3:3 How the thesis structure addresses the general, and specific, research gaps.  
Given those general, and specific research gaps, this thesis seeks to answer five specific 
research questions and generate findings that will be central to public health and public 
financing challenges in the Pacific that have not been covered well in the literature to 
date. The five specific research questions then have a corresponding, separate, peer–
reviewed chapter in this thesis. Table 2 refers. Furthermore, each chapter leads logically 
and progressively on to the next chapter, for reasons explained below. 
To summarise, Chapters 2 and 3 aim to fill the general research gap identified in the 
previous section relating to the inability of existing literature to fully reflect the 
particular circumstances of PICs. Chapter 2 sets the scene. It provides the (then) latest 
research on the distinctive health challenges of five countries in the Pacific – Fiji, Samoa, 
Solomon Islands, Tonga and Vanuatu – and asks what are the public expenditure options 
available to those countries to respond.  Consistent with the themes running throughout 
this thesis, Chapter 2 concludes that improving technical and allocative efficiency 
through better prioritisation and allocation of scarce resources is the most urgent, 
affordable and practical option for those countries. Chapter 2 then identifies seven 
specific policy interventions41 that all PICs could consider as an agenda for 
implementation in the short to medium term. (The specific policy interventions, and 
their sequencing for implementation, will then vary between each PIC, and over time, 
depending upon the nature of the health challenge each country faces and the financial 
resources available at the time).      
Chapter 3 then asks what the health financing options are that are available to the 
Government of Samoa given its particular public health and health financing challenges. 
Chapter 3 also aims to address the specific research gap relating to health financing and 
the cost of treatment by identifying – for the first time - the cost to government of 
dialysis treatment in Samoa for (mainly) diabetes patients.  
                                                        
41 In essence, give priority to primary and secondary prevention; equity of access and outcomes; 
strengthening the evidence base for decision making; better alignment of development partners’ 
investments with national priorities; preventive maintenance of existing investments; improved 
public financial management and preparing for second round effects of scaling up.  
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Chapter 4 also addresses the existing specific research gap of what is the cost to 
government of treating specific diseases42.  In this case, the research identifies and 
publishes– again for the first time - what is the actual cost to the Government of Vanuatu 
of treating diabetes and hypertension with drugs, analysing how affordable and 
sustainable current arrangements are.  
The country-specific studies of Samoa (Chapter 3) and Vanuatu (Chapter 4) provide a 
degree of geographical and ethnic-cultural balance given that Samoa is a Polynesian 
country and Vanuatu a Melanesian country. 
Chapter 5 aims to fill the other specific research gap identified43 relating to the 
implications for the health system in the Pacific if a growing percentage of the 
population is ageing.  Given the links between ageing and NCDs (274, 275) Chapter 5  
therefore builds on, and adds another perspective, to the challenge of preventing and 
treating NCDs in an affordable and sustainable manner in the Pacific: a theme that runs 
through the rest of this thesis.   
Chapter 6 then addresses the fifth and final research question addressed in this thesis: 
what can Ministries of Health now do to improve their planning and resource allocation 
decisions? This chapter complements and rounds off the preceding chapters of this 
thesis. It does so by providing research and insight into how Ministries of Health can 
shift from presenting to Ministries of Finance and development partners poorly 
conceived and unprioritised budget proposals that are essentially just “shopping lists” 
and instead prepare genuine investment plans based on economic reasoning and 
principles. Chapter 6 has lessons for all low and middle-income countries, and uses 
investing in women’s, children’s and adolescent’s health to illustrate the principles, for 
reasons explained in section 4.6 below. Nevertheless, chapter 6 has particular 
applicability for PICs which already allocate a large share of public resources to the 
health sector and so need to demonstrate to Ministries of Finance that this is a sound 
investment if additional resources are to be forthcoming.  
                                                        
42 This is the third specific research gap. See Table 2 for details.  
43 Research question 4 as set out in Table 2. 
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Table 2 shows the relationship between the specific research questions and each 
corresponding chapter.  
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Table 1: Key socio-economic data on the 14 Pacific Island countries that are the subject of this thesis 
Country  Estimated total 
population, mid year 
2016. 
Source: Pacific 
Community (42). 
Life Expectancy in years at 
birth (total, combining 
male and female life 
expectancy) 
Source: Pacific Community 
(42). 
Human Development 
Index Ranking out of 188 
countries in 2016  
Source: United Nations 
(43). 
GDP 
$US current million in 
2016. 
Source: World Bank 
World Development 
Indicators (41). 
GDP per capita in 
current $US in 2016. 
Source: World Bank 
World Development 
Indicators (41). 
GDP per capita 
growth rate (%) in 
2016 (latest year 
available). 
Cook Islands 15,200 75.3 Not available  $NZ 413 (preliminary) 
(44)  
$NZ 21,216 
(preliminary) 
(44) 
1.6 
(preliminary) 
(44) 
Federated States of 
Micronesia  
104,600 70 Not available 329 3,143 0.54 
Fiji  880,400 67.5 91 4,703 5,233 0.36 
Kiribati  109,693 (in 2015) 62.2 137 181 1,587 0.62 
Marshall Islands  55,000 71.8 Not available  194 3,665 1.7 
Nauru 10,800 61.2 Not available  102 
 
7,821 5.54 
Niue 1,600 
 
73.2 Not available  $NZ 31,273 (45) $NZ 16,575  
(46) 
Not available  
Palau  17,800 73 60 310 14,428 0.91 
Papua New Guinea  8,151,300 54.2 154 20,213 2,500 0.3 
Samoa  194,000 74.2 104 786 4,030 6.4 
Solomon Islands  651,700 70.2 156 1,202 2,005 0.9 
Tonga  100,600 70.6 101 401 3,748 2.65 
Tuvalu  10,100 69.6  34 3,083 1.85 
Vanuatu 289,700 71.1 134 773 2,860 1.7 
Source: World Bank World Development Indicators (41) unless otherwise shown. 
Note: Countries in bold are classified by the World Bank as upper middle income.* Palau is classified high income. The remaining countries are classified as lower middle income.
                                                        
* The World Bank’s latest advice is that “For the current 2018 fiscal year, low-income economies are defined as those with a GNI per capita, calculated using the World Bank Atlas method, of $1,005 or less in 2016; lower 
middle-income economies are those with a GNI per capita between $1,006 and $3,955; upper middle-income economies are those with a GNI per capita between $3,956 and $12,235; high-income economies are those with 
a GNI per capita of $12,236 or more. Further details are available at https://datahelpdesk.worldbank.org/knowledgebase/articles/906519 
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Table 2: Summary of the research questions and the thesis structure: Five specific research questions have corresponding research findings in 
published, peer reviewed journals or publications 
Research question  Title of article where I was lead 
or sole author 
Name of journal or publication. Impact factor of the 
journal or publication 
Chapter in this thesis 
Question 1 
What are the public 
expenditure options that Pacific 
Island countries now have to 
respond to the health 
challenges they face? 
The challenges of health 
financing in five South Pacific 
countries. 
Asian‐Pacific Economic Literature, 
28: 29-46. 
2014 
0.455 according to the 
Journal Citation Report 
2016 
Chapter 2 
Question 2 
What are the health financing 
options for Government of 
Samoa given (i) the challenge to 
stem, and then reverse, the 
rapid rise of NCDs and (ii) to put 
the country on a health-
financing path that is effective, 
efficient, and financially 
affordable and sustainable.  
Health Financing Options for 
Samoa: Challenges and 
Opportunities. 
World Bank Health Nutrition and 
Population Discussion Paper Series. 
2013 Report Number 89506* 
See footnote † Chapter 3  
Question 3 
What is the cost to government 
of treating a specific disease at 
the country level, and what are 
the public policy implications? 
The costs and affordability of 
drug treatments for type 2 
diabetes and hypertension in 
Vanuatu. 
Pacific Health Dialogue, the Journal 
of Community Health and Clinical 
Medicine for the Pacific Region., 
19: 1. 2013 
0.33 according to the 
Research Gate 
methodology.‡ 
Chapter 4  
                                                        
* This paper has been revised prior to inclusion in the thesis to incorporate additional and original research findings on the cost of dialysis treatment for (mainly) diabetes to the Government of Samoa. See the start of 
Chapter 3 for further discussion. 
† The HNP Discussion Paper series is a high profile, high status, long running set of publications designed to encourage discussion and debate in the international community about current issues in health policy especially 
affecting low and middle-income countries. In July 2017 the World Bank website says this particular document where I was the sole author has been downloaded 559 times since January 2014. 
‡ In consultation with my co-authors I specifically chose this journal as it is published by, and targets, the Pacific Basin Medical Officers Training Program and the Fiji School of Medicine.  
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Research question  Title of article where I was lead 
or sole author 
Name of journal or publication. Impact factor of the 
journal or publication 
Chapter in this thesis 
Question 4 
What are the public policy 
implications for the health 
system in the Pacific if a 
growing percentage of the 
population is ageing, and 
largely living with ill health and 
chronic, expensive to treat 
diseases? 
The implications of aging on the 
health systems of the Pacific 
Islands: challenges and 
opportunities. 
Health Systems & Reform. 2017. 
Volume 3 
See footnote § Chapter 5  
Question 5 
What can Ministries of Health 
now do to improve their 
planning and resource 
allocation decisions? 
How can health ministries 
present persuasive investment 
plans for women’s, children’s 
and adolescents’ health? 
Bulletin of the World Health 
Organization, 94: 468-74. (2016) 
5.089 in 2014 according to 
the Web of Science 
ranking. 
Chapter 6 
Note: The layout of Chapters 4-6 is as per the journal in which the article was published. Chapter 2 is a Word document of the Journal article, as per the Journal’s request. Chapter 
3 is a revised version of the original Discussion Paper as published (the linking page to Chapter 3 provides details of the changes).  
 
                                                        
§ Health Systems & Reform commenced in April 2015 so does not have an impact factor at this stage. However, the Editors in Chief are Professor Michael Reich from Harvard University and Dr Joseph Antoun of the 
University of Chicago. 
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Section 4: Research method. 
To address the research questions identified in Table 2 I used a combination of literature 
searches, analysis of publicly available data bases, analysis of country specific 
expenditure data, and discussions with officials. These methods are the most 
appropriate research tools given the research questions that drive this thesis for the 
reasons outlined below in Sections 4:1-4:4. 
I did not use Randomised Control Trials or economic modelling as those research 
techniques are not particularly suited to the gaps in the international literature that I 
have identified in Section 3 above.   I did consider the possibility of comparing the public 
expenditure costs (and health outputs / outcomes) of the National Kidney Foundation 
dialysis centre in Samoa with dialysis treatment in neighbouring American Samoa, as the 
similar ethnic composition, diabetes prevalence, and culture could have generated some 
useful contrasts and insights. However, it was not practicable to do so in the time 
available.      
4:1 Literature searches. 
Each of the chapters involved extensive review of peer-reviewed and grey area 
publications. Each of the chapters in this thesis, including literature surveys for Chapter 
1, provide a list of references directly cited as part of the research. Many other peer-
reviewed and grey literature resources were consulted, but have not necessarily been 
cited. The specific search strategy varied for each chapter. Care was taken to use 
inclusive search terms. For example, when researching public health challenges in the 
Pacific I used a combination of search terms including “public health”, “health 
challenges”, “health sector”, “health”, “life expectancy”, “death”, “mortality and 
morbidity” in combination with terms such as “Pacific Islands”, “Oceania”, and individual 
country names. The fact that all search terms were in the English language is not a 
particular constraint or source of bias because all fourteen countries that are the subject 
of this thesis have English as the main language for academic literature and official 
reports.  
The thesis draws on reports and documents published by the World Bank and the World 
Health Organization, particularly in Chapters 2 and 3. This is intentional. I have already 
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shown in Sections 3:2 and 3:3 that there is surprisingly limited published peer-reviewed 
material on health financing issues in the Pacific, despite the importance of those issues 
to the PICs themselves and the uniqueness of the situations in a global context. Making 
use of recent analysis by the World Bank and WHO in the academic articles I wrote 
therefore acts as a bridge in knowledge-sharing between reputable international 
organisations concerned with health financing and the broader international academic 
community.  
The academic validity and reliability of the World Bank and WHO reports is acceptable 
in a thesis of this nature given that all such World Bank reports were subject to stringent 
peer review1, and checking with the governments of the countries concerned, prior to 
publication.  As a further test of the academic validity and reliability, the World Bank and 
WHO reports were also acceptable to the (unidentified) peer-reviewers of all the 
academic journals.  
4:2 Analysis of publicly available on-line data bases. 
I accessed publicly available on-line data bases containing relevant information on 
health systems, and public expenditure, from several international sources. These 
included, in alphabetical order: Demographic and Health Surveys; the IHME data base; 
the International Monetary Fund; Secretariat of the Pacific Community; the World Bank; 
and the World Health Organization. These sources are cited in each of Chapters 2 to 7. 
To update and extend the analysis in Chapter 1, I continued to interrogate and analyse 
publicly available data bases. I then generated all the Figures in this Chapter. At the 
country level I analysed publicly available national budget documents and reports 
including National Health Accounts and publicly available Annual Reports of Ministries 
of Health and / or Ministries of Finance and National Planning.  
                                                        
1 Usually internal peer review, but occasionally involving senior country officials and / or development 
partners with direct experience of the country concerned. Internal peer review personnel from the 
World Bank were always senior professional grade officials, always involving at least one person from 
another geographical region of the World Bank to facilitate dispassionate and objective comments. Peer 
reviewers for articles I researched and wrote for the World Bank (for example Chapter 3) were drawn 
from the World Bank’s team working on health financing issues in the Caribbean as that involved 
another perspective on health financing in small island states.  
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4:3 Analysis of country-specific expenditure. 
I sought and used all the available Annual Reports of the National Kidney Dialysis centre 
in Apia to analyse the public expenditure implications of diabetes related kidney 
treatment in Samoa (chapter 3). I used the latest, current, financial and cost data 
available from the Central Medical Store in Vanuatu to generate the public expenditure 
implications of diabetes and hypertension prevention and control in Vanuatu (chapter 
4). In both Vanuatu and Samoa I checked my cost estimates and research findings with 
the senior most officer in-country responsible for those programs. 
There are factors that make the estimates of the cost of treating diabetes in Samoa 
(chapter 3) and diabetes and hypertension in Vanuatu (chapter 4) reliable.  More 
specifically, the then current cost data for pharmaceuticals in Vanuatu came from the 
government’s Central Medical Store. This is the sole source of purchasing and dispensing 
pharmaceuticals in the public sector so gives confidence that such data represents the 
true cost to the public health budget in Vanuatu. Similarly, the cost data for diabetes 
patients in Samoa was genuinely representative of the actual cost to government 
because I used the then current data from the National Kidney Foundation, the only 
public (or private) dialysis centre in Samoa.  
I deliberately took the most conservative approach to estimating costs. For example, in 
Vanuatu we restricted the analysis to just pharmaceutical costs, deliberately excluding 
nurse costs and other overheads which were nevertheless also borne by government. 
To further ensure a conservative approach we also assumed that patients did not have 
co-morbidities or particular complications.  These research approaches were explained 
in the published articles so that other researchers and policy makers could have 
confidence in the costing estimates that had hitherto never been published before.    
I received formal approval from the Governments of Samoa and Vanuatu, and from the 
World Bank, to publish the underlying data and the findings (see Ethical Approval at 
Section 4:5 below). 
4:4 Meetings with relevant officials.  
I met a range of government officials from Ministries of Health as well as Ministries of 
Finance / Planning as part of the research for chapter 3 (Samoa) and chapter 4 
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(Vanuatu).  I also met with senior officials from the Australian and New Zealand bilateral 
aid agencies as well as multilateral agencies working in the health sector of Samoa and 
Vanuatu including Secretariat for the Pacific (SPC), UNICEF, World Bank and WHO. All 
were aware in advance of the discussions that the research would be published, and 
that individual’s comments would not be directly quoted or cited in a way that identified 
them.  
The international meeting that triggered the research and writing of Chapter 6 involved 
views being expressed by senior representatives from 48 countries and organisations, 
including previous Ministers of Health and Heads of Departments of Health. At the 
outset of that international meeting I explained, as Chair, that all discussion was under 
the Chatham House rule2. Chapter 6 therefore takes into account informed views by 
senior officials expressed at the international meeting but does not cite or identify any 
individual or institution.        
4:5 Ethical approval.  
Ethical approval for the research undertaken for this PhD was granted by Curtin 
University on 19 June 2014. I undertook the Research Integrity Training Course while at 
Curtin University in 2014. 
Prior approval to undertake research and publish the findings was arranged by the 
World Bank with respect to chapter 3 (Samoa) and chapter 4 (Vanuatu) before I entered 
those countries. I gave the Government of Samoa, and the Government of Vanuatu, an 
opportunity, in writing, to comment on drafts of the articles that now appear as Chapter 
3 and Chapter 4. No objection was raised. I obtained confirmation, in writing, from the 
World Bank Sector Manager for East Asia and the Pacific, as well as the World Bank 
Senior Health Economist, PNG and Pacific, that there was no objection to me using the 
analytical work and findings that I undertook as part of paid consultancy assignments of 
the World Bank in my Ph D or publishing the reports. This confirmation is available on 
request. 
                                                        
2 Chatham House defines that rule as “When a meeting, or part thereof, is held under the Chatham 
House Rule, participants are free to use the information received, but neither the identity nor the 
affiliation of the speaker(s), nor that of any other participant, may be revealed.” Further details are 
available at https://www.chathamhouse.org/chatham-house-rule 
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I undertook and passed the Research Integrity Training course in 2014. I am aware of 
the Australian Code for the Responsible Conduct of Research, and ANU’s policies on 
research integrity. I am a member of the Australasian Evaluation Society, the 
International Health Economics Association, and the Australian Institute of 
Management, and am bound by their codes of conduct including the requirement for 
fair, accurate, dispassionate, professional and unbiased treatment of evidence.  
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Annex 1: Life expectancy in the Pacific 
Table Annex 1: Life expectancy is plateauing for males in 8 countries of the Pacific 
and for females in 7 countries of the Pacific 
Age group Males life 
expectance 
increasing 
trend 
Males life 
expectancy 
plateauing 
trend 
Females life 
expectancy 
increasing 
trend 
Females life 
expectancy 
plateauing trend 
≥ 80 years     
75-79 years   Niue  
70-74 years Cook Islands; 
Niue; Republic 
of the Marshall 
Islands; 
Samoa. 
 Cook Islands; 
Republic of the 
Marshall 
Islands; 
Federated 
States of 
Micronesia; 
Samoa; 
Solomon 
Islands; 
Vanuatu. 
Tokelau; Tonga; 
Palau; Kiribati. 
65-69 years Solomon 
Islands. 
Vanuatu.  
Federated 
States of 
Micronesia; 
Fiji; Palau; 
Tokelau; 
Tonga.  
Tuvalu. Fiji 
60-64 years Tuvalu.    
55-59 years  Kiribati  Nauru 
< 50 years  Nauru; PNG  PNG 
Source: Linhart et al (2014) (276). 
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Introductory note: Relationship between Chapter 1 and Chapter 2 
Chapter 2 researches the policy responses available to five Pacific Island countries: Fiji, 
Samoa, Solomon Islands, Tonga, and Vanuatu. Chapter 2 addresses the general research 
gap identified in Chapter 1: that existing literature on priority setting and resource 
allocation in middle-income countries does not adequately capture the distinctive public 
health and public financing characteristics of the Pacific. Chapter 2 identifies a common 
theme among all five Pacific Island countries: improved prioritisation and resource 
allocation is the most strategic available policy option to respond to the public health 
and public financing challenges they face. 
For copyright reasons, Chapter 2 is the pre-publication version of the article, accepted 
by the journal Asia Pacific Economic Literature (APEL) for publication. The attached 
chapter was then published in May 2014 in Asia Pacific Economic Literature Volume 28 
Issue number 1, pages 29-46 with some copyediting changes to suit the journal format 
(but which did not alter the substance of the article). The published article is available 
from the Asia Pacific Economic Literature journal here: 
 http://onlinelibrary.wiley.com/doi/10.1111/apel.12052/abstract  
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Chapter 2: The challenges of health financing in five South 
Pacific countries 
Ian Anderson, Susan Ivatts, Aparnaa Somanathan, and Benjamin Rolfe1 
 
Abstract 
Health is a central development issue. Arrangements for health financing also have 
important implications for national and household budgets and broader 
macroeconomic conditions. The latest evidence from Fiji, Samoa, Solomon Islands, 
Tonga and Vanuatu shows these five South Pacific countries have substantial – and 
changing – health challenges, especially given rapid population growth and the rise of 
noncommunicable diseases. Yet each country faces important constraints to expanding 
public expenditure on health. Several options for obtaining better health outcomes for 
health expenditure are canvassed: improving technical and allocative efficiency is the 
most urgent, affordable and practical option. An agenda for action is provided.  
Key words: health financing; fiscal space; South Pacific; Fiji; Samoa; Solomon Islands; 
Tonga; Vanuatu.  
 
1. Background and context 
Health is a central issue in development. Healthier people are potentially more capable 
of learning at school; being productive at work; living longer and therefore changing 
                                                        
1 Ian Anderson, Centre for International Health, Curtin University, Western Australia; Economic 
Consultant, World Bank., Canberra, Australia. E-mail: ian.anderson.economics@gmail.com; Susan 
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Economist, Human Development Sector, World Bank, Colombo, Sri Lanka and Benjamin Rolfe, 
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(AusAID) Canberra, Australia.  
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incentives and opportunities for accumulating savings at both the household and 
macroeconomic level; and reducing expenditure on often otherwise preventable health 
expenditure that could have been spent on other, perhaps more productive, alternative 
uses (Spence M and Lewis M 2009) (Giullem Lopez-Casasnovas 2005) (IMF 2004) 
(Commission on Macroeconomics and Health 2001) (Sen 1999). Health services, 
including family planning, contribute to strategic and beneficial changes in the 
population size and structure of society, potentially leading to a ‘demographic dividend’. 
Estimates suggest that between 30% and 50% of Asia’s economic growth  between 1965 
and  1990 can be attributed to favourable demographic changes, including reductions in 
total fertility rate, and infant and child mortality (Bloom DE and Williamson JG 1998). 
Health affects development at the household level as well. The poor tend to have higher 
health burdens due to environmental and other social determinants; have more 
children; are less likely to seek medical care when needed; and can be tipped below the 
poverty line as a result of   out of pocket payments. There is emerging evidence that 
maternal health and birthweight are also associated with subsequent incidence of 
obesity and chronic non-communicable diseases (NCDs) including diabetes and high 
blood pressure in later life (Adair, Fall et al. 2013), (Bhutta 2013), (Barker D 1990).  
The level, sourcing, and nature of health expenditure also have important financial, 
budgetary, and macroeconomic implications. How much a country should spend on 
health care is a vexed question (Baltussen 2006, Savedoff W 2007). However, population 
growth, more people living to old age, new technologies, and rising incomes combine to 
generally increase expenditure pressures on health over time. Demand for health 
services grows at an average rate 20 % higher than overall economic growth rates in 
middle income countries (Langenbrunner J and Somanathan A 2011).  Wagner’s Law 
suggests that as countries get richer they do not only spend more in absolute terms on 
health (and education): they also spend a higher proportion of their resources on those 
sectors (Tandon A 2006).  Many of the determinants of health outcomes - including 
genetics, lifestyle factors, female empowerment, education levels, and poverty - lie 
outside the formal health sector but many of the costs of ill health are then ultimately 
borne within the government financed health sector or in some countries by 
households.  
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This paper shows that achieving adequate – but sustainable – health financing is a 
particular challenge in the Pacific.  This is partly because population growth and the rise 
of NCDs are putting increasing demands on the health system (Section Two below). It is 
also a challenge because Pacific governments already shoulder most of the health 
expenditure and have limited options to spend more (Section Three below).  This paper 
draws on several recent analytical reports that highlight the challenges and options of 
sustainable health financing in five countries of the South Pacific:  Fiji (WHO 2011, 
Rannan-Eliya R 2013), Samoa (World Bank 2013), Solomon Islands (World Bank 2010) 
(World Bank 2011), Tonga (World Bank 2012), and Vanuatu (World Bank 2013) (World 
Bank 2012). Section Four of this paper identifies options to respond to these challenges 
based on the recent reports. Section Five provides a recommended agenda for action.   
2. The health challenges in the five countries of the South Pacific.  
Despite some important differences, there are some features common to all five 
countries. All  are classified as lower-middle income,2 with a combined population of 
1.95 million in 2011. As seen in Table 1 below, all have relatively small populations, small 
Gross National Incomes (GNIs), and per capita incomes. All five countries have achieved 
some substantial health gains. Infant mortality has been falling (World Bank 2011). Life 
expectancy has generally been increasing, although life expectancy in Fiji and Tonga has 
recently fallen due to the rise of NCDs (World Bank 2012) (World Bank 2011).  There is 
generally a negligible difference in access to health care or health outcomes based on 
gender, but gender-based violence is a serious issue in many countries (AusAID 2009, 
Moriaty A 2012). The widespread use of government financed, usually ‘free’, health 
services means there is a high level of financial protection against out of pocket, 
‘catastrophic’ health expenditure that otherwise impoverishes individuals or 
households.  However poor quality health services leave little protection when ill health 
subsequently affects income generation and livelihoods. 
 
                                                        
2 Lower middle-income countries have a Gross National Income per capita of $ 1026 - $ 4035 in 
2011 using the World Bank Atlas method. 
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Table 1: Key macroeconomic and health indicators 
 Fiji Samoa Solomon 
Islands 
Tonga Vanuatu 
Population size (2012) 874,742 188,889 549,598 104,941 247,262 
      
Basic needs poverty (%)* 35 27 23 23 13 
GNI per capita, Atlas 
method $US (2012) 
4,200 3,220 1,130 4,240 3,080 
      
Life expectancy, total 
(2011) 
69 73 68 72 71 
Infant mortality rate per 
1000 births (2011) 
14 16 18 13 11 
Maternal mortality rate, 
per 100,000 live births* 
23 (2010) 46 
(2006) 
100 (2008) 37 (2010) 86 (2007) 
 
Health workers per 
1,000 population** 
No data 21.6*** No data 7.52 5.47 
Source: World Development Indicators, *Pacific MDG Tracking Report 2012, ** Health Service Delivery 
Profiles 2012 Samoa HRD Project: Analysis of HRD Priorities Stewart Forsyth and Tyrone Laurenson July 
2013. 
Demographic pressures 
Demographic pressures are putting additional demands on health financing in all five 
countries.  As shown in Figure 1, all five countries except Fiji have a Total Fertility Rate 
(TFR) higher than the global average for other lower middle-income countries of 2.9 
births per woman. A high TFR places significant ongoing demands on maternal, newborn 
and child health services (as well as expenditure on public education) in the short term, 
and increased health care needs for populations growing old in the long term.  A high 
TFR is also associated with a rapidly growing total population although this tends to be 
offset by out-migration in the Polynesian countries of Samoa and Tonga.   
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Figure 1: Total fertility rate, 2010 
Source: WHO (WHO 2011). 
Population growth rates - past and present - influence the structure, as well as the total 
size, of the population and have economic consequences.  But the tangible benefits and 
‘demographic dividend’ of having a large share of working age population only arise if 
men and women can find productive employment, earn incomes, and pay taxes. This is 
by no means assured in the five countries where formal sector employment 
opportunities are limited (World Bank 2013).  Fiji, Solomon Islands and Vanuatu are “off 
track” to achieve Millennium Development Goal 1b (‘to achieve full and productive 
employment and decent work for all, including women and young people’) while Samoa 
and Tonga are judged to have ‘mixed progress’ (Pacific Islands Forum Secretariat 2012).   
Communicable diseases, maternal and newborn health, and nutrition 
There is an unfinished agenda of communicable, maternal, newborn, and nutritional 
challenges. Figure 2 shows that communicable, maternal, perinatal and nutritional 
challenges are still the cause of nearly one fifth (18%) of all deaths in Fiji, more than 20% 
in Samoa, Tonga and Vanuatu, and over one third (35%) deaths in Solomon Islands. The 
Solomon Islands has one of the highest incidence of malaria in the world outside of 
Africa (World Bank 2010). Under-nutrition is a challenge: 20 % of children less than five 
years of age in Vanuatu were moderately stunted (low height for age), 16 % moderately 
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underweight (low weight for age) and 6.5 % moderately wasted (low weight for height) 
(UNICEF 2012, World Bank 2013). Measles vaccines coverage in Vanuatu – an indication 
of the overall effectiveness of service delivery in a health system - was estimated at just 
37.2% for children in 2009 (UNICEF 2012) although subsequent catch up campaigns 
improved vaccination coverage (Tyson S 2012) (Government of Vanuatu 2013).  Latest 
analysis finds that rates of progress in reducing maternal, infant and child deaths fall ‘far 
short’ of achieving MDG targets in Fiji (WHO 2011) with another report concluding that 
Fiji’s maternal mortality ratio of 26/100,000 live births is ‘off track’ for achieving MDG 5 
(WHO 2012). Sexually transmitted infections are relatively high in many of the countries. 
For example, possibly 40.7 % of 300 ante-natal women under 25 years of age had 
chlamydia in Samoa (World Bank 2013).  There is also a need for expanded reproductive 
health services in most countries of the South Pacific. The Contraceptive Prevalence Rate 
(CPR) for all five countries ranges from 27% in Tonga to 38% in Vanuatu: still well below 
the average CPR of 62% for developing countries globally. (Pacific Islands Forum 
Secretariat 2012).  
 
Figure 2: Importance of communicable, MNCH, and noncommunicable diseases 
Source: WHO (WHO 2011). 
0 10 20 30 40 50 60 70 80 90
Vanuatu
Tonga
Solomon Islands
Samoa
Fiji
Per centage of all deaths
Importance of communicable, MNCH, and 
NonCommuniable diseases
Communicable, maternal, perinatal and nutritional conditions
NonCommunicable Diseases, especially cardiovascular disease
Chapter 2 
84 
Non-communicable diseases 
All five countries also face a growing challenge of NCDs especially cardiovascular disease, 
cancer and diabetes. Figure 2 shows that NCDs now account for more than three 
quarters (77%) of all deaths in Fiji and well over half (60%) of all deaths even in the 
Solomon Islands.3 Although cause of death data are patchy, cardiovascular disease is 
considered to be the major cause of death in all five countries (WHO 2011). Importantly, 
many of these NCD related deaths are premature (before age 60).  Figure 3 shows that 
men die prematurely from NCDs in all five countries in the Pacific at rates higher than 
the average for low income4 countries globally, with Fiji’s rate more than double that of 
the global average.5 Figure 4 shows more than one third of female NCD related deaths 
in Vanuatu, Solomon Islands, and Fiji are premature, at or higher than the global average 
for low income countries. Life expectancy has decreased in Fiji (WHO 2011) and Tonga 
(World Bank 2012) particularly as a result of NCDs.  
                                                        
3 Injuries across the South Pacific tend to be a small percentage of deaths (around 5%) but an 
important source of morbidity including violence to women. 
4 Estimates are not available for lower middle-income countries. 
5 45.6% of all NCD male deaths in Fiji occur below age 60, compared to 22% for low income 
countries globally. 
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Figure 3: Premature (less than age 60) deaths of males 
Source: WHO (WHO 2011). 
 
Figure 4: Premature (less than age 60) deaths of females 
Source: WHO (WHO 2011). 
NCDs are also an important determinant of morbidity, including strokes, and diabetic 
related amputations and blindness. Diabetes is now the leading cause of morbidity in 
Fiji, and some estimates suggest that Fiji now has the third highest prevalence of 
diabetes in the world (WHO 2011). In Vanuatu, diabetes vascular disease is the most 
common reason for admittance to surgery wards, representing around half of all 
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patients admitted at Vanuatu’s Northern District Hospital and one quarter at Vila Central 
Hospital.  Diabetes and stroke are now estimated to be the leading two causes of 
premature death in the Solomon Islands in 2010, displacing lower respiratory infections 
and diarrheal diseases: the two leading causes in 1990 (IHME 2013). 
Importantly, all five countries have widespread risk factors that are feeding a future 
pipeline of increased incidence of NCDs unless very strong and effective promotive and 
preventive measures are taken. The recent WHO NCD STEPS survey in Vanuatu found 
that more than one fifth (22 %) of adults of working age (25 – 64 years) have three or 
more risk factors for acquiring any NCD. Only around 10% of adult men and 5% of adult 
women did not demonstrate signs of any of the major NCD risk factors (World Bank 
2013). In Samoa, WHO confirm that NCDs ‘including obesity, diabetes, heart disease, 
high blood pressure, stroke and cancer, are a top health priority, with high and 
increasing prevalence rates: the obesity rate is currently 57.0%, the diabetes rate is 
23.1% and high blood pressure rate is 21.4%’ (World Bank 2013).   The average weight 
for a woman in Tonga increased by 21.1 kg over 30 years to reach 95 kg, and increased 
by 17.4 kg to reach 95.7 kg for men: overweight being a risk factor for various NCDs 
including heart disease and diabetes (World Bank 2012). Recent Global School Based 
Student Health Surveys also identify important risk factors for NCDs among 13- 15 year 
olds in all five South Pacific countries. Nearly one quarter of boys in Tonga and more 
than one fifth of girls in Samoa are obese;6 at least one third of children drank 
carbonated soft drinks one or more times a day; and around 42% of 13-15 year old boys 
in Samoa smoked cigarettes on one or more days during the past 30 days.  
3. Are health financing systems in the five countries well placed to 
respond to these health challenges? 
Health expenditure is relatively high in the five countries of the Pacific on several 
measures. As seen in Table 2, total health expenditure per capita is significantly and 
consistently higher than the average for other lower middle-income countries, in 
Samoa’s case more than three times higher than other lower middle-income countries 
spend globally.  Table 2 also shows that total health expenditure is dominated by 
                                                        
6 > + 2 Standard Deviations from median for Body Mass Index for age and sex. 
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government public expenditure. More specifically, over 80% of total health expenditure 
in Samoa, Solomon Islands, Tonga and Vanuatu comes from government, often 
supported by aid donors, more than double the average 36.4% share in lower middle-
income countries globally.  And if government looms large in total health expenditure in 
these five Pacific countries, health also looms large in their respective government 
budgets.  One quarter of the total government budget, including external funds,  in 
Samoa and Solomon Islands is now devoted to the health sector, more than three times 
the level of lower middle-income countries globally. 
Table 2: Health expenditure characteristics in 2011 
Health 
expenditure 
characteristics  
Fiji Samoa Solomon 
Islands 
Tonga  Vanuatu Lower 
Middle 
Income 
Countries 
average 
globally 
Health 
expenditure 
per capita 
(current US$) 
167 248 133 219 133 79 
Health 
expenditure 
per capita PPP 
(constant 
2005 
International 
dollars) 
183 321 259 245 190 160 
Public health 
expenditure as 
a % of total 
health 
expenditure 
68 88 94.7 83.5 87 36.4 
Public health 
expenditure as 
a % of total 
government 
expenditure 
9 25 25.4 15.7 15 7.6 
Total Health 
Expenditure as 
% of GDP 
3.8 7.0 8.8 5.25 4.1 4.2 
Source: (World Bank 2014). 
The relatively large role of public health expenditure in the five countries therefore 
raises questions about the sustainability of current financing arrangements. This is 
especially true in the face of current demographic and epidemiological trends, and 
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limited prospects for economic growth.  This is a consistent theme in the recent analysis 
of all five countries.  
For example, the latest analytical work on Fiji noted that total hospital admissions 
increased by 19% in the five years to 2008, compared to a 4.5% population increase over 
the same period. The average length of stay in hospitals also increased, from 4.5 to 6.3 
days, putting further pressure on health budgets (WHO 2011). Another recent report 
finds a failure to achieve productivity improvements in Fiji Ministry of Health since the 
mid-1980s, particularly in terms of hospital inpatient turnover and average length of 
stay (Rannan-Eliya R 2013).   
The rise in chronic NCDs is also putting significant – and sometimes unsustainable -  
additional pressure on health budgets: one patient requiring insulin absorbs the 
equivalent notional drug allocation of 76.4 other citizens in Vanuatu. Only 1.31% of the 
total population could be treated with insulin before the total government 
pharmaceutical and medical supplies budget was used up (World Bank 2013).  The 
estimated average total cost of dialysis for patients with diabetes related kidney failure 
to the Government of Samoa was $ 38,686 per patient per year in 2010/11. While less 
than the previous approach of sending patients to New Zealand, the cost to Government 
is still more than twelve times the Gross National Income of Samoa. The cost-
effectiveness of dialysis is further undermined by the fact that almost two thirds have 
died two years after commencing treatment.  
Overseas medical treatment also imposes large – and growing - costs on public health 
systems. The Samoa Overseas Medical Visits Treatment Scheme (OVT) program, which 
exists to send usually complex NCD cases to Australia or New Zealand for treatment, 
absorbed 15 % of total public health expenditure in 2009/10, to the private benefit of 
less than 0.1 % of the nation’s population. OVT absorbed 11 % of total public health 
funding in 2008/9, but this had grown to 15 % by 2009/10. Expenditure on OVT almost 
matched the entire public expenditure on outpatient curative care in 2006/7.  Since that 
study was undertaken, expenditure on OVT has continued to grow. Total expenditure 
on OVT has increased 30 % in nominal terms since 2007/8. Expenditure on the OVT 
scheme is now 30 % higher than the total personnel costs at the main hospital in Apia 
and associated allied services.  Public expenditure on OVT ($T10.5 million in 2011/12) is 
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larger than the total budget of at least ten other important government departments or 
authorities, including the Ministry of Women, Community, and Social Development; 
Ministry of Revenue; the Ministry of the Prime Minister; and the Legislative Assembly 
(World Bank 2013). 
In summary, faced with growing populations and changing disease profiles, 
Governments cannot continue with a ‘business as usual’ approach to health financing.  
Governments need to increase their capacity for health expenditure (‘fiscal space’7) but 
in ways that are economically and administratively efficient; politically and financially 
sustainable; and retain the best features of existing health financing arrangements. The 
following section summarises analysis from the recent reports about the options. 
4. Options for health financing in the face of increased pressures 
Sustained economic growth as a source of increased government revenues  
In principle, sustained economic growth is the most obvious and fundamental option for 
generating increased government revenues to meet rising pressures for health care. 
However, history shows (Figure 5) that all five countries have been subject to volatile 
changes in GDP growth. This reflects the vulnerability of the Pacific Island countries to a 
variety of external and internal economic shocks including cyclones and tsunamis, 
political instability, and global economic downturns. As a result, growth in GDP per 
capita has also been volatile (Figure 6). Importantly, trends in real (taking into account 
inflation) GDP per capita over the longer term have also been quite volatile (Figure 7).  
Figure 7 shows that real GDP per capita is lower in the Solomon Islands than it was in 
1995; and that real GDP per capita has been generally flat in Fiji, Samoa, and Tonga from 
around 2005.  
                                                        
7 ‘Fiscal space’ has been defined by Heller as ‘the capacity of government to provide additional 
budgetary resources for a desired purpose without any prejudice to the sustainability of its 
financial position’. Tandon and Cashin further state that ‘fiscal space exists when a government 
has budgetary room to increase spending and can do so without impairing fiscal solvency, i.e. the 
government’s present and future ability to cover its recurrent expenditures and service its debt’.  
Chapter 2 
90 
 
Figure 5: GDP growth (annual % change) 
Source: World Bank (World Bank 2013). 
 
Figure 6: Annual percentage change in GDP per capita  
Source: World Bank (World Bank 2013).  
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Figure 7: GDP per capita, constant 2005, PPP 
Source: World Bank (World Bank 2013). 
History therefore suggests that the five countries cannot necessarily rely on sustained 
economic growth to expand fiscal space for health. Recent analysis also confirms that 
Pacific Island countries face a suite of unique geographical and political economy 
circumstances constraining rapid economic growth. These constraints include small 
population size (preventing economies of scale in the private sector as well as in 
government service delivery); distance from markets; high cost structures; political 
instability and / or volatile political coalitions that inhibit economic reform; 
unsustainable rent seeking from natural resources; and land ownership and contract 
enforcement practices that inhibit private investment (Duncan Ron (Editor) 2011, World 
Bank 2011, Duncan R 2012). Even if future economic growth was strong and stable, 
governments would need to have the political will and administrative capacity to raise 
increased revenue from taxes, including from the often large informal sector.  
Increased share of government expenditure going to the health sector 
In the absence of reliable, economic growth over the long run, an option for many 
developing countries would be to increase the share of government expenditure going 
to health. However, this is not a realistic option in the case of these five countries where 
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government expenditure on health (including support from development partners) is 
already above 15% of total government expenditure in all countries except Fiji, and at 
25% for Samoa and Solomon Islands (Figure 8).  Furthermore, Ministries of Finance, and 
development partners, would be reluctant to increase the share of expenditure going to 
the health sector when they have concerns about chronic overspending, underspending, 
as well as other problems with basic public financial management. 
 
Figure 8: Public health expenditure as % total government expenditure 
Source: World Bank (World Bank 2013). 
Increased reliance on development partners 
Increased reliance on development partners is a theoretical option but one with 
practical limits in current circumstances and with certain risks. That is because external 
resourcing for health is already more than 20% of total health expenditure in all five 
countries except Fiji, and up to 45% in the Solomon Islands (Figure 9). External 
resourcing is also volatile (Figure 10) leaving Pacific island countries vulnerable to 
shortfalls in ongoing programs (World Bank 2010). Development partners may also be 
reluctant to expand their financial contribution to the health sector if they have 
reservations about the effectiveness, efficiency, and value for money of expenditure to 
date. They will also be reluctant to increase their own expenditure in the health sector 
 -
 5.0
 10.0
 15.0
 20.0
 25.0
 30.0
 35.0
 40.0
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
%total 
government 
expenditure
Public health expenditure as % total 
government expenditure
Fiji Samoa Solomon Islands Tonga Vanuatu
Chapter 2 
93 
if they believe this displaces or substitutes for government’s own expenditure effort or 
are facing their own budgetary constraints.  
 
Figure 9: External resources as % total health expenditure, 2011 
Source: World Bank (World Bank 2013). 
 
Figure 10: External resources as % total health expenditure 
Source: World Bank (World Bank 2013). 
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User fees 
User fees for government services are very low in most of the countries. Total receipts 
from all sources in the health sector in 2011/12 in Samoa were projected to be just $US 
25,000, or just 0.08 % of the total Government appropriations to the health sector in 
that year (World Bank 2013). On the other hand, citizens of Samoa (World Bank 2013) 
and Vanuatu (World Bank 2013) are prepared to pay quite high amounts for perceived 
services from traditional healers, in Vanuatu’s case around ten times the current 
government user fees where they exist. However several reports cast doubt on whether 
imposing user fees is an effective, efficient, equitable, or politically sustainable approach 
to expanding fiscal space (Yates 2009, WHO 2010, Sachs 2012).  Reports  note that user 
fees often act as a barrier to health care, especially for the poor, and require good 
administrative systems as well as involving costs,  in collecting and targeting fees 
(Gottret and Schieber 2006, World Bank 2010).  Experience in Fiji suggests user fees have 
not been a source of additional revenue generation: generating an average of just 0.83% 
of health expenditure over the period 2003 -2008. Recent analysis for Fiji also notes that 
‘despite the fact that fees were based on costs in the 1940s, they have remained largely 
unchanged, apart from some minor modifications in the early 1980s’  (WHO 2011).   
Social Health Insurance 
Social Health Insurance8 (SHI) has been discussed as a means of generating additional 
revenue for the health sector in some countries, and Samoa passed legislation allowing 
it to be introduced at some time in the future. However, all the recent analytical reports 
are clear that SHI is not an appropriate source of health financing in the Pacific for the 
foreseeable future. As noted in the case of the Solomon Islands: 
Far from being an additional source of revenue for health, it is likely to be a 
further drain on Solomon Islands Government revenues, as additional 
government spending will be required to scale up insurance…. In the Solomon 
Islands, weak economic growth prospects and the need for fiscal restraint in 
the short to medium term would rule out any substantial increase in 
government subsidies to finance the scaling up of SHI. Significant additional 
                                                        
8 Social Health Insurance has been defined as ‘generally characterised by independent or quasi-
independent insurance funds, a reliance on mandatory earmarked payroll contributions (usually 
from individuals and employers) and a clear link between these contributions and the right to a 
defined package of benefits’ Gottret, P. and G. Schieber (2006). Health Financing Revisited:  A 
Practitioner’s Guide,  World Bank. Washington DC.  
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health spending would be needed to expand SHI to the 80% or more of the 
population that is in the informal sector. Moreover, the establishment of SHI 
involves relatively high start up costs, which will also have to be financed 
through general revenues. (World Bank 2010) 
A World Bank study (World Bank 2013) of health financing options in Samoa cited  recent 
research that found   
‘SHI is complicated and implementation takes many years; achieving universal 
population coverage has taken decades in most countries; benefit packages 
must be explicit and costed carefully; user fees must be in place and must be 
sufficient to motivate populations to join SHI voluntarily; stakeholders must be 
convinced of the actuarial soundness of SHI; SHI agencies need to be able to 
negotiate and implement purchasing and provider payment mechanisms that 
ensure delivery of services and goods at minimal cost’.  
That study also noted that Samoa still had a relatively small formal sector and that ‘the 
existence of compulsory SHI premiums, on top of compulsory income taxation, may 
actually discourage individuals from joining the formal sector: the opposite of 
Government intentions’. 
Reports for Fiji, Tonga and Vanuatu come to similar conclusions.  A specific study 
assessing the feasibility and desirability of SHI in Fiji concluded that while some technical 
aspects for introducing SHI were present, including the capacity to collect revenues from 
contributing members, there were significant risks and challenges. For example, SHI was 
unlikely to drive the necessary efficiency gains in the health sector; would likely involve 
increased general taxes to cover those not able to pay SHI contributions; may not result 
in a net addition to the level of health financing; and could add to pressures on cost-
control (Rannan-Eliya R 2013). The  Vanuatu report (World Bank 2013) noted that in the 
Organisation for Economic Cooperation and Development (OECD) countries: 
‘adopting Social Health Insurance in preference to tax financing increases per 
capita health spending by 3-4 per cent, reduces the formal sector share of 
employment by 8-10 per cent, and reduces total employment by as much as 6 
per cent. For the most part, Social Health Insurance adoption has no significant 
impact on amenable mortality, but for one cause – breast cancer among 
women – Social Health Insurance systems perform significantly worse, with 5-
6 % more potential years of life lost.’  
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Raising revenue from tobacco, alcohol, and other products that affect health 
Reduction in tobacco consumption is a key development priority because tobacco 
related illness and premature deaths impose large - but preventable - social and 
economic costs at the macroeconomic level, and reduce incomes at the individual and 
household level, particularly among the poorest sectors of society (Abedian I 1998). The 
report on the Economic Costs of Non Communicable Diseases (World Bank 2012)  notes 
that tobacco consumption significantly contributes to, or accelerates, the adverse health 
outcomes of each of the four main NCDs: heart disease, cancers, lung disease and 
diabetes (Beaglehole R et al 2011).  
Raising taxes on tobacco would be a ‘win - win’ for both Ministers of Health - who would 
see a reduction in use and uptake of cigarettes - but also Ministers of Finance - who 
would see an increase in general revenue (Jha P 2012).  WHO recommends that excise 
duties should be at least 70 % of the retail prices of cigarettes as an important 
instrument in curbing tobacco consumption and uptake, especially among the young 
(WHO 2010, WHO 2013).   
Modelling suggests that raising the excise rate on cigarettes by 50% would increase 
cigarette excise revenue by around 14% and 20% per annum in Samoa and Tonga 
respectively. This would translate into extra excise revenue of 3.6 million Tala ($1.6 
million) for Samoa and 2.5 million Pa'anga ($1.45 million) for Tonga each year (World 
Bank 2012).  Raising taxes on alcohol is also a viable option for raising revenue and 
promoting public health. The Cook Islands has imposed increased import duties on 
sweetened and carbonated soft drinks – each of which have up to 8 teaspoons of sugar 
– as a means of reducing overweight and obesity. 
Improving efficiency as the most strategic, achievable, option to increasing resources 
and fiscal space 
The recent reports are unanimous that making better use of existing resources through 
improved efficiency is the best and most achievable option for increasing the fiscal space 
for health, especially given the alternatives canvassed earlier. This is consistent with 
WHO findings that 20% to 40% of all health spending globally is currently wasted 
through inefficiency and waste. The WHO report identifies ten leading sources of 
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inefficiency in health. These include: purchasing practices for medicines (under-use of 
generics; use of substandard or counterfeit medicines; irrational prescribing policies); 
misaligned incentives (fee for service payments); management practices (medical 
errors, costly staffing mixes); and poor investment decisions (hospital size; technology 
choices) (WHO 2010). 
The various reports recognise that there will be some natural limits to efficiency:  high 
level of population dispersion in the Pacific Islands region demands a higher ratio of 
health inputs per capita than more densely populated countries. However, they each 
argue there are still large opportunities for achieving allocative (‘doing the right things’) 
and technical (‘then doing them right’) efficiency. Specific, practical examples for 
improving efficiency are offered. For example:  
The Solomon Islands could shift resources towards more cost-effective primary 
care services; maintain a physical investment plan and budget adequately for 
the incremental recurrent costs of new investment; improve the mix and 
productivity of inputs; leverage resources allocated for vertical programs to 
strengthen health services more broadly; and improve the geographic 
targeting of expenditures. Underlying these improvements is the need to 
strengthen budget planning and expenditure management, and alignment 
with national priorities. Improving the effectiveness and coordination of 
external donor resources will be equally important (World Bank 2010). 
In Tonga inefficiencies include:  
‘the use of doctors for child delivery when well-trained midwives could 
perform the same role; the failure of procurement systems to purchase 
medicines at the lowest available prices; the use of tertiary care hospitals for 
the provision of basic, primary care simply because primary care facilities are 
inadequately supplied; or more generally, an inefficient mix of medicines and 
personnel being used to provide a service. Technical inefficiency can also arise 
due to low productivity of health care workers, who see fewer patients than 
they could. In some countries, inefficiencies account for a ten-fold variation in 
the unit cost of delivering the same services but at different health facilities’ 
(World Bank 2013). 
5. An agenda for the short to medium term 
Countries cannot do everything at once: strategic priority setting is therefore important.  
While each of the five countries has quite specific health and financing challenges to 
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address, there are some common themes for early priority action that arise in the 
various reports. These are summarised below.  
Focus on primary and secondary prevention of communicable and non-communicable 
diseases to improve health and reduce subsequent cost burdens 
Investing in prevention is an important strategic option identified in each of the reports 
for all five countries. Strengthening evidence-based primary and secondary prevention 
will increase both allocative and technical efficiency. Improving the quality of primary 
care services would allow the treatment and control of diseases early in their onset. In 
turn, this would lower, or at least delay hospital admissions and lengths of stay, and thus 
overall costs. Yet the analyses in the reports show a different trend.  In Tonga for 
example prevention of communicable and NCDs and health promotion accounted for 
less than 5% of total government expenditure, and about 6% of donor health 
expenditures. Allocation to in-patient curative care accounted for 29% of total 
expenditure (World Bank 2012). There were similar findings in the other countries as 
well. The report on Samoa (World Bank 2013) notes that  
‘Per capita expenditure on total inpatient curative care, including overseas 
treatment, was recently over one hundred times more than per capita 
expenditure on prevention of NCDs, and almost eighty times what was spent 
per capita on maternal and child health and family planning. Even per capita 
expenditure on traditional health care was more than seven times that which 
was spent on prevention of NCDs’ 
Focus on equity of access and outcomes, especially for women  
Recent analysis shows that some public expenditure, including in-patient hospital 
services in the Solomon Islands, is  pro-poor: the poorest quintiles receiving more than 
a proportional share of public expenditure (World Bank 2010). On the other hand, that 
same analysis finds that ‘the geographic distribution of health spending is skewed in 
favour of Honiara and not consistent with the pattern of population health needs’. 
Average health expenditure per capita was $SI 10,830 in Honiara, compared to a 
national average of $SI 4795, falling to $SI 2850 per capita in more remote provinces like 
Temotu. Similarly, Honiara had a ratio of 1.32 doctors per 1000 population, compared 
to the national average of 0.2 doctors per 1000 population, and just 0.04 doctors per 
1000 in more remote provinces.  
Chapter 2 
99 
Similar concentration of funding occurs elsewhere. In Vanuatu, like the Solomon Islands, 
Government is trying to decentralise health financing and services to address the needs 
of more remote islands. In Tonga, analysis finds that the poorest quintile reported 0.86 
outpatient consultations per person per year, compared to 1.39 in the richest quintile 
(World Bank 2012). The poorest quintile was also less likely to see care when ill. A recent 
study by UNICEF in Vanuatu found that the most remote northern and southern 
provinces received only 40% to 50% of six basic essential health, nutrition and education 
services, compared to those in the capital, Port Vila, which received 80% of the six 
nominated services (UNICEF 2012).   
Investing in the health of young women is a worthwhile investment in its own right, 
which can improve equity and strengthen health outcomes in both communicable and 
NCDs simultaneously. Adverse maternal health, including under?nutrition, obesity, and 
diabetes, can also program chronic disease in the developing foetus in-utero  
transferring increased NCD risks (and costs) to the next generation. Chronic diseases 
amongst pregnant women can also raise the risk of complications and costs (World Bank 
2012). 
Improve the evidence and information base for improved decision making 
Governments and their development partners cannot allow relatively scarce health 
resources go to waste. But the evidence and information base for making good public 
policy choices is weak with respect to the major causes and drivers of disease. The report 
on Vanuatu (World Bank 2013) for example notes that the leading cause of death in 
Vanuatu, involving 199 cases, or over half (51%) of all recorded deaths, is classified as 
‘unknown’. Similarly, the second highest cause of death in Tonga after diseases of the 
circulatory system was ‘unknown’. Less than half of health facilities provided the 
expected Health Information System reports in Vanuatu during 2010. Reporting 
coverage of this basic piece of information had fallen to just 34% in 2011 although this 
has since improved.  There is little data on mental health in each of the five countries, a 
potentially large and costly public health issue as the population lives to older age. More 
than 50% of total deaths in Tonga occur outside the health infrastructure system and 
are vulnerable to having no death certificate unless the family requests it (World Bank 
2012).  Data on health financing is also patchy: most National Health Accounts are 
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around five years old, and rarely capture financing at the program level as distinct from 
line items such as salaries.  
Work with development partners to align investments with national priorities and 
strengthen the health system more broadly 
Development partners have an important – but potentially distorting – role in 
supporting health outcomes. As just one example, the report on the Solomon Islands 
(World Bank 2010) notes that:  
Malaria has attracted significant donor funding and other development 
partner resources but, as a result, the malaria program now accounts for the 
largest share of primary and preventive health expenditures – nearly three 
times the amount allocated to reproductive health. Donors and the national 
malaria program are also mindful of the problems that were associated with 
premature winding back of technical and financial support during the global 
eradication program of the 1960s and 70s, and understand their ethical 
responsibility to maintain support until a very high and sustainable level of 
control has been achieved……  Premature cessation of interventions may result 
in a resurgence of malaria transmission, the emergence of drug resistance in 
the parasite and insecticide resistance in the mosquito vectors.  
Invest in maintenance 
Inadequate maintenance shortens the lifespan of expensive equipment, resulting in 
items becoming unusable, or replaced with financing that could have been used for 
other purposes. The report (WHO 2011) on Fiji notes that  
‘the  technical efficiency of hospitals has been compromised over many years 
by inadequate investment in health infrastructure upgrading and 
maintenance. This has been compounded by the purchase and donation of 
biomedical equipment from a variety of sources, without a coherent plan for 
the maintenance and supply of consumables, parts and trained technicians’.  
In Samoa ‘maintenance’ is allocated only $T 60,000 under the recurrent budget of $ST 
68.8 million for 2010/11. ‘Maintenance’ attracted just $T 2 million out of a total budget 
of $T 53.5 million – just 3.8 % – of the latest National Health Service budget (World Bank 
2013). A costing study of the Vila Central Hospital (VCH) found that the repairs and 
maintenance budget for this 38 year old key facility should be around Vt 9.5 million per 
year, but that the actual funding was Vt 0.6 million. The line item budget for repairs and 
maintenance was 2% of the total annual budget for VCH, or 0.7% of the total value of 
Chapter 2 
101 
fixed assets. What little had been set aside for repairs and maintenance at VCH was used 
for other purposes, including freight charges (World Bank 2013). 
Improve public financial management 
Reports for Solomon Islands and Vanuatu particularly demonstrate the need for 
improved public financial management as a means of achieving value for money and 
accountability in the immediate term, and giving Ministries of Finance and development 
partners confidence to provide additional financing in the medium term. The specific 
areas for reform and improvement are identified in each of the various reports. In the 
case of the Solomon Islands, for example:  
The Public Expenditure Review team found three main issues related to budget 
formation: a) policy priorities, plans, and budgets are not well linked or integrated; b) 
budgetary allocations are made with little consultation with the line ministries or citizens 
and without a feed-back process to facilitate corrections; and c) there is a general lack 
of consistency over time in allocations to public services.  Ministry of Health had nearly 
400 virements. Accountability for and measuring ‘results’ is weak. (World Bank 2011)  
Identify and plan for the second-round effects of new initiatives to scale up health 
services 
As at April 2013, these five countries have over 700 medical students in training (136 
currently in Cuba, the rest in regional universities). These countries are now estimating 
the direct salary and allowance costs of theses personnel. However, consideration 
should also be given to the implications for health financing of the likely induced 
increases in prescribing additional medical tests and pharmaceuticals as the doctors take 
up their posts.   
All countries in the Pacific have committed themselves to an NCD Crisis response 
package that covers ten9 broad areas for preventing and treating NCDs. This package 
includes scale up to national levels of a series of ‘best buys’ known as the Package of 
                                                        
9 Reducing tobacco use; alcohol use; unhealthy diet and inactivity; use of package of essential 
NCD interventions for cardiovascular disease and diabetes; cancer interventions (including 
immunisation against HEP B and screening for cervical cancer); strengthen vital registration and 
cause specific mortality; adult NCD STEPS survey; youth survey; cancer registry; health system 
(including referral system, coverage of PEN trained health workforce and PEN equipment). 
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Essential Noncommunicable Disease Interventions (PEN). It will be important to 
estimate accurately – and then reflect in the budgets - the cost of national scale up. For 
example, will unit costs of diagnostic equipment and medicines increase as a result of 
reaching remote and outlying islands, or decrease as a result of economies of scale? It 
will also be important to accurately estimate and then budget for routine maintenance 
of equipment and other recurrent costs.    
Governments in Samoa, Solomon Islands, Tonga and Vanuatu have also received aid 
funding for hospitals recently. Again, it is important that recurrent costs including 
electricity and maintenance are explicitly reflected and planned for in future budgets. 
Controlling hospital costs will be an important priority, as high expectations for NCD 
related treatment among urban populations place spending pressures on highly visible 
and politically important hospital services. 
Conclusion 
The various recent reports on the five countries – Fiji, Samoa, Solomon Islands, Tonga 
and Vanuatu – demonstrate that each of these countries have significant strengths on 
which to build a more effective, efficient, equitable and financially sustainable health 
financing system. Despite their many differences, there are some important common 
challenges, and recommended responses, to address in the coming months and years. 
There are limited options to expanding fiscal space for health given historic and 
projected rates of economic growth, the relatively high share of government 
expenditure going to health, and constraints in tapping private funding.  Making better 
use of existing resources through improved efficiency is the most urgent and practical 
policy response.  
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Introductory note: Relationship between Chapter 2 and Chapter 3 
Chapter 2 addressed the general research gap identified in Chapter 1: that existing 
literature on priority setting and resource allocation in middle-income countries does 
not adequately capture the distinctive public health and public financing characteristics 
of five middle-income countries of the Pacific.  
Chapter 3 now provides a more detailed analysis of this general research gap at an 
individual country level: Samoa. I explain in Chapter 3 the national context of Samoa and 
the public health and public financing challenges the country faces. I explore in detail 
the policy options for public financing available to Samoa and make recommendations 
based on the evidence presented.  
I also estimate for the first time the financial cost to Government of Samoa in treating 
diabetes patients with dialysis: thereby in part addressing the specific research gap 
regarding health costs in the Pacific I identified in Chapter 1. I show in Chapter 3 why 
reallocating public resources away from largely ineffective attempts at curative cure and 
investing more in primary and secondary prevention would simultaneously improve 
health outcomes and public financing.  
Editorial note: The detailed estimate of costs at the Samoa National Kidney Foundation 
(NKF) was first published in another World Bank peer-reviewed publication where I was 
the sole author entitled The Economic Costs of Non-communicable Diseases in the Pacific 
Islands: A Rapid Stocktake of the Situation in Samoa, Tonga and Vanuatu (1). I have 
included my specific analysis of the NKF costs as Annex 1 in Chapter 3 for completeness 
of that country analysis. That has required minor drafting changes and alignment of text 
in the Preface, and paragraphs 3.18; 3.25; 4.47 and 4.56, from the originally published 
text of what is now Chapter 3. These changes did not involve any changes to the 
substance of the original text. Chapter 3 is therefore a revised version of the peer 
reviewed article. 
1. Anderson I. The Economic Costs of Noncommunicable Diseases in the Pacific Islands: A 
Rapid Stocktake of the Situation in Samoa, Tonga, and Vanuatu. Washington DC; 2013.  
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Chapter 3: Health-financing options for Samoa: Challenges and 
opportunities 
Abstract 
Samoa currently faces two important public policy challenges in the health sector. One 
is to stem, and then reverse, the rapid rise of noncommunicable diseases (NCDs). The 
second challenge is to put the country on a health-financing path that is effective, 
efficient, and financially affordable and sustainable. The two challenges are 
interconnected.  
This paper examines eight options to address these challenges. The eight options are 
the following: (1) increasing government expenditure via higher general taxation; (2) 
increasing government expenditure via deficit financing; (3) increasing the share of 
government expenditure to health; (4) increasing external and donor financing; (5) 
increasing specific taxes; (6) mobilizing additional nongovernment resources via 
insurance (including social health insurance, and community and private insurance); (7) 
increasing cost-recovery measures; and (8) increasing efficiency.  
The paper concludes that the chief opportunity arises from more efficient use of 
resources already in the health system that are not presently used to maximum effect. 
Improving technical and allocative efficiency of the existing system has the potential to 
make a large difference and is technically feasible. 
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Preface  
“The spread of noncommunicable diseases (NCDs) presents a global crisis;  in 
almost all countries and in all income groups, men, women, and children are 
at risk of these diseases. Worldwide, substantial gains have been achieved in 
economic growth, health, and living standards in the past century. This 
progress is now threatened by crises of our own creation — climate change, 
finance, and food insecurities, and the crisis in NCDs, principally heart disease, 
stroke, diabetes, cancers, and chronic respiratory disease.” (Beaglehole et al. 
2011). 
Samoa is currently facing two important public policy challenges in the health sector. 
One is to stem, and then reverse, the rapid rise of noncommunicable diseases (NCDs). 
The second challenge is to put the country on a health-financing path that is effective, 
efficient, and financially affordable and sustainable. The two challenges are 
interconnected. This paper therefore analyses options for reducing Samoa’s burden of 
disease (especially otherwise preventable NCDs) in a way that is financially sustainable 
for both government and individual households. 
Section 1 of the paper provides background and context. It is noted that Samoa has 
achieved some important health outcomes over time, especially compared to other 
similar countries. Section 1 also notes that Samoa, like many other countries, is facing 
an epidemic of NCDs that can impose heavy health burdens on individuals and families, 
and heavy economic costs on households and government. The challenge of NCDs 
should not eclipse the ongoing and important challenges with respect to communicable 
diseases and family planning in Samoa (paragraphs 1.1–1.14). 
Section 2 of the paper briefly summarizes the current structure of the health system, 
emphasizing that public financing — and public provision — dominates the health 
system. Development partners are also active supporters of the health-reform agenda 
(paragraphs 2.1 – 2.5). 
Section 3 of the paper analyses the current health-financing system in Samoa. This 
section shows some distinctive features of health financing. For example, health 
expenditure, including by government, is relatively high in Samoa in absolute and 
relative terms, and in comparison to other lower middle-income countries. Conversely, 
private expenditure, including out-of-pocket expenditure, is relatively low, with 
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negligible “catastrophic” health expenditures. But there are also important policy 
challenges in health financing. Long-term financial sustainability of health expenditure 
is ultimately in doubt. There is negligible cost recovery — just 0.08% of government 
expenditure on health in 2011/12. Some programs have high, and rapidly rising, costs to 
Government, including dialysis treatment for kidney disease, usually as a result of 
diabetes. The estimated average annual cost of dialysis is SAT 92,110 or $US 38,686 in 
2010/11. This is around 12 times GDP per capita, yet has limited health outcomes, with 
31 % of patients dying in less than one year and nearly two thirds dying within 2 years.  
Annex 1 provides details. Importantly, resources generally are still focused on inpatient 
curative care rather than primary and secondary prevention: per capita expenditure on 
total inpatient curative care, including overseas treatment, was recently over one 
hundred times more than per capita expenditure on prevention of NCDs, and almost 
eighty times what was spent per capita on maternal and child health and family 
planning. Even per capita expenditure on traditional health care was more than seven 
times what was spent on prevention of NCDs (paragraphs 3.1–3.25). 
Section 4 of the paper examines eight options for addressing health financing in Samoa, 
given the challenges of population growth, ageing, and the rise of expensive- to-treat 
NCDs. This section comprises the bulk of the paper. It starts by suggesting some 
principles to screen the eight options in the best interests of Samoa. It then canvasses 
the strengths and weaknesses of the eight options in the context of Samoa. The eight 
options assessed are the following: (1) increasing government expenditure via higher 
general taxation; (2) increasing government expenditure via deficit financing; (3) 
increasing the share of government expenditure to health; (4) increasing external and 
donor financing; (5) increasing specific taxes; (6) mobilizing additional nongovernment 
resources via insurance (including social health insurance, and community and private 
insurance); (7) increasing cost-recovery measures; and (8) increasing efficiency 
(paragraphs 4.1–4.59). 
Section 5 draws some conclusions and makes recommendations for government. It 
concludes that Samoa already has many of the building blocks in place to make some 
substantive improvements to health outcomes and financial sustainability of the health 
system. In particular, the paper states there are some potentially “low hanging fruit” 
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that could be harvested to achieve better health outcomes at reduced financial cost to 
Samoa (paragraphs 5.1–5.8). 
The paper concludes that the chief opportunity for health financing comes from making 
better use of resources already in the health system that have not been used to 
maximum effect. Improving technical and allocative efficiency of the existing system has 
the potential to make a large difference and is technically feasible. Specific 
recommendations include significantly reorienting public expenditure from curative to 
primary and secondary prevention; increasing investments in maintenance; proactively 
reducing future recurrent costs from large infrastructure projects; exploring contracting 
out and private/public partnerships; leveraging the power of public expenditure to drive 
incentives on the demand side and supply side of health care; understanding better the 
true cost of services and underlying cost drivers; and investing in operational research 
to build up the evidence base for policy making. 
The paper further concludes that Samoa has some other opportunities to mobilize 
additional revenue. Increasing taxation on tobacco and maintaining its value in real 
terms against inflation is an option, given the inevitable rise of (preventable) tobacco- 
related NCDs and the simultaneous need to generate revenue in Samoa. Some potential 
exists to generate more investment from the supportive group of external development 
partners over the longer term via the sector-wide approach existing in Samoa, but this 
is limited and should not be assumed. It is also likely that development partners will be 
more favourably inclined if Samoa continues to take additional reform and resource- 
mobilization efforts. There is arguably some potential for cost recovery, which at 0.08% 
of expenditure is currently quite low. However, this should only be considered if there 
is sound evidence that cost sharing will lead to significant revenues without detrimental 
impacts on access, equity, and financial protection. 
The paper also concludes that social health insurance (SHI), and other forms of formal 
insurance, are useful options for the longer term, but their implementation is premature 
at this stage, given the formidable technical and managerial challenges of introducing 
such schemes in Samoa at present. Additionally, there are arguably higher, quicker, and 
more feasible gains to be made by improving efficiencies with the resources already in 
the health system.  
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The paper also concludes there is only limited capacity to see additional financing 
directly from government over the longer term, given that health is now the second- 
largest item in the government’s budget and is expected to absorb 16% of government 
expenditure in 2011/12. The paper argues strongly against deficit financing at the 
national level to raise additional financing for the health sector. 
Section 6 suggests possible next steps, including government’s consideration of options 
with key stakeholders, including the private sector and development partners.  
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Section 1: Background and context 
1.1 Samoa has achieved some solid economic results, but remains vulnerable to 
external economic shocks. The July 2010 IMF Article IV consultation notes: 
Real per-capita income growth since the mid-1990s has been significantly 
higher than for most comparator countries. Prudent fiscal and monetary 
policies and structural reforms underpinned this performance.… Samoa’s 
external position remained comfortable … as remittances and tourism 
receipts, Samoa’s main foreign exchange earners, continued to grow. Official 
reserves remained stable, well above the central bank’s target … Samoa has 
low risk of debt distress (IMF 2010). 
1.2  The IMF Article IV consultation further finds that real GDP growth was projected 
to return to 3% in 2010/11, and continue to the period 2016–30, after falling from a high 
of 7% in 2004/05 to -4.9% in 2008/09 as a result of the September 2009 tsunami. The 
IMF Article IV consultations estimated GDP per capita at US$2,967 in 2009/10. This is 
similar to the World Bank estimate of US$ 2,980 for 2010 (World Bank 2012a). 
1.3 However, the consultations note that Samoa is vulnerable to external shocks. 
The September 2009 tsunami caused physical damage estimated at 10% of GDP, led to 
a fiscal deficit of 10% in 2009/10, and is projected to continue at 7% for the following 
three years before returning to less than 3% of GDP thereafter. Samoa also remains 
vulnerable to global economic downturns, including reductions in tourism numbers. 
1.4 The latest budget outlook confirms the prospects for modest growth and 
vulnerability to external shocks. The 2012/13 Budget Address by the Minister for Finance 
in Samoa in May 2012 notes that after two consecutive years of contraction, GDP grew 
by 2.0% in 2010/11, largely the result of fiscal stimulus and monetary easing as well as 
post-tsunami reconstruction. GDP growth however, slowed considerably in the last 
quarter of 2011 and is expected to remain subdued until the second quarter of 2012. It 
is forecasted that GDP will grow by about 1% in 2011/12. In summary, “The continued 
uncertainty and possible slowdown expected in the medium term, provides a 
challenging situation for the government in its efforts to achieve its longer-term 
macroeconomic targets stated in the 2012–16 Samoa Development Strategy” 
(Government of Samoa 2012). 
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1.5  Samoa has also already achieved some substantial health outcomes. Life 
expectancy at birth was 71.5 years for males, and 74 for females (latest figures available) 
(Samoa Bureau of Statistics 2012). The December 2010 Health Forum concluded that 
Samoa is on track, or has already achieved, internationally agreed targets for infant and 
under-five mortality (Millennium Development Goal [MDG] 4), maternal mortality and 
skilled birth attendance (MDG 5), and HIV prevalence and TB treatment (MDG 6).1 The 
government states that the infant mortality rate has fallen from 37 per 1,000 live births 
in 1981 to 25 in 1991 and 17 in 2001; that the under-five mortality rate was 13.7 per 
1000 live births in 2002; and that the maternal mortality ratio was 19.6 per 100,000 live 
births in 2002 (Government of Samoa, Ministry of Finance 2008). The Ministry of Health 
advises there is virtually no difference2 in the infant mortality rate between males and 
females (Government of Samoa, Ministry of Health, Annual Report 2006/7). 
1.6  Samoa has also achieved some substantial health outputs and service coverage 
levels that are known to be important for sound public health. The 2009 Demographic 
and Health Survey (DHS) found that over 90% of women in Samoa had at least one 
antenatal care (ANC) visit, and 60% had all four recommended ANC visits. (However, it 
is of some concern that only 13% of those seeking ANC do so in the important first 
trimester). Additionally, over 80% of women delivered their babies in a health facility. 
Initial vaccination rates for infants are relatively good: over three-quarters of infants 
received BCG injections and their first injection against polio and DPT. Only 15% of 
infants had no immunization at all. (However, rates of follow-up vaccinations are less 
encouraging: only about one-third of children completed the courses for measles, polio, 
and DPT, and only 25% of children — one in four — were fully immunized) (Government 
of Samoa, Ministry of Health 2010a). 
1.7  Samoa’s health outcome and health output levels are generally good compared 
to other lower-middle-income countries. Comparisons between Samoa — a unique 
Pacific Island country with a population of 184,000 in 2010 — and other lower- middle-
income countries, many of which are in Africa, can be misleading. However, some very 
broad benchmarking against its peers places Samoa’s achievements in some context. 
                                                        
1 Details about the Millennium Development Goals are available at 
http://www.un.org/millenniumgoals/ 
2 Reported as 19.5/1,000 live births for males and 19/1,000 for females. 
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Using a somewhat different data set from government of Samoa statistics,3 but one that 
is still generally comparable across countries, The World Health Organization (WHO) 
estimates show that Samoa has achieved higher health outcomes and outputs than 
other lower-middle-income countries on a range of indicators, especially infant, child, 
and maternal mortality, births attended by skilled health personnel, and access to 
sanitation. This is summarized in table 1.1 below. It is evident that Samoa is closer to, or 
performing less well than, its peers on other criteria, including physicians per population 
and the total fertility rate.  
                                                        
3 For example, the latest government of Samoa statistics estimate the life expectancy at birth in 
Samoa is 71.5 years for males and 74 years for females (Government of Samoa, Ministry of Health 
Annual Report 2009/10) However the latest statistics from WHO estimate the life expectancy at 
birth was 68 years for males and 72 years for females in 2009. 
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Table 1.1: Selected health outcome and output indicators 
Indicator Samoa Other lower-middle- 
income countries 
Selected health outcomes 
Life expectancy at birth 
(2009, both sexes) 
70 years 68 years 
Infant mortality rate 
(both sexes) in 2009 
21/1,000 42/1,000 
Under-five mortality rate 
(both sexes) in 2009 
25/1,000 57/1,000 
Maternal mortality ratio 58/100,000 live births in 
2012 
180/100,000 (94–300/ 
100,000 range; WHO 
interagency estimates) 
Total fertility rate 
(per woman, 2009) 
3.9 2.5 
Selected health-service coverage and factors conducive to good 
public health 
Births attended by skilled health 
personnel (%, 2000–10) 
81 64 
Population using improved 
sanitation (%, 2009) 
100 49 
Physicians (per 10,000 population, 
2000–10) 
2.74 10.0 
Nursing and midwifery personnel 
(per 10,000 population, 2000–10) 
9.4 14.0 
Adult literacy rate 
(%, 2000–10) 
99 81 
Female net primary school 
enrolment rate (%, 2000–10) 
93 83 
Source: WHO, World Health Statistics 2011. 
1.8 Other indicators would suggest that the health system in Samoa is performing 
relatively well in terms of other, broader criteria. The low level of out-of-pocket 
expenditure implies that financial protection for health expenditure is generally 
satisfactory. There is some evidence to suggest that capacity utilization of the main 
hospitals in Apia is also generally satisfactory: occupancy rates range from 72% for 
postnatal care to 95% for other acute cases, although utilization rates at rural health 
facilities in Upolu and Savaii are much lower5 (Government of Samoa 2009). Average 
                                                        
4 Government of Samoa, Ministry of Health advised in May 2012 that it had 87 registered doctors 
in Samoa in 2012, 60 of whom worked in the public sector and 27 in the private sector. With a 
total population of 184,000 in Samoa, 87 registered doctors implies 4.7 doctors per 10,000. 
5 Table 7.1 from NHS for 2007/08 (latest year available). Upolu Rural Health Facility has occupancy 
rates ranging from 1 to 33 percent. Savaii Island has occupancy rates ranging from 213 % in 
Maleitoa Tanumafili II Hospital to 30 % for other hospitals. 
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length of stay at the main hospital in Apia ranges from 1.6 days for postnatal to 7.8 days 
for the high-dependency ward. The evidence on the quality of services provided, 
responsiveness to need, and infection control is harder to obtain. 
1.9 However, Samoa also faces some important health challenges, including the rise 
of noncommunicable diseases. To its credit, the government of Samoa explicitly 
recognizes this challenge in its own overarching, Strategy for the Development of Samoa. 
That high-level, forward-looking strategic vision states: 
Noncommunicable diseases (NCDs) are increasing causes of ill health and 
leading causes of death, with injuries and wounds. Over the past two decades 
there have been almost epidemic rises in coronary heart disease, stroke, high 
blood pressure, and maturity onset diabetes, along with gallstones, digestive 
disorders, and joint problems. This is linked to changing diets, increased use of 
tobacco and alcohol, and limited public understanding of associated health 
risks. The prevalence of diabetes increased from 9.8% in 1987 to 23.0% in 2001. 
Obesity rates have grown dramatically from 25.5% in 1978 to 50.3% in 1991 
and 67.5% in 2001, among the highest rates in the world. Among adolescents 
there is a high suicide rate; a low but rising number of teenage pregnancies; 
and growing use of marijuana, tobacco, and alcohol (Government of Samoa, 
Ministry of Finance 2008). 
1.10 The WHO comes to a strikingly similar conclusion. In its country health 
information profile, it confirms that NCDs “including obesity, diabetes, heart disease, 
high blood pressure, stroke, and cancer are a top health priority, with high and 
increasing prevalence rates: the obesity rate is currently 57.0 percent, the diabetes rate 
is 23.1%, and high blood pressure rate is 21.4%.... The four main risk factors are smoking 
(tobacco), poor nutrition, excessive alcohol consumption, and physical inactivity (SNAP)” 
(WHO Country Health Information Profile for Samoa 2009). 
1.11  Samoa is not alone in confronting a pronounced rise in NCDs. In a major new 
report (WHO 2011b), WHO concludes that NCDs are the leading cause of death globally, 
killing more people each year than all other causes combined. Almost two-thirds of 
global deaths in 2008 (latest year then available) were due to NCDs, especially 
cardiovascular diseases, cancers, diabetes, and chronic lung diseases. WHO makes the 
important point that “the combined burden of these diseases is rising fastest among 
lower-income countries, populations, and communities, where they impose large, 
avoidable costs in human, social, and economic terms…. Contrary to popular opinion, 
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available data demonstrate that nearly 80% of NCD deaths occur in low- and middle-
income countries” (2011b). 
1.12 NCDs impose important economic costs on households and society. In addition 
to their impact on health, NCDs undermine economic growth. A recent report in The 
Lancet notes that “for every 10% rise in mortality from NCDs, the yearly economic 
growth is estimated to be reduced by 0.5%. On the basis of this evidence, the World 
Economic Forum now ranks NCDs as one of the top global threats to economic 
development” (Beaglehole et al. 2011). WHO notes that people with diabetes require at 
least two to three times as many health care resources as people who do not have 
diabetes, and diabetes care may account for up to 15% of national health care budgets. 
In addition, people with diabetes have a 2-3 times higher risk of tuberculosis compared 
to people without diabetes (WHO 2011). In a separate study reported in The Lancet, 
researchers found that the cost of diabetes care per patient in Cameroon was US$489 
per year in 2002, exceeding the annual per-head income by 1.5 times, and exceeding 
the per-head governmental health spending by about 50 times (Allotey et al. 2011). 
1.13 Some prevalent and important NCDs appear to have a pronounced 
socioeconomic gradient in Samoa, disproportionately affecting the wealthier. As shown 
in figure 1.1 below, the reported level of diabetes among the richest quintile in Samoa 
is, according to the DHS 2009 (Government of Samoa 2010), just over three times that 
found in the poorest quintile: 29% compared to 9%. The reported level of hypertension 
in the richest quintile is also just over twice that of the poorest quintile: 25% compared 
to 12 percent. It is not clear whether this apparent dominance among wealthier 
Samoans reflects true underlying behaviour and lifestyle factors, or whether poorer 
Samoans simply remain undiagnosed and are therefore underrepresented in the 
statistics. This is, in itself an important area for future study. What is clear, however, is 
that this pronounced socioeconomic gradient of diagnosed NCDs has some important 
implications for public financing in Samoa, and not just in public health. More 
specifically, to the extent that wealthier quintiles in Samoa with these diagnosed NCDs 
use “free” public health services treating NCDs, public expenditure becomes pro-rich 
rather than pro-poor. This is an important point of public policy in Samoa where, at the 
national level, the richest 10% of households earned 31% of total income, while the 
poorest 10% earned 1.8% of income (Government of Samoa, Ministry of Finance 2008). 
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Figure 1.1: Diabetes and Hypertension in Samoa (by wealth quintile) 
Source: Samoa DHS 2009. 
1.14  The challenges of NCDs should not eclipse the ongoing and important issues 
with respect to communicable diseases and family planning in Samoa. As noted in 
paragraphs 1.5 and 1.6 above, Samoa has a good overall record with respect to primary- 
level care, but there are some important gaps that need to be addressed. Approximately 
only 25% of children are fully immunized, and only 13% of women obtaining ANC do so 
in the important first trimester. Furthermore, almost half (46%) of currently married 
Samoan women have an unmet need for family planning (Government of Samoa, 
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Ministry of Health 2010a). Some reports suggest high rates of sexually transmitted 
infections (STIs): possibly 40.7% of 300 antenatal women under age 25 had chlamydia 
(Enoka 2011). The December 2010 Annual Health Forum found insufficient progress with 
respect to the proportion of one-year olds immunized against measles (MDG 4). The 
Annual Health Forum also found that contraceptive prevalence rate is low; there are 
unmet needs for family planning; and adolescent birthrates have increased since 1990 
(MDG 5). There is also a high prevalence of STIs, and condom use at last high-risk sex is 
relatively low (MDG 6). 
Section 2: Structure of the health system 
2.1 Publicly funded — and provided — services dominate the health system in 
Samoa. The Ministry of Health (MOH) is responsible for regulatory oversight, policy, and 
priority setting. MOH has recently produced a wide range of policy position papers and 
facilitated legislation on a range of health-related issues.6 The Health Sector Plan 2008–
2018 provides a well-articulated vision of future directions in health, including a set of 
six key strategies.7 The Health Sector Plan has four explicit strategic objectives for health 
financing.8 The plan also provides a clear output-focused performance framework that 
is, along with the involvement of other ministries, now being elevated to a health 
outcomes focus, with key indicators explicitly listed in the nation’s next national plan. 
(Government of Samoa Ministry of Health 2008) 
2.2 The government-owned National Health Service (NHS) is the publicly funded 
provider of preventive and clinical services. It manages the national referral hospital in 
the capital, Apia, as well as seven district hospitals and several smaller clinics throughout 
the two main islands of the country. Of the SAT 54 million provided to the NHS in 2010, 
SAT 25 million (46%) was allocated to personnel costs, including health professionals; 
                                                        
6 Recent legislation that came into effect includes the Tobacco Control Act, the Mental Health Act, 
Nurses and Midwives Act, Health Care Professions Registrations and Standards Act, Pharmacy Act, 
Dental Practitioners Act, and the Medical Practitioners Act. 
7 The six key strategies are to strengthen health promotion and primordial prevention; enhance 
quality health care–service delivery, including management of infectious diseases; strengthen 
governance, human resources, and health systems in the sector; partnership commitment; 
financing health services; and donor harmonization. 
8 “Improve equitable allocation of resources; strengthen financial management systems, including 
procurement; long-term financial health plan; develop financial sector policies.” 
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SAT 16 million (30%) went to operating costs (National Health Services 2010). The main 
hospital in Samoa (Tupua Tamasese Meaole Hospital, commonly referred to as TTM) 
absorbed at least SAT 10.7 million (20%) of the NHS budget in 2010, excluding costs for 
the pharmacy and laboratory services provided at the hospital.9 Influenza and 
pneumonia are the main cause of hospital admissions. The Overseas Treatment scheme 
(OVT), whereby eligible patients are treated in New Zealand, is a significant part of the 
overall health system (discussed in more detail in paragraphs 3.21 to 3.24 below). 
2.3 Nurses and midwives make up two-thirds of the Samoan health workforce. Over 
90% of the 316 registered nurses, midwives, and student nurses work in the public 
sector. Over half (53%) of registered nurses are now age 40 or older, with approximately 
20 registered nurses expected to retire in 2010 and each year thereafter. Workforce 
planning to replace retirees, and some loss of younger nurses to New Zealand and 
Australia, is therefore a priority issue. Shortage of midwives is a particular workforce 
challenge (Government of Samoa, Ministry of Health 2010c). There were 87 registered 
doctors in Samoa in 2012, 60 working in the public sector, and the rest in the small 
private sector. Most doctors in Samoa have studied in Australia, at the Fiji School of 
Medicine, or in New Zealand. The relatively new Oceania University of Medicine in Apia 
now trains doctors. 
2.4 There is a small private health sector, with one private hospital (Medcen 
Hospital), fourteen private medical clinics, and four private pharmacies, mainly 
concentrated in Apia and focusing on curative interventions. Some modest — and 
apparently successful — public-private partnerships have produced diabetes clinics in 
Apia. Private insurance is negligible (see paragraph 3.9 below). 
2.5 Samoa has a strong, active, well-resourced network of churches throughout the 
country, which provide deep and wide outreach and support to families and 
communities. The Catholic Church supports the Mapuifagalele Old People’s Home; the 
Seventh Day Adventists promote healthy lifestyles; and the church-supported Fiaola 
Crisis Centre provides counselling for young people, including suicide prevention. 
                                                        
9 The NHS financial statements reveal that there were SAT 6.6 million personnel costs for TTM; 
SAT 3.87 million for operating costs for TTM; and SAT 282,000 for capital costs. However this does 
not include the “laboratory” or the “pharmacy” line items in the NHS financial statements. 
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However, unlike Papua New Guinea, where churches deliver up to half of the nat ion’s 
health services, sometimes on a contractual basis with government or development 
partners; churches play a surprisingly peripheral and marginal role in health care in 
Samoa. Civic support for health care is also provided by women’s committees, especially 
at the village level.  
Section 3: Health financing and health systems in Samoa 
3.1 At the outset, it is worth recalling the importance — but also the limitations — 
of analysing health financing. On the one hand, health financing is important: how much 
money is raised for health, by whom, from whom, for whom, and for what are all issues 
that affect not just health outcomes, but broader economic aspects at the household 
and macroeconomic levels. On the other hand, health financing is clearly not the only 
determinant of health outcomes. Other factors outside the health system and health 
financing per se are also important, including genetics, hygiene practices, lifestyle 
decisions, culture, food security, girls’ education, vulnerability to natural disasters, and 
environmental factors such as availability of water and sanitation. The quantity and 
quality of health financing are therefore necessary but not sufficient parts of improving 
and sustaining good health outcomes. 
3.2 Against that background, the following tables and figures show several 
distinctive aspects of health financing in Samoa. Table 1.2 provides an overall picture of 
expenditure trends using the currently available National Health Accounts (NHAs), which 
end in 2009. Table 1.3 uses latest government of Samoa budget documents to highlight 
the main sources and uses of funds. (Not all items are displayed so the subtotals do not 
necessarily sum to 100%).  
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Table 1.2: Selected health expenditures (current prices) and ratios for 1995, 2000, 
and 2004–09 (latest years available using NHAs) 
 1995 2000 2004 2005 2006 2007 2008 2009 
Total expenditure on health 
(THE), SAT millions 
25 43 55 65 78 87 85 101 
General government expenditure 
on health, SAT millions 
17 30 45 54 67 74 72 88 
General government expenditure 
on health as % of THE 
70.4 70.9 81.4 83.3 85.8 85.3 84.7 87.3 
Total expenditure on health as % 
of GDP 
5.0 5.6 5.2 5.5 6.2 6.1 5.9 7.0 
Total expenditure on health per 
capita in PPP terms 
107 149 186 224 260 277 264 312 
General government expenditure 
on health per capita in PPP terms 
75 106 151 187 223 237 224 273 
Source: Samoa NHAs 2002/3; 2004/5; 2006/7; 2008/9. 
Table 1.3: Main sources and direction of public expenditure on health 2008/09 to 
2011/12, nominal 
Item 2011/12 
(SAT 
millions) 
2010/11 
(SAT 
millions) 
2009/10 
(SAT 
millions) 
2008/09 (SAT 
millions) 
Total government resources for health 110.610 107.8 79.9 81.0 
Of which, coming from: 
• Government-appropriated expenditure 69.0 64.8 58.9 70.0 
• Donor cash funded/foreign capital 
project grants 
17.8 16.8 19.9 10.5 
• Foreign loans 23.7 26.1 1.0 0.5 
And then directed to Ministry of Health of 
which (descending order by amount): 
69.06 64.89 58.90 70.06 
• Samoa National Health Service 57.6 54.1 48.9 58.4 
• Ministry of Health outputs 5.5 5.3 4.6 4.6 
• Samoa National Kidney Foundation 4.9 4.5 4.3 5.3 
Source: Approved estimates of receipts and payments of the government of Samoa for the financial 
years ending June 30, 2009/10; 2010/11; 2011/12 (Government of Samoa 2011). 
3.3 The first distinctive feature shown in table 1.2 is that total health expenditure 
(THE) is relatively high in Samoa. Using Samoa NHA figures, table 1.2 shows THE at SAT 
101 million (US$42.6 million) in 2009 (latest year available). At SAT 205 per capita 
(US$86.5 at market exchange rates, or International $312 per capita in purchasing 
                                                        
10 If SAT 3.2 million “in kind donor assistance” is included, this rises to SAT 113.9 million. 
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power parity [PPP]11 terms), this is much higher than the US$38 per capita minimum 
total expenditure estimated by the WHO Commission on Macroeconomics and Health 
needed to fund essential health interventions in low-income countries in 2015 (WHO 
Commission on Macroeconomics and Health 2001). It is also higher than the 
recommended US$54 per capita to fund a basic package of essential health services in 
low-income countries, developed recently for the G8 Leaders Summit by the High-Level 
Taskforce on Innovative Health Financing (Taskforce on Innovative Health Financing for 
Health Systems 2009). Table 1.2 also shows these relatively high figures have occurred 
over time and do not simply reflect any lumpy, one-off expenditures. Like many other 
Pacific Island countries, the relatively high absolute expenditures per capita do,  
however, reflect a combination of comparatively small populations, limited 
opportunities for economies of scale, and relatively high levels of government 
expenditure on health. 
3.4 A second distinctive feature of health financing in Samoa is that government has 
clearly given priority to health (and education): absolute and relative levels of 
expenditure on health are quite high compared to other government expenditures. 
Government’s own appropriations for health — and excluding any external loans or 
grants — were SAT 69,064,202 in 2011/12. This represents 16.02 percent12 of total 
government appropriations for the 2011/12 financial year and is not a one-off 
aberration. Health received 14% of total government expenditure in 2006/07 (latest 
year for full NHAs) and 15% since then, including 17%  in 2008/09. Sustaining 15% or 
more of total government appropriations to health over many years is noteworthy given 
that the Abuja Declaration, signed by 53 heads of state in Africa, sets 15% as the 
benchmark government expenditure for health (WHO 2011a). 
3.5 The government’s clear political commitment to the health (and education) of 
its people is further illustrated by the overall ranking given to health in the national 
                                                        
11 PPP stands for purchasing power parity. In essence, PPP approaches seek to avoid distortions 
caused by market fluctuations in exchange rates. PPP approaches recognize that actual costs in 
one country may well be lower than in another, so that the actual purchasing power of local 
currency may be higher than might otherwise seem to be the case. PPP uses a notional 
“international dollar” to distinguish it from US$. 
12 Actual expenditure, as distinct from approved estimates, gives a figure of 14.8% to health as a 
percentage of total government payments in 2010/11, or SAT 64.88 million going to health out of 
a total expenditure of SAT 437.8 million (Government of Samoa 2011). 
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budget. As shown in figure 1.2 below, the Ministry of Health was the second-largest 
appropriation item in Samoa in 2011/12, after the Ministry of Education and Culture 
(Government of Samoa 2011). The health sector is also the third-largest item in the 
government’s overall development budget, including external grants and loans to the 
country after the Ministry of Finance and the Ministry of Education. Total financing to 
health at SAT 113 million in 2011/12 (SAT 69 million government appropriations plus 
SAT 44 million loans and grants) is even larger than resources available to the Ministry 
of Works, Transport and Infrastructure (SAT 109 million). 
 
 
Figure 1.2: Largest Expenditures by Ministry 
Source: Government of Samoa 2011. 
3.6 Government expenditures on health are also relatively high compared to other 
lower-middle-income countries. Latest available figures that enable comparisons with 
other countries come from World Health Statistics 2011 and relate to 2008. Table 1.4 
below shows that the share of government expenditure on health, as a percentage of 
THE, was double that of other lower-middle-income countries in 2008. It was also 
noticeably higher as a share of total government expenditure (14.9% in Samoa, 
compared to 7.8% in other lower-middle-income countries) in that year. Per capita 
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government expenditure on health is between 2.5 and 3.3 times higher in Samoa than 
it is in other lower-middle-income countries, depending upon whether current market 
exchange rates or PPP13 approaches are used. However, comparing Samoa’s 
expenditure to other lower-middle-income countries should be approached with some 
caution: unit costs will be very different in a relatively small Pacific Island country with 
thin population coverage in outer islands.14  Further, what really matters is where the 
money is spent, and how effectively. Nevertheless, these broad indicators do give a 
broad sense that health expenditure in Samoa is relatively well supported compared to 
other countries of similar per capita income. 
Table 1.4: Selected health financing indicators for Samoa and other lower- middle-
income countries, 2008 
Indicator Samoa Other lower- 
middle-income 
countries 
Total health expenditure as % of GDP (2008) 5.9 4.3 
General government expenditure on health as % of total 
health expenditure 
84.7 45.4 
General government expenditure on health as % of total 
government expenditure 
14.9 7.8 
External resources for health as % of total expenditure on 
health 
7.115 1.0 
Private expenditure on health as % of total expenditure 
on health 
15.3 54.6 
Out-of-pocket expenditure as % of private expenditure 
on health 
62.9 82.7 
Per capita total expenditure on health (PPP, $) 264 197 
Per capita government expenditure on health (average 
exchange rate, US$) 
152 45 
Per capita government expenditure on health (PPP, $) 224 88 
Source: WHO 2011b. 
3.7 Samoa is also spending comparable amounts on health as other Pacific Island 
countries. As table 1.5 below shows, Samoa is around the median for other Pacific Island 
                                                        
13 See footnote 11 for a definition of PPP. 
14 The impact of small, remote, and dispersed economies — typical in the Pacific — on unit costs 
for health care would be a useful subject for further research and analysis. 
15 See paragraph 3.12 for an update. 
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countries in terms of total health expenditure per capita, and for the share of 
government expenditure going to health. 
Table 1.5: Selected health statistics: Samoa and other Pacific Islands 
Country Total health 
expenditure per 
capita (US$, 2008) 
Total health 
expenditure per 
capita PPP )16 
Total health 
expenditure (as % 
of GDP, 2008) 
Government 
health expenditure 
(as % of total 
government 
expenditure, 2008) 
Cook Islands 442 361 4.4 11.7 
Fiji 154 168 3.5 10.2 
Kiribati 171 304 12.5 16.8 
Marshall 
Islands 
351 251 14.0 14.6 
Micronesia 
(Federated 
States) 
306 408 13.3 18.9 
Nauru 653 440 14.0 18.5 
Niue 1,348 2,360 13.5 12.6 
Palau 961 991 10.8 16.6 
Papua New 
Guinea 
39 70 3.2 7.4 
Samoa 179 264 5.9 14.9 
Solomon 
Islands 
68 139 5.3 14.4 
Tonga 140 194 5.0 14.2 
Tuvalu 291 266 9.7 8.0 
Vanuatu 104 170 3.9 14.3 
Median 235 265 7.8 13.1 
Source: WHO 2011b. 
3.8 Of course, care should be taken in drawing conclusions from these cross- country 
comparisons. What a government “needs” to spend on health is a complex question and 
depends primarily on local needs and resources (Savedoff 2007). Comparing Samoa with 
other lower-middle-income countries, many of which are larger countries in Africa with 
different health and economic challenges, also has limitations. Furthermore, Pacific 
Island countries face particular challenges in terms of cost structures that make health 
services expensive, including transportation costs to remote and thinly populated outer 
                                                        
16 See footnote 11 for an explanation of PPPs. 
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islands. Relatively small economies also mean that “lumpy” expenditures, such as 
construction of a hospital, can make a noticeable impact on year- by-year expenditures. 
Nevertheless, to the extent that the international community believes there should be 
“more money for health,” especially in low- and lower-middle-income countries, Samoa 
is spending reasonable amounts on health care. What then becomes important is 
whether such expenditure is sustainable over time, and if it is achieving intended 
outputs, outcomes, and impact (see section 4). 
3.9 A third distinctive feature of Samoa’s health financing is that the share of total 
health expenditure from private expenditure is low. As shown in table 1.4, an estimated 
15% of total health expenditure comes from the private sector in Samoa compared to 
54.6% in the comparator lower-middle-income group. Of the relatively little that is spent 
privately on health in Samoa, a smaller percentage (62.9%) is actually “out-of-pocket” 
than is the average for other lower-middle-income countries. 
3.10 Indeed, it would appear that generous government subsidies, combined with 
almost “free” public health care, have protected virtually all citizens from 
“catastrophic”17 out-of-pocket health care expenditure. Some research, however, is 
required to confirm the underlying situation. While it does appear to be the case that 
few people, if any, are pushed or kept below the poverty line because of out-of-pocket 
health expenditures, it is also conceivable that poorer and marginalized people simply 
refrain from spending money on essential heath care, and so die prematurely. For 
example, some in the lower quintiles may not be able to afford the cost of airfare to 
New Zealand, withdraw from seeking overseas treatment for NCDs, and die 
prematurely. There is not sufficient evidence to make an informed judgment. A useful 
research study would examine levels of self-reported health status and determine if 
those who believe they are ill are deterred from seeking care as a result of any significant 
direct or indirect out-of- pocket expenditure. 
3.11 Clearly, a balance must be found here. On the one hand, no individual should be 
pushed or kept below the poverty line, or made bankrupt, by paying for essential health 
                                                        
17 Generally defined as out-of-pocket health expenditure between 5 and 20 percent, but as high 
as 40 percent, of a household’s capacity to pay. Capacity to pay is, in turn, defined as the effective 
household income remaining after basic subsistence needs are met (Xu et al. 2003). 
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care, although that is the case in several developing countries of Asia and, arguably, the 
United States. Financial protection is now widely recognized to be an intrinsic objective 
of a health system, at par with the objective of improving health outcomes. On the other 
hand, achieving decent health outcomes, while simultaneously providing financial 
protection, does have to be affordable within the available fiscal and resource envelope. 
(See discussion in paragraphs 4.28 to 4.40 below.) 
3.12 Conversely, while private expenditure is relatively low, the share of total health 
expenditure from external sources — multilateral and bilateral development partners 
— is high, especially in recent years. This is a fourth distinctive feature of health 
financing in Samoa. Table 1.6 and figure 1.3 below show that of the total SAT 110.6 
million available to the Ministry of Health in 2011/12, SAT 69 million (62.4%) was 
provided through government of Samoa appropriations, and SAT 41.5 million (37.6%) 
through overseas development partners. External resourcing to the health sector 
constitutes a higher share than in 2008, as figures in table 1.5 show, reflecting the more 
recent increases in external sources. This includes the recent large and “lumpy” loans 
from China to build the new hospital and MOH headquarters in Apia. 
Table 1.6: Domestic and external sources of financing for health 2011/12 
Item Total SAT ‘000 Share of total 
resources available to 
health (%) 
Government of Samoa appropriation 69,064 62.4 
Donor cash funded, of which largest component is SAT 
14 million provided to the Health Sector 
Program by Australia and New Zealand 
17,860 16.1 
Loan funded, of which largest component is SAT 
20.3 million provided to the National Medical Centre 
and Ministry of Health HQ by government of China, and 
SAT 3.4 million provided to the Health Sector Program 
Phase 11 by the World Bank (IDA). 
23,760 21.5 
Total available to the health sector 110,625 100.0 
Source: Government of Samoa 2011. 
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Figure 1.3: Total Government resources available to health in recent years, 
showing Government appropriations, bilateral grant funding, and soft loans 
Source: Government of Samoa 2011. 
3.13 Figure 1.3 above suggests that external financing has not strongly substituted for 
government’s own expenditure efforts on health. Rather, external financing has tended 
to be supplemental to government resourcing. This is in contrast to the situation in some 
other Pacific Island, and other, countries where external financing has sometimes 
substituted for domestic financing effort.18 
3.14 There are also some distinctive features about external financing arrangements 
in Samoa. Three (Australia, New Zealand, and the World Bank) of Samoa’s main bilateral 
and multilateral development partners work through, or in close collaboration with, a 
sectorwide approach19 and have pooled funding, albeit not through government 
                                                        
18 Generally referred to as “fungibility.” Money is “fungible” in the sense that it can be used for 
many purposes: health, education, agriculture, or even less developmentally worthwhile activities 
such as subsidies for national airlines, sports stadiums, and prestige projects. 
19 SWAPs have many definitions but include concepts such as an agreed multiyear sector plan, 
ownership of the plan by the government (“government in the driving seat”), which provides 
leadership for collaborative partnerships with other stakeholders including bilateral and 
multilateral donors. There is also an expectation of more predictable, hopefully increased, and 
less volatile external financing, often pooled, and preferably financed “on budget” by the 
government. The movement to a more programmatic, sectoral approach, in contrast to a project 
enclave approach, is also expected to be accompanied by greater policy dialogue between 
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systems. Other stakeholders, including United Nations agencies, the Secretariat of the 
Pacific Community, and the WHO are “non-pool partners.” All stakeholders — “pool” 
and “non-pool” — state they work in ways that support Samoa’s own policy and 
programming reforms over the longer term. They also state they support Samoa’s 
Second Medium-Term Expenditure Framework (MTEF 2), which covers the period 
2009/10 to 2013/14, and involves an estimated SAT 622 million over the five-year 
period: SAT 345 million (55 percent) for recurrent expenditure and SAT 260 million (41 
percent) for development expenditure.20 Reviews find that, unlike other parts of the 
Pacific, the government in Samoa was actively involved in the initial SWAP (sector wide 
approach) process, believing that “traditional projects had high transaction costs and 
that they had a distorting effect on priority setting and coherence of activities” (Negin 
2010). This is important given more recent developments. 
3.15 The single most striking feature of current external financing is that 
infrastructure financing by one donor — the People’s Republic of China (PRC) — now 
constitutes just over three-quarters of donor development expenditure. More 
specifically, PRC is providing SAT 159 million for the MOH headquarters building and the 
NHS main hospital, which is 76% of the total other donor development expenditure (SAT 
208 million) over the period of MTEF 2 (Government of Samoa, Ministry of Health 2011). 
External loan funding for the hospital and MOH headquarters is the equivalent of 29% 
of the government’s total appropriations to health in 2011/12.21 The creation of these 
two new buildings in Apia has substantial implications to the extent that development 
financing now directly addresses national health priorities, for it swings resource 
allocation toward infrastructure. The extent to which the possibly long tail of recurrent 
expenditure associated with these two new buildings (electricity, air conditioning, 
maintenance, and cleaning) has been factored into future budget planning is also 
unclear. 
                                                        
government and development partners. Such approaches are designed to be more in keeping 
with the Paris Declaration on Aid Effectiveness and the Accra Agenda for Action. 
20 The balance of SAT 15.4 million (2.4%) is a balancing item. 
21 Page XIII of the budget statement for 2011/12 states that SAT 20.3 million is being provided for 
the National Medical Centre and MOH headquarters from the government of China. This is 29% of 
the SAT 69 million in government appropriations for 2011/12. 
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3.16 Against that background, it is important to assess current and future health- 
financing challenges in Samoa. One obvious challenge is government’s capacity to keep 
funding increases in health expenditure in a sustainable manner. Several factors are 
driving this. Government expenditure on health is already relatively high in per capita 
terms, and as a share of government budgets. As can be seen in figure 1.4 below, 
absolute levels of government expenditure have been rising. General government 
expenditure on health (including external financing) rose from SAT 30 million in 2000 to 
SAT 88 million in 2009 (latest year available under the National Health Accounts) and is 
estimated to be SAT 110.6 million in 2011/12. Government appropriations to health 
have more than doubled in nominal terms since the first NHAs were produced nearly 
ten years ago.22 Long-term financial sustainability under current arrangements must be 
questionable when government expenditure on health in 2010/11 (SAT 64.8 million) is 
expected to exceed total Pay As You Earn (PAYE) income tax (SAT 46.8 million) and 
company income tax (SAT 9.59 million) combined by 15% (Government of Samoa, 
“Approved Estimates of Receipts and Payments for the Financial Year Ending 30 June, 
2011,”(Government of Samoa 2011) p.vi). Government expenditure on health is high, 
and rising, in relative terms too: table 1.2 shows that general government expenditure 
on health was 70.4% of total health expenditure in 1995. This had risen to 87.3% by 2009 
(latest year available under the NHA).  
                                                        
22 Government appropriations were SAT 30.5 million in 2002/03 and SAT 69 million in  2011/12. 
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Figure 1.4: Expenditure on health (SAT, millions, current prices) 
Source: Samoa NHAs: 2002/3; 2004/5; 2006/7; 2008/9 (Government of Samoa 2012). 
3.17  Second, and related to the preceding point about long-term financial 
sustainability, government receives negligible receipts and cost recovery from the 
health sector. For reasons discussed in paragraph 4.29 onwards, cost recovery is a 
complex and sensitive issue. Among other things, it may be a financial barrier to 
accessing health care and requires very careful targeting so that it is introduced for those 
who can afford to pay user fees. However, at this point it is worth noting that total 
receipts from all sources in the health sector in 2011/12 in Samoa are projected to be 
just SAT 60,600 (US$25,000). This represents just 0.08% of the total SAT 69,064,202 
(US$28.4 million) government appropriations to the health sector in that year 
(Government of Samoa 2011). Cost recovery will never solve the challenge of 
sustainability. However, the government must decide if this small revenue effort — an 
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estimated 0.08% of government expenditure — from the health sector is appropriate 
for a country with a GDP per capita of about US$2,980. 
3.18 Cost recovery from the National Kidney Foundation (NKF) is similarly small. 
Patient treatment fees totalled SAT 84,340 or just 1.6% of the government appropriation 
to the NKF; not sufficient to cover the electricity charges of the Foundation: see Annex 
1.  
3.19 The third health-financing challenge is that expenditure is still largely focused on 
inpatient curative care more than primary and secondary preventive care.  Table 1.7 
below presents the main items of expenditure by function from the latest available 
National Health Accounts. It shows that inpatient curative care absorbed over one- 
quarter (26.4 percent) of total health expenditure in 2006/07 (latest year available). Per 
capita expenditure on total inpatient curative care, including overseas treatment, was 
over one hundred times more than per capita expenditure on prevention of NCDs, and 
almost eighty times what was spent per capita on maternal and child health and family 
planning. Even allowing that hospitals and clinics provide some health promotion and 
education, which is captured as inpatient care, it is clear that the focus is on curative 
care. Furthermore, per capita expenditure on traditional health care was more than 
seven times the amount spent on prevention of NCDs. And while allocating more 
resources to promotive and preventive care would appear to be a strategic investment, 
care should be taken to ensure that it is actually effective. Many countries have found 
that simply spending money on general advice about nutrition and exercise is ineffective 
and wasteful: the complex social determinants of health behaviour also need to be 
addressed.  
Chapter 3 
136  
Table 1.7: Allocation of total health expenditure by function, selected items, 2006/07 
(latest year available) 
Function Amount (SAT) Total health 
expenditure (%) 
Per capita (SAT) 
Total inpatient curative 
care 
20,769,519 26.4 114.91 
Of which: 
• Inpatient curative 
care 
• Inpatient curative 
• (overseas) 
 
13,360,769 
 
7,408,750 
 
17.0 
 
9.4 
 
73.92 
 
40.99 
General government 
administration of health 
13,480,875 17.1 74.59 
Basic outpatient medical 
and diagnostic services 
8,424,424 10.7 46.61 
Pharmaceuticals and other 
medical nondurables 
8,061,703 10.2 44.60 
Capital formation of health 
care providers 
7,002,458 8.9 38.74 
Traditional health care 2,237,664 2.8 12.38 
Prevention of communicable 
diseases 
5,400 0.0 0.03 
Prevention of 
noncommunicable diseases 
305,204 0.4 1.69 
Maternal and child health, 
family planning, and 
counselling 
260,843 0.3 1.44 
All other expenditure items 
(including education and 
training of health personnel, 
research, outpatient dental 
care)  
18,132,718 23.2  
Total 78,680,808 100.0 435.30 
Source: Government of Samoa, Ministry of Health, Samoa National Health Accounts FY 2006/7, p. 20. 
3.20 In one sense this heavy emphasis on inpatient curative care is certainly 
understandable. Households may not wish to spend money on prevention but will seek 
treatment when serious disability occurs. Government has also explicitly recognized (see 
paragraph 1.4 above) that the country is already in the midst of an epidemic of NCDs, 
and wishes to help its citizens by treating (although rarely curing) those most seriously 
affected. The proportion going to treatment is also consistent with levels found in 
developed countries. However, the policy challenge facing the government is whether 
Chapter 3 
137  
health resources achieve better health outcomes for more people and lower overall 
costs for governments if more resources are shifted toward prevention. 
3.21 Another health-financing challenge for Samoa is that some fast-growing items of 
public expenditure have questionable health outcomes, and are not pro-poor. For 
example, a study by the Ministry of Health noted that the Overseas Treatment (OVT) 
scheme absorbed 15% of total public health expenditure in 2009/10, to the private 
benefit of less than 0.1% of the nation’s population. OVT absorbed 11% of total public 
health funding in 2008/09, and this had grown to 15% by 2009/10. Expenditure on OVT 
almost matched the entire public expenditure on outpatient curative care (SAT 6.98 
million) in 2006/07 (Government of Samoa, Ministry of Health 2010b). Since that study 
was undertaken, expenditure on OVT has continued to grow. Total expenditure on OVT 
has increased 30% in nominal terms since 2007/08.23 Expenditure on the Overseas 
Treatment scheme is now 30% higher than the total personnel costs and associated 
allied services at the main TTM Hospital in Apia.24 As figure 1.5 below shows, public 
expenditure on OVT (SAT 10.5 million in 2011/12) is now also larger than the total 
budget of at least ten other important government departments or authorities, 
including the Ministry of Women, Community, and Social Development; the Ministry 
of Revenue; the Ministry of the Prime Minister; and the Legislative Assembly.  
                                                        
23 From SAT 8.0 million in 2007/08 to SAT 10.5 million in 2011/12. 
24 SAT 10.5 million for OVT compared to SAT 8.0 million for personnel at the TTM hospital in 
2011/12. 
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Figure 1.5: Overseas treatment budget exceeds budget of other key ministries 
and agencies 
Source:(Government of Samoa Ministry of Health 2011). 
3.22  Despite its high cost, it is not clear that OVT is generating strong health 
outcomes, especially for the poor. The uncertainty surrounding actual health benefits 
occurs because the medium- to longer-term health outcomes of OVT patients is not 
collected, let alone systematically analysed. However, interviews with well-informed 
Samoan health managers yield some important insights. Their informed view is that 
those Samoans receiving kidney stone treatment or eye cataract surgery in New Zealand 
generally have many years of subsequent good health. 
3.23 On the other hand, their impression is that cancer patients — constituting about 
12% of the program — typically have their life extended by two to three years. A simple 
Budget for Overseas Treatment exceeds 
other Ministries and Agencies in 2011/12 
Overseas Medical Treatment 
Ministry of Women and Community 
Ministry of Revenue
Justice and Courts Administration
Ministry of Prime Minister
Legislative Assembly 
Ministry of Communications and IT 
Bureau of Statistics
Public Service Commission 
Office of Controller and Chief Auditor
Office of Attorney General
Office of Electoral Commissioner 
Ombudsman's Office 
     10 12 
Million Tala in 2011/12 
Chapter 3 
139  
(unweighted) average cost25 of OVT treatment at SAT 36,965 per patient, (US$16,135) 
is 5 times the average GNI per capita of Samoans.26 Samoa will need to decide if this 
is affordable, and the best use of scarce health resources in a lower-middle- income 
country. Clearly, no one should suffer pain from cancer, and all Samoans should have 
access to good quality, affordable, compassionate palliative care and pain management. 
However, OVT does involve a high opportunity cost:27 the average cost of SAT 36,965 
for one patient could be used to provide a wide range of health care for a larger number 
of Samoans. 
3.24 Nor is it clear that the OVT is pro-poor. As noted in figure 1.1 of this paper, some 
important NCDs in Samoa appear to be disproportionately concentrated among the 
wealthier quintiles. The co-payment of an airfare to New Zealand and accommodation 
for any person accompanying the patient are important financial barriers in a country 
where the average per capita income is US$3,220 per year. 
3.25 A similar question about the balance between the public cost and the private 
benefits of health care arises with the National Kidney Foundation. While much cheaper 
than sending patients to New Zealand, dialysis at the NKF is still expensive at 
approximately SAT 92,110(US$38,686) per patient per year: see Annex 1 for details. 
However, cost recovery from patient fees covers less than 1.6% of NKF’s budgets. 
Importantly, about one- third (31%) of patients die in less than a year after starting 
treatment, and nearly two thirds (64%) have died within two years As is the case with 
cancer patients, it is essential that all Samoans with end stage kidney failure are treated 
compassionately and kindly, with good access to palliative care and pain relief. Whether 
government can afford expensive dialysis treatment, when health outcomes are 
measured largely in months, is something that Samoa will need to decide. Certainly, 
informal musings among some health professionals about the desirability of having a 
                                                        
25 The average cost of treatment for a cancer patient under the OVT is not known. This would be 
an important figure to know and understand. 
26 GNI per capita of US$3220 using the World Bank Atlas Method. Reference:   
http://siteresources.worldbank.org/DATASTATISTICS/Resources/GNIPC.pdf. 
27 Opportunity cost seeks to measure the benefit of the next best alternative use of resources. 
Opportunity cost has been defined by The Economist magazine as follows: “The true cost of 
something is what you give up to get it. This includes not only the money spent in buying (or 
doing) the something, but also the economic benefits that you did without because you bought, 
or did, that particular something and thus can no longer buy, or do, something else”  (2000) 
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kidney transplant facility in Samoa appears to be technically and economically 
unjustified at this stage. Officials at the NKF believe a key explanation for the relatively 
poor outcomes in terms of extending life are that patients are diagnosed, referred and 
commence treatment for kidney disease too late. This, in turn, suggests that reallocating 
resources from extending life by a few months through dialysis to primary and especially 
secondary prevention to prevent or at least postpone onset of sever kidney disease and 
dialysis would appear to be a good investment in both public health and public finance. 
Annex 1 has further details. 
Section 4: Options to respond 
4.1 The “business as usual” case is, ultimately, not sustainable. The preceding 
sections show that while Samoa has many positive health and health-financing features 
on which to build its future, the country also faces important challenges. Samoa must 
therefore prepare for even greater demands from NCDs on the public health system in 
coming years. That is because the existing risk factors for increased levels of chronic and 
expensive-to-treat NCDs, such as diabetes, are clear: 86% of adult Samoans are 
overweight or obese according to the 2011 Village Health Survey (Government of Samoa 
Ministry of Health 2011), of these 26% are overweight, 46% are obese, and 14% are 
morbidly obese. Yet health is already the second-highest recipient of government 
expenditure and, at 16% of total government expenditure, may not have much more 
room to grow. Fast-growing economies can continue to devote increased absolute, if 
not relative, levels of resources to health to meet the rising challenge of NCDs. But the 
government’s own projections are cautious about future economic growth (and 
therefore revenue) prospects (Government of Samoa 2012). 
4.2 Furthermore, there is no reason to think that the current health-financing system 
can self-correct and put itself on a more financially sustainable and equitable path. 
Indeed, a sense of entitlement about “free” health care and rising expectations are likely 
to put more pressure on government over time. In the absence of self- correcting 
mechanisms, government, supported by the Ministry of Health, needs to continue 
taking proactive policy decisions about public expenditure and resource allocation to 
put the country on a more affordable, effective, efficient, equitable, and sustainable  
basis. 
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4.3 Before considering specific options for health financing in Samoa, it is worth 
establishing some higher-order principles and criteria against which options can be 
judged. Only government, supported by the MOH, can ultimately decide those 
principles, because they are at the heart of the sort of health outcomes Samoa wants 
for its people, and what it can realistically afford. There is certainly a role here for 
vigorous public debate and discussion about what Samoans at the personal and 
community level believe should be key public health priorities. Public finance theory and 
international experience offer some insights into principles that Samoa might find useful 
in screening various options. 
4.4 More specifically, government in Samoa might decide that any options for health 
financing should be screened against the following criteria. Government might decide 
that options should be demonstrably and substantively outcomes-oriented, promoting 
or restoring health and avoiding premature deaths rather than being input- or activity-
focused, or extending life for only a few months for the very elderly. Government might 
also decide that selected options should also be affordable, not just for individuals and 
households, but ultimately for government as well. Selected options should also strike 
the right balance between the public and the private sector: Government should focus 
on those areas where it has comparative advantage (promoting public goods, 
responding to market failures, reducing poverty and inequity) and encourage (viable and 
suitably regulated) private sector participation. Government in Samoa might also decide 
that selected options should strike the right balance between efficiency and equity. 
Ideally, selected options should also be technically effective, economically efficient, and 
politically feasible, and should build on the strengths of any existing system. 
4.5  While no country has been able to apply all these principles, they are arguably a 
good starting point for screening options and prioritizing policy responses. 
4.6 Against that background, this section now assesses eight broad health- financing 
options for Samoa. The eight options are the following: (1) increasing government 
expenditure via higher general taxation; (2) increasing government expenditure via 
deficit financing; (3) increasing the share of government expenditure to health; (4) 
increasing external and donor financing; (5) increasing specific taxes; (6) mobilizing 
additional nongovernment resources via insurance (including social health insurance, 
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and community and private insurance); (7) increasing cost-recovery measures; and (8) 
increasing efficiency. These eight options build on well-established and systematic ways 
of assessing health financing, especially in developing countries (Tandon and Cashin 
2010; World Health Report 2010; Roberts et al. 2008; Gottret and Schieber 2006; WHO 
Western Pacific Region 2006). 
Option 1: Increasing general taxation 
4.7 Increasing the general level of taxation, and then applying some or all of that 
planned-for increase in revenue to the health sector has some advantages in Samoa. 
Raising the taxation level is technically and administratively a relatively simple option 
compared to other options — such as social health insurance (SHI) — although it may 
well be politically difficult. To the extent that taxation is raised from income taxes, it is 
progressive, drawing more from wealthier Samoans than poorer ones (although excise 
taxes and VAT are regressive, taking proportionately more from lower-income groups). 
Development partners are likely to welcome government efforts to raise its own 
resources and may even be more inclined to support such efforts with their own 
financing. 
4.8 However there are also important counterarguments. Tax revenue is an 
estimated 25.1% of GDP,28 which is already quite high for a lower-middle-income 
country. Raising taxes can introduce distortions to the economy,29 and/or raise 
inflationary pressures if firms have the capacity to pass on increased taxes. If general 
taxes were to be raised to pay for health, the sequencing of events would need to be 
taken into account to make the tax increases more politically acceptable. For example, 
government might need to borrow or rely on external financing to first refurbish and 
rehabilitate existing health facilities so that the public sees tangible improvements and 
benefits in the health sector before the tax impost occurs. More fundamentally, 
however, a “business case” would need to be established for additional financing 
from general taxation, when the health sector already receives approximately 16% of 
                                                        
28 IMF 2010; table 1.2. 
29 Generally known as “deadweight losses,” as the tax drives a wedge between the prices 
consumers would have otherwise been prepared to pay and suppliers would have otherwise 
received, in the absence of the tax. 
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total government expenditure and was the second-largest call on the government 
budget in 2011/12. 
Option 2: Increase the budget for health through broader macroeconomic-level deficit 
financing 
4.9 In theory, government could increase its fiscal deficit (that is, spend more than 
it generates through revenues) and/or borrow to pay for increased public expenditure 
on health.30 The most recent (July 2010) IMF Article IV consultations note that Samoa 
has had a prudent approach to fiscal deficits, and had at that time “low risk of debt 
distress” (IMF 2010). Some might argue this provides room to increase the fiscal deficit 
to provide more funds for health expenditure. 
4.10  However, deficit financing at the macroeconomic level to support increased 
health expenditure is a very unattractive option in Samoa for several reasons and is not 
recommended for any further study. Prudent deficit financing is appropriate for 
investments that generate returns greater than the cost of borrowing, or to make up 
shortfalls in private expenditure; neither of which is the case with respect to recurrent 
health financing in Samoa. Borrowing should usually be used to finance investment, not 
running costs. Deficit financing also imposes financial costs on the macroeconomic 
indicators and reduces the capacity of government to respond to economic shocks to 
the system. Fiscal 2009/10 already saw the need for an expansionary budget in Samoa, 
with a deficit equivalent to 11% of GDP in view of the need to stimulate economic 
activity following the global financial crisis and earlier reconstruction efforts from the 
tsunami. Government has prudently stated its intention to reduce — not increase — the 
fiscal deficit to about 3% of GDP, which the IMF concludes “would stabilize the net 
present value of public debt to about 40% of GDP a comfortable level, providing room 
to absorb future shocks” (IMF 2010). What matters from a macroeconomic perspective 
is the ability of the government to take on any more borrowing without jeopardizing 
debt sustainability or introducing distortions into the country’s capital markets. Again, a 
strong business case would be needed to explain why the health sector needs additional 
                                                        
30 In theory, governments also have the option of increased expenditure through inflation by, in 
effect, printing money. This, however, is a potentially high-risk approach as inflationary 
expectations and inflation can become embedded in the economy with consequent heavy social 
and economic costs on society, and is therefore not a recommended option. 
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financing from broader macroeconomic deficit financing, when it is already the recipient 
of about 16% of total government expenditure, the second-largest of the government 
budget. 
Option 3: Increase the share of government expenditure to health 
4.11 In a growing economy, the health sector will receive an increased level of 
resources, assuming government tax revenue increases with economic growth, and the 
health sector’s share of government expenditure stays the same. However, given the 
increase in government health expenditure over recent years (table 1.2) and recent 
growth experience (-3.9% in 12 months to September 2009, and real GDP growth of 
2% in year to September 2010), this is not a solid foundation on which to expect 
increased funding. 
4.12 Government could, of course, increase the proportion of funding to the health 
sector. This is essentially a political decision, reflecting national priorities, rather than an 
economic decision. And it could only really be justified if the MOH was able to 
demonstrate with convincing evidence that public expenditure is generating the public 
health benefits that government expected. This, of course, is difficult to do in any 
country, not least because so many factors outside the health sector affect health 
outcomes, including socioeconomic determinants, genetics, and lifestyle factors. 
4.13 However, this option is not recommended, given Samoa’s circumstances. 
Reallocating resources to the health sector is a zero sum event, with any increases being 
offset by reductions in other sectors. Once again, it is hard to sustain an argument that 
the health sector is more deserving of an increased share of government resources, 
when it already absorbs about 16% of government expenditure, and is the second-
largest recipient of government resources. This is therefore not a strong or compelling 
option. 
Option 4: Increasing the call on external resources 
4.14 This is a plausible option. Samoa has already attracted long-term support from 
bilateral and multilateral development partners. The characteristics that attracted such 
long-term external support to Samoa’s health sector — modest prospects for economic 
growth, committed and reforming government, a health ministry prepared to explore  
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more evidenced-based policy making, a desire among development partners to support 
Samoa’s own response to the rapid growth of NCD’s — are all still present. Accessing 
additional resources from development partners has the added advantage that it can 
“buy reform space” among the community while government works on other reforms. 
For example, it is often politically easier for government to introduce higher taxes or 
cost- recovery measures in the health sector if the community first sees tangible 
improvements in facilities. Development partners can help here: they can fund 
refurbishment and rehabilitation of rural clinics and other facilities, knowing that 
government will then be better placed to mobilize domestic resources, either through 
increased taxation or cost recovery linked to the health sector. Unfortunately, 
experience elsewhere suggests that, far from aid “buying reform space,” the existence 
of aid actually allows governments to defer much-needed reform. Fortunately, the 
existence of a SWAP in Samoa and of a Medium-Term Expenditure Framework provides 
a potential framework for government and development partners to engage 
strategically in a way that uses external financing to support, not defer, reform. The 
existence of the SWAP and a MTEF actively led by government also offers the 
opportunity for negotiating longer-term, predictable, financing by development 
partners. 
4.15 However, over-reliance on external financing should be avoided. External 
financing is already relatively high in Samoa. Development partners provided 37% of the 
total SAT 110.6 million publicly financed allocation to health in Samoa during 2011/12 
(Government of Samoa 2012).  Even after deducting the large (SAT 26.12 million) 
“lumpy” externally sourced one-off soft loan for the MOH headquarters and hospital 
buildings, development partners still account for about 20% of total health financing in 
2010/11.31 Government and development partners may be prepared to see a relatively 
high dependence on external financing to help Samoa advance against the NCD 
epidemic; invest in primary and secondary prevention; and carry out other reforms that 
put Samoa on a long-term, sustainable path to better health outcomes for all. However, 
government, and development partners themselves, will not wish to see Samoa overly 
                                                        
31 SAT 16.8 million from foreign capital project grants, compared to government-appropriated 
expenditure for health of SAT 64.88 million in 2010/11 (Government of Samoa (2011) Approved 
Estimates of Receipts and Payments for the Financial Year Ending 30 June, 2011, p. VIII. 
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dependent on foreign aid, as this raises fundamental questions about long-term 
sustainability. This is all the more the case as Samoa moves from lower-middle-income 
to middle-income status over time. 
Option 5: Raising specific taxes 
4.16 Increasing taxation on tobacco is a high priority and strongly recommended 
option for Samoa because it simultaneously raises revenue for government while 
stemming the rise of NCDs. Samoa faces two large public policy challenges in the health 
sector: How to stem the rise in NCDs, and how to make the financing of its health system 
more sustainable. Taxation on tobacco directly — and simultaneously — addresses 
these two overarching challenges. 
4.17 Like most other developing countries, Samoa now faces a tobacco epidemic. 
Almost half (49.4%) of males age 30 to 34 smoke; of those that do, 62.4% smoke more 
than ten cigarettes per day. Similarly, almost one in five females age 25 to 35 now 
smoke; of those that do, about one-third smoke more than ten cigarettes a day 
(Government of Samoa 2010a). Households now spend, on average, SAT 2.48 on 
tobacco and alcohol for every SAT 1 they spend on medicines (Samoa Bureau of Statistics 
2008). WHO recommends that excise duties alone (that is, before import duties or value-
added taxes) should be at least 70% of the retail price of cigarettes. Excise duty at that 
level then becomes an important component in curbing tobacco consumption and 
uptake, especially among the young (WHO 2010b). Analysis undertaken by Ministry of 
Finance officials during WHO Workshops on Tobacco Taxation in Auckland, New 
Zealand, in June 2012, highlighted the benefits of increasing excise rates on tobacco in 
the Pacific. For example, in the case of Samoa, it was estimated that raising the excise 
rate on cigarettes by 50% would increase cigarette excise revenue by approximately 14% 
per annum. This translates to an extra excise revenue of SAT 3.6 million per annum. Final 
consumer prices of cigarettes in Samoa would increase by about 30%, with the share of 
excise in the final price rising from 47% to 54%. This would also reduce uptake (and 
addiction) by the young. 
4.18 Reducing tobacco use is now seen as one of the highest and most effective public 
health interventions available to developing countries. As noted in a recent article on 
NCDs in The Lancet: 
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The main risk factors for NCDs for individuals are well known and are similar in 
all countries. Tobacco use, foods high in saturated and trans fats, salt, and 
sugar (especially in sweetened drinks), physical inactivity, and the harmful 
consumption of alcohol cause more than two-thirds of all new cases of NCDs 
and increase the risk of complications in people with NCDs. Tobacco use alone 
accounts for one in six of all deaths resulting from NCDs. 
The Lancet NCD Action Group and the NCD Alliance propose five overarching 
priority actions for the response to the (NCD) crisis — leadership, prevention, 
treatment, international cooperation, and monitoring and accountability — 
and the delivery of five priority interventions — tobacco control, salt reduction, 
improved diets and physical activity, reduction in hazardous alcohol intake, 
and essential drugs and technologies. The priority interventions were chosen 
for their health effects, cost-effectiveness, low costs of implementation, and 
political and financial feasibility. The most urgent and immediate priority is 
tobacco control. 
We propose as a goal for 2040, a world essentially free from tobacco where 
less than 5% of people use tobacco (Beaglehole et al. 2011). 
4.19 Raising the price on tobacco to a significant level, and then maintaining it in real 
terms in relation to inflation, may not decrease consumption among those already 
addicted, but it does have the demonstrated benefit of reducing new uptake (and 
subsequent addiction) by the young in Samoa (Abedian et al. 1998). Increasing the tax 
on tobacco, and ensuring it is maintained in real terms in line with inflation, has a high 
likelihood of increasing government revenue, due to the price inelasticity of the product 
(Abedian et al. 1998). Such action is administratively easy compared to other ways of 
raising government revenue. As an island, Samoa will have fewer difficulties with 
smuggling (although it will inevitably have some) than if it were landlocked with highly 
porous borders. Earmarking taxation on tobacco as an additional source of income for 
the health sector also sends an important public message, alerting the community to 
the adverse links between tobacco and health. Another argument in favour of such 
earmarked (“hypothecated”) taxes on tobacco is that it may be easier to convince the 
public if they can see exactly where the tax is being spent and that it is being put to good 
use. 
4.20 There will be some criticism about raising tobacco taxes and ensuring excise 
duties are maintained in real terms against inflation, but these can be managed. One 
criticism is that tobacco taxation is regressive, taking more of poorer people’s income 
than that of the rich. That is true, although it can be equally argued that spending by the 
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poor on tobacco is itself a potential cause of impoverishment (money spent on tobacco 
could have been spent on food, housing, or education) and is an example of market 
failure (tobacco consumption is addictive) that governments are entitled — indeed 
obliged — to correct. Another criticism is that hypothecated taxation directed to the 
health sector violates good public finance policy: taxes should be pooled nationally and 
allocated to their best use rather than directed to a favoured sector. Although this is 
also true in principle, in the context of Samoa, where NCDs are prominent and health 
financing must be made more sustainable, there are good reasons for arguing that 
taxation on tobacco should be raised and added to the health budget. (Whether or not 
to earmark additional taxes to the health sector is ultimately the decision of ministers 
and the Ministry of Finance, bearing in mind the arguments for and against 
hypothecated taxes). A third criticism is that tobacco taxation can damage a legitimate, 
legal industry, costing jobs. This tends to be an exaggerated claim (Abedian et al. 1998). 
It ignores the offsetting costs imposed on the public health system in treating otherwise 
preventable cancers, heart ailments, and lung disease, and the likelihood that resources 
freed up from producing or selling tobacco will be reabsorbed elsewhere in the 
economy. 
Option 6: Mobilizing revenue through insurance, including social health insurance 
4.21 Social health insurance32 (SHI) is a plausible, but longer-term, option for Samoa. 
4.22 SHI has, at least in principle, several advantages. In developing countries where 
the general tax base is small, SHI can mobilize additional financial resources. Premiums 
may also be easier to collect than general taxes because they can be collected directly 
by employees. SHI can be a more stable and predictable form of financing, possibly less 
reliant on overall business cycles than general taxation, and/or yearly negotiations with 
ministries of finance. SHI can be mildly progressive (wealthier pay proportionately more 
than poorer) and redistributive (revenue raised from wealthier people in the formal 
sector can cross-subsidize poorer people). SHI can reflect a country’s sense of “social 
                                                        
32 Social Health Insurance, as noted by Gottret and Schieber (2006, p. 84), is not an easy term to 
define. However, SHI typically involves, or starts, as compulsory payroll deductions in the formal 
sector. Those deductions are pooled (as are the health risks) to help pay certain defined health 
expenditures, either directly or through third parties. Governments sometimes extend SHI to 
those outside the formal sector by, in effect, subsidizing their premiums and contributions. 
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solidarity” and concern to ensure vulnerable people are not excluded from essential 
care (Gottret and Schieber 2006; WHO 2010c; WHO 2005; Roberts et al. 2008; Normand 
and Weber 2009). 
4.23 However, SHI has some important weaknesses and involves several challenges 
that are relevant to Samoa’s current situation. SHI works well when there is a formal 
sector large enough to mobilize additional revenues and pool risks. It is not clear that 
this is yet the case in Samoa, where the formal sector employment was just 20, 745, or 
just 11% of the total population of around 184,000 at the end of September 2010/11 
(Government of Samoa, Ministry of Finance 2011). Worse, the existence of compulsory 
SHI premiums, on top of compulsory income taxation, may actually discourage 
individuals from joining the formal sector: the very opposite of government long-term 
intentions. Compulsory SHI is also a cost to industry, which — depending upon its level 
of employment intensity and price elasticities of the market — could result in either 
reduced profits for the firm or increased costs for consumers. SHI is also, in effect, an 
earmarked (hypothecated) tax on members and employers, which ministries of finance 
in some countries resist, believing it better to bring all revenues into a central pool.33  
4.24 Perhaps most significantly, SHI involves formidable technical, managerial, 
actuarial, and administrative demands even — or perhaps especially — in developing 
countries. While acknowledging the benefits and importance of SHI, Hsiao et al. (2007) 
identified fourteen such substantive challenges to introducing SHI in developing 
countries. Among these is the fact that SHI is complicated, and implementation takes 
many years; achieving universal population coverage has taken decades in most 
countries; benefit packages must be explicit and costed carefully; user fees must be in 
place and must be sufficient to motivate populations to join SHI voluntarily; stakeholders 
must be convinced of the actuarial soundness of SHI; SHI agencies must be able to 
negotiate and implement purchasing and provider payment mechanisms that ensure 
delivery of services and goods at minimal cost (WHO and Republic of Rwanda, Ministry 
of Health 2008). Even with these conditions in place, SHI premiums may still prove 
                                                        
33 They do so because they believe it is better public policy to bring all revenues into a central pool 
— not reserve revenue for the sector in which it was first generated — and then reallocate 
resources according to overall national priorities. For the same reason, ministries of finance in 
some countries resist the idea of hypothecated taxes on tobacco or alcohol, where the revenue is 
retained in the health sector. 
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insufficient to cover health care, and so additional general taxation and/or user fees may 
be required. 
4.25 If these set-up and implementation challenges are met, there is still an additional 
challenge in the case of Samoa: the more successful SHI is in Samoa in breadth and depth 
of coverage, the more demands will likely be placed on the health system for curative 
care. SHI schemes rarely cover promotive or preventive care but do encourage or 
facilitate people to make use of their contributions by accessing the curative health care 
system. 
4.26 Samoa passed legislation that allows it to introduce SHI at some time in the 
future. This is a useful long-term goal. Government may wish to keep the option of 
introducing SHI under active review, while concentrating on policy interventions that 
are administratively easier and yield quicker results than SHI. 
4.27 For similar reasons — including management and technical complexity — 
community-based insurance, medisave accounts, and private health insurance are more 
medium- to longer-term options goals in Samoa. They are useful options to keep under 
active review by the MOH but are unlikely to yield significant new and additional 
resources or improved health outcomes in the coming years so are not considered 
further in this paper. 
Option 7: Increasing levels of cost recovery 
4.28 Increasing the level of cost recovery is a plausible — but complex — option for 
Samoa. Should government choose to pursue that option, it must be managed carefully. 
4.29 Increasing the level of cost recovery, particularly through user fees, has long and 
rightly been viewed with scepticism by health-financing professionals (Gottret and 
Schieber 2006; Creese 1991; Gilson 1997; McPake 1993). That is because user fees 
impose an additional cost that disproportionately affects the poor, unless carefully 
targeted exemption mechanisms are put in place. Even then, experience suggests 
that exemptions are very hard to target properly or enforce, particularly if those 
applying the exemptions then lose earnings, or are in a position to extract bribes. User 
fees may create an additional barrier to health care access for the poor, on top of 
existing barriers (for example, indirect costs such as transport costs from outlying rural 
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villages, income foregone). There is good evidence in the US context that even small 
copayments for drugs to treat chronic diseases lower patients’ adherence and 
compliance to treatment (Choudry 2009). Flat user fees tend to be regressive, taking 
proportionately more from the poorer than the richer members of society. Collecting 
user fees also produces administrative costs. User fees have political costs as people are 
required to pay for them but see no ostensible improvement over time in the quality of 
facilities or services. This suggests that user fees, if they are to occur, be retained at the 
point of collection, added to existing revenue, and be used to improve facilities in ways 
that customers can see and appreciate. However, once again, this involves a form of 
hypothecated tax, which ministries of finance are usually reluctant to endorse (see 
footnote 33). User fees, once established, are also politically hard to maintain in real 
terms; with inflation, their resource-mobilizing benefits erode over time. 
4.30 However, it could be argued that there is a case for considering some level of 
cost recovery — for those who can afford it — in Samoa, where user fees are currently 
negligible. As noted previously, total receipts from all sources in the health sector in 
2011/12 are projected at just SAT 60,600 (US$25,000). This represents 0.08% of the total 
SAT 69,064,202 (US$28.4 million) government has appropriated to the health sector in 
that year (Government of Samoa 2011). 
4.31 Cost recovery from the National Kidney Foundation (NKF) is similarly small. 
Patient treatment fees totalled SAT 104,320 in the year to June 30, 2011. This 
represented 2.3% of expenditures for the year by the NKF. As noted previously, and to 
put this into context, the collection of treatment fees from patients covered just 6% of 
medical supplies used by NKF and 24% of the NKF’s electricity bill for the year. 
4.32 Roberts et al. (2008) put the issue of user fees, especially out-of-pocket user fees, 
into perspective. On the one hand, they note: 
From both risk protection and equity perspectives, out-of-pocket payment is 
the worst possible system for health financing. Those who are both sick and 
poor face the risk of either untreated disease or impoverishment — or some 
combination thereof. From the viewpoint of vertical equity, direct payments 
are highly regressive, especially given the correlation of poor health and low 
income. They are even worse than private insurance, which at least offers 
some risk-pooling possibility when there is group purchasing or when rates are 
regulated (p. 174). 
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4.33 On the other hand, the same authors make this point: 
Providing financial risk protection, however, does not allow the population to 
avoid all the costs of health care. In fact, that cannot be done. Foreign aid aside, 
all health-care costs in a country are ultimately paid for by its citizens — 
directly or indirectly. It is simply not possible to protect those in the middle of 
a country’s income distribution against the costs of routine medical care. If 
they don’t pay those costs directly, they will do so indirectly via various taxes. 
What is relevant for achieving risk protection is helping people avoid the large 
and unpredictable costs of a serious illness — that is, to provide a risk-
spreading or insurance, where revenues from citizens are pooled and used to 
pay for care for those who do get seriously ill (p. 97). 
4.34 The balance between financial protection for its citizens and citizens’  eventual 
responsibility for their own health care, ultimately is a policy point for the government 
of Samoa and MOH to decide. As Roberts et al. (2008) note above, user fees, especially 
out-of-pocket, should clearly not act as a barrier to essential care. Nor should they 
further impoverish poor people, increase inequity, or encourage self- medication. On 
the other hand, some would argue that neither should a government lean so much in 
the other direction that virtually all services are provided “free” or at notional cost to 
citizens. This might be especially so for relatively minor and inexpensive, curative 
treatments, when the individual could be expected to share some responsibility for 
payments. User fees will never make a health system simultaneously financially self- 
sufficient and accessible to all those in need. But as countries develop, there comes a 
point where notionally “free” services to everyone, including the wealthier members of 
society for virtually all services, need to be managed and brought into some sort of 
relationship with rising GDP per capita. 
4.35 The government of Samoa and the MOH might therefore need, at some stage, 
to consider options for raising user fees above the current level of 0.08 of health 
expenditure for certain targeted groups and nonessential services. However, the 
overarching guiding principle should then be that cost sharing should only be considered 
if there is good evidence it will lead to significant revenues without detrimental impact 
on access, equity, and financial protection. Furthermore, some items should definitely 
be free at the point of delivery for most if not all Samoans: ANC, immunizations, family 
planning advice, infectious disease control, and screening for NCDs among high-risk 
groups. Indeed, there is a case for paying poorer people, through conditional cash 
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transfers (CCTs), to fully immunize their children, attend ANC visits earlier in pregnancy, 
and adopt targeted preventive measures against NCDs and other high cost diseases. 
4.36 If government did at some stage decide to trial user fees, it would also be 
important to ensure that both equity and efficiency aspects of the health system were 
simultaneously strengthened, and not traded off against each other. For example, it is 
possible to envisage a system whereby wealthier people (those known to be in paid 
employment, with a health card government could issue), who bypass lower-level 
facilities and present at the outpatient department of TTM for nonurgent care, pay a 
user fee. 
4.37 It is worth noting that user fees are not, in themselves, necessarily a problem or 
constraint for Samoans, including those in rural and poorer areas. National Health 
Account figures show, for example, that Samoans paid SAT 1.63 million to traditional 
healers in Upolo island, at an average of SAT 22 per visit for the top five illnesses in 2006 
(Government of Samoa, Ministry of Health, Samoa National Health Accounts 2006/7). 
While much of this was “in kind” payments, it does demonstrate a willingness to pay, 
even for services that may or may not have been effective. 
4.38 In summary, user fees may need to be considered at some stage in Samoa, given 
pressures on the health budget and the current low level of cost recovery. However as 
noted above, the overarching guiding principle should be that cost sharing will only be 
considered if there is good evidence it will lead to significant revenues without 
detrimental impact on access, equity, and financial protection. Furthermore, some items 
particularly those with a public good characteristic, like immunization — should 
definitely be free at the point of delivery for most if not all Samoans. 
Option 8: Increased efficiency 
4.39 Virtually all countries, including those in the OECD, could achieve more effective 
and equitable — health outcomes by improving the efficiency of resource use in the 
health system. Indeed, the World Health Organization recently estimated that between 
20% to 40% of all health spending globally is currently wasted through inefficiency and 
waste. The report identifies ten leading sources of inefficiency in health. These include 
purchasing practices for medicines (underuse of generics, use of substandard or 
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counterfeit medicines, irrational prescribing policies); misaligned incentives (fee-for- 
service payments); management practices (medical errors, costly staffing mixes); and 
poor investment decisions (hospital size, technology choices) (WHO 2010c). 
4.40 Improving efficiency is potentially the greatest source of increased resources and 
improved health outcomes for Samoa. It relies on the relatively simple but powerful 
argument that Samoa could do more with the valuable resources — financial, human, 
and management — that it already has, and that services, drugs, and equipment 
currently being used are not costless. In improving technical and allocative efficiency,34 
Samoa will not necessarily have to raise extra taxes or provide more resources to the 
health system. Rather, it will generate increased — and possibly more equitable — 
outcomes from existing resources. In doing so, it will relieve pressure on the 
government’s overall budget and help make health financing more sustainable. It will 
have the added benefit that development partners — seeing government make best use 
of its own resources — will be more willing to support government efforts. 
4.41 Initial analysis suggests there are seven substantive areas where Samoa could 
reap large technical and efficiency gains. These are discussed below in order of priority 
(most important first). 
4.42 First, Samoa could consider sharply reallocating resources toward primary and 
secondary prevention. Table 1.7 shows that inpatient curative care absorbed over one-
quarter (26.4 percent) of total health expenditure in 2006/07 (latest year available). Per 
capita expenditure on total inpatient curative care, including overseas treatment, was 
over one hundred times more than per capita expenditure on prevention of NCDs, 
and almost eighty times what was spent per capita on maternal and child health and 
family planning. Even per capita expenditure on traditional health care was more than 
seven times what was spent on NCD prevention. 
                                                        
34 A simple but appealing explanation of the difference between these two concepts is that 
technical efficiency is doing things right, allocative efficiency is doing the right things. That is, 
technical efficiency seeks to get the maximum possible given output — number of hip 
replacements for example — for a given mix of doctors, nurses, and equipment. Allocative 
efficiency, on the other hand, seeks to drive a higher level of health outcomes by reallocating 
scarce resources to where they are likely to have the biggest (or most equitable) impact. See Liu 
(2003) for further details. 
Chapter 3 
155  
4.43 Samoa will not be able to stem, let alone reverse, the NCD epidemic unless it 
urgently and substantively shifts the balance in favour of primary and secondary 
prevention. Good, effective, affordable, and cost-effective options exist for primary and 
secondary prevention (WHO and World Economic Forum 2011; WHO 2010a). As noted 
in the WHO landmark report on NCDs: 
Currently, the main focus of health care for NCDs in many low- and middle- 
income countries is hospital-centred acute care. NCD patients present at 
hospitals when cardiovascular disease, cancer, diabetes and chronic 
respiratory disease have reached the point of acute events or long-term 
complications. This is a very expensive approach that will not contribute to a 
significant reduction of the NCD burden. It also denies people the health 
benefits of taking care of their conditions at an early stage…. 
At least three interventions for prevention and management of diabetes are 
shown to reduce costs while improving health. Blood pressure and glycaemic 
control, and foot care are feasible and cost-effective interventions for people 
with diabetes, including in low- and middle-income countries …. 
Participation in 150 minutes of moderate physical activity each week (or 
equivalent) is estimated to reduce the risk of ischaemic heart disease by 
approximately 30 percent, the risk of diabetes by 27 percent, and the risk of 
breast and colon cancer by 21 to 25 percent. Additionally, physical activity 
lowers the risk of stroke, hypertension, and depression. It is a key determinant 
of energy expenditure and thus fundamental to energy balance and weight 
control (WHO 2011b). 
4.44 Other studies confirm the costs of curative care versus the benefits of primary 
and secondary prevention. For example, Allotey et al. (2011) find that the cost of 
diabetes care per patient in Cameroon was US$489 per year in 2002. This cost exceeds 
the annual per head income by 1.5 times and exceeds the per-head governmental health 
spending by approximately 50 times. 
4.45 On the other hand, others find good results from use of relatively simple 
interventions, such as aspirin. One study, for example, found that in the primary 
prevention trials, aspirin allocation yielded a 12% proportional reduction in serious 
vascular events (0.51% aspirin versus 0.57% control per year, p = 0·0001), due mainly to 
a reduction of about a fifth in nonfatal myocardial infarction (0.18% versus 0.23% per 
year, p < 0·0001) (ATT Collaboration 2009). 
Chapter 3 
156  
4.46 Another recent study demonstrates the costs and benefits of using a multidrug 
regime to combat cardiovascular disease. That study is worth quoting in some detail:  
We aimed to estimate the number of deaths that could be averted and the 
financial cost of scaling up, above current coverage levels, a multidrug regimen 
for prevention of cardiovascular disease (a statin, aspirin, and two blood-
pressure–lowering medicines) in 23 such countries. Identification of individuals 
was limited to those already accessing health services, and treatment eligibility 
was based on the presence of existing cardiovascular disease or absolute risk 
of cardiovascular disease by use of easily measurable risk factors. Over a ten-
year period, scaling up this multidrug regimen could avert 17.9 million deaths 
from cardiovascular disease (95% uncertainty interval, 7.4 million to 25.7 
million). 56% of deaths averted would be in those younger than 70 years, with 
more deaths averted in women than in men owing to larger absolute numbers 
of women at older ages. The ten-year financial cost would be US$47 billion 
(US$33 billion to US$61 billion) or an average yearly cost per head of US$1.08 
(US$0.75 to US$1.40), ranging from US$0.43 to US$0.90 across low-income 
countries and from US$0.54 to US$2.93 across middle-income countries. This 
package could effectively meet three-quarters of the proposed global goal with 
a moderate increase in health expenditure (Lim et al. 2007). 
4.47 Of particular importance in the case of Samoa is to identify the health and 
financial benefits of secondary prevention: preventing patient “progress” of an already 
diagnosed patient to a higher level of treatment. Annex 1 shows the high absolute and 
relative cost of treating a diabetic patient with dialysis: an estimated $US 38,686 per 
patient per year or around 12 times the GNI per capita. If government focused more on 
screening, early referral, and early adherence to interventions that retard the 
progression of a disease like diabetes, then health outcomes for a large number of 
Samoans would be improved and public savings would occur. The net savings to 
government could potentially be very large. As noted in Annex 1, even if secondary 
prevention through provision of medicines and testing cost $US1000 per patient per 
year, government would still save an estimated $US37,686 per patient per year in 
averted costs of dialysis, other things being equal.  
4.48 Indeed, it may be far more cost-effective for the health system to pay patients a 
“performance payment” if they reduce their blood pressure and stabilize at a lower level 
of care, than it would be to have them flown overseas. The use of such conditional cash 
transfers and pay for performance has a mixed record internationally but, if carefully 
designed, it can be a useful mechanism for attacking constraints on the demand or 
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supply side, providing incentives for better health outcomes, and providing financial 
support for the poor and vulnerable. 
4.49 Conditional cash transfers (CCTs) might also be used to address some of the gaps 
in primary and preventive care. As noted previously, there are relatively low rates of 
immunization among one-year-olds against measles, and women tend not to make ANC 
visits in the first trimester of pregnancy. Because both immunization and ANC visits are 
usually pro-poor35 and highly cost-effective, they yield potentially large strategic gains 
in helping to close such coverage gaps. The first step would be to better understand the 
underlying reasons for these gaps and ascertain if they are due to factors on the demand 
side (lack of perceived need, or means, to access the service) or the supply side (lack of 
incentive, or funds, to provide outreach services). Depending on the findings, CCTs could 
be trialled to see if providing women (or, if a supply-side constraint, health providers) a 
performance payment on completion of immunizations or for ANC visits closes the gaps. 
If so, such payments may prove to be cost saving if they avert more expensive-to-treat 
medical complications. 
4.50 Reallocating funds to primary, including currently underfunded family planning 
and maternal care, as well as secondary care is possible in Samoa. That is particularly 
the case if government were able to limit expenditure for the OVT program, where 
curative costs are high and benefit less than 1% of the population. Allocating increased 
revenue from taxation on tobacco, and/or revenues via some level of cost recovery, is 
also possible. Different approaches are possible to facilitate any such reallocation. One 
option is to directly cut budgets in certain lower-impact (or pro-rich) activities, to allow 
expansion in more high-impact (and pro-poor) ones, such as promotion of family 
planning. This course of action, of course, has political visibility and may therefore be 
difficult to achieve. An alternative might be to freeze current budgets in real or nominal 
terms for lower-priority/lower-impact activities and allow growth to occur in the higher-
priority/higher-impact activities. 
                                                        
35 That is, lower quintiles tend to then capture disproportionately large benefits, because infants 
in poorer circumstances are arguably more exposed to communicable diseases such as measles, 
and because poorer women tend to have more children, and so would benefit from ANC visits. 
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4.51 A second priority worth exploring in Samoa is reallocating expenditure to 
maintenance. Currently maintenance is allocated only SAT 60,000 under the recurrent 
budget of SAT 68.8 million for 2010/11 (Government of Samoa (2011), “Approved 
Estimates of Receipts and Payments for the Financial Year Ending 30 June, 2011”). This 
means it is so small it is recorded as 0% of the recurrent budget. Maintenance attracts 
just SAT 2 million out of a total budget of SAT 53.5 million — just 3.8% of the latest NHS 
budget (Government of Samoa (2010), National Health Services 2010). Of course, it may 
be that maintenance expenditure is actually captured by some other costing labels, or 
perhaps even the responsibility of other departments, such as the Ministry of Public 
Works. Whatever the explanation, the fact remains that useful, usable, and reliable 
information on maintenance expenditure is not available, and will inevitably remain 
below the radar of policy makers. 
4.52 The lack of investment in maintenance imposes large — and largely preventable 
— longer-term costs for the public health budget. Some of these costs are direct and 
obvious: facilities and equipment will need to be replaced sooner than their technical or 
economic life would otherwise require had there been proper periodic maintenance. 
Other costs are more indirect: rural villagers may understandably walk past dilapidated 
rural clinics and go directly to (higher-cost) secondary and tertiary clinics, imposing high 
(but hidden) costs on the public health system. 
4.53 A third priority for efficiency would be for government to consider trialling 
public/private partnerships and contracting with the private sector. A well- conducted, 
and well-publicized, study in Cambodia shows that contracting models can 
simultaneously improve access, outputs, efficiency, and equity, even in low-income 
settings such as Cambodia (Bhushan et al. 2005). While conditions in Cambodia are, of 
course, very different than those in Samoa, there are nevertheless some interesting and 
important underlying principles that emerge and could be broadly relevant in Samoa as 
well. Key findings from that study are as follows: 
Contracted-out districts experienced an impressive increase in the use of 
reproductive health services, where, for example, coverage of antenatal care 
increased by more than 400 percent, compared to contracted-in and control 
districts where coverage rose by 233 and 160 percent, respectively. Success in 
the coverage of child health services also followed a similar pattern. 
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Immunization rates increased in contracted-out districts by 158 percent, in 
contracted-in districts by 82 percent, and in control districts by 56 percent. 
The evaluation survey measured the productive time lost due to illness by 
patients and their caretakers. The results showed that on an average, people 
in contracted- out districts lost about 15% less time on illness and seeking 
health care compared to control districts. People in contracted-in districts lost 
about 5% less. Thus, the results suggest that contracting-out, besides being 
cost-effective, is also the most efficient option for providing health care 
services. 
The evaluation study shows, furthermore, that the contracted districts 
provided more than proportionate benefits to the poor. Much of the increase 
in health care utilization in contracted districts was attributable to the 
increased use of services by households of low socioeconomic status. For 
example, use of curative health services at district hospitals by the bottom half 
of the socioeconomic group increased about twelve-fold in contracted-out 
districts and six fold in contracted- in districts in 2.5 years. The corresponding 
increase in the control districts was considerably less than double. The poor 
benefited more than proportionately in the contracted-out districts because of 
the improved accessibility of health services in villages, where most poor 
people live. The reduction in costs of health services also raised the demand 
for health services by the poor (Bhushan et al. 2005). 
4.54 A fourth strategic area where government and the MOH are likely to achieve 
significant and long-term efficiency gains is in the recurrent cost implications of recent 
large infrastructure projects. The new headquarters for the MOH and the new tertiary- 
level hospital are potentially attractive new buildings in Apia, replacing much older ones. 
However, both are large investments, involving well over SAT 26.1 million in direct soft 
loans. Importantly, the sheer size of these two large infrastructure projects will carry 
with them a large, long-term, “tail” of recurrent costs: electricity, air conditioning, 
cleaning, and maintenance. It is by no means clear that these long-term recurrent costs 
have been factored into future budgets. 
4.55 More importantly, it is not clear that everything is being done to reduce such 
long-term — and often avoidable and unnecessary — costs, including by modern design 
and architectural techniques, passive solar generation for electricity. Nor is it clear if the 
hospital design is best suited to secondary prevention of NCDs, as distinct from 
expensive inpatient curative treatment. Similarly, the most efficient mix of staffing for 
the new hospital in terms of doctors, nurses, midwives, and other health professionals 
is uncertain. Retrofitting more affordable solutions to recurrent costs will be a very 
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expensive option for Samoa. It is in Samoa’s interests to therefore urgently review the 
plans and designs for the new tertiary-level hospital, before ground breaking, to ensure 
that every possible opportunity has been taken to reduce long-term recurrent costs, 
consistent with good health standards and protocols. 
4.56 A fifth strategic area where efficiency and effectiveness can be improved is in 
developing a better and more explicit understanding of the cost of treating major 
diseases in Samoa. Policy makers cannot make informed choices about the best mix of 
inputs because they do not have essential data on the true cost of providing services 
(costs including, for instance, overheads or depreciation). Managers cannot tell if a 
primary or secondary prevention treatment is two, three, or four times as expensive as 
another for a given outcome. Nor can they tell how much the true cost to the public  
health system is if a patient “progresses” from a hypertension or glucose impairment 
regime, to a stent, bypass or dialysis regime. Understanding the true cost of treatment 
for the key drivers of the health system budgets would help managers make more 
informed, evidenced-based decisions about where to allocate scarce financial and 
management resources. Having a good knowledge of cost structures will also enable 
managers to identify cost drivers for a particular intervention and seek out lower cost 
but equivalent efficacy alternatives. This will also enable policy makers to identify 
cheaper but equally effective alternatives (for example, use of generic drugs) or mix of 
inputs. Highlighting the cost of treatment, including x-rays and lab tests, might help to 
sensitize health care providers to avoid unnecessary or duplicate tests. Development 
partners are likely to be supportive of analytical work that helps establish such an 
evidence base, as it will help all stakeholders make better and more transparent choices. 
Annex 1 provides an example of how the cost of diabetes treatment in Samoa can be 
estimated and then used for policy analysis. 
4.57 Sixth, government and MOH might also wish to consider analytical work on how 
public expenditure can be better used to drive incentives. Most, if not all, health 
professionals in Samoa are guided by a sense of professionalism and compassion to do 
their work well. However, monetary incentives and the form of provider-payment 
systems also clearly matter in any country’s health system: hence the debates over 
capitation, fee for service, salaried employment, and diagnostic-related groups. When 
the health sector absorbs approximately 16% of government expenditure it is 
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strategically important for government to understand how, and for what services, health 
workers are paid and how those payment mechanisms then affect the level and quality 
of service delivery. Government and MOH might therefore wish to identify stubborn 
gaps and blockages in service delivery, including reaching rural and remote areas and 
transitory peri-urban migrants. Government and MOH might then trial quasi- 
experimental and operational research to see if performance payments are a cost-
effective intervention compared to existing payment arrangements. 
4.58 A seventh strategic area to target for efficiency is for government and MOH to 
use more applied operational research to provide an evidence base for policy making. 
For example, the vast majority of experienced Samoan doctors interviewed during the 
research for this paper noted that patients do not usually complete their course of 
medication, despite being urged to do so. From a health perspective, the doctors noted 
that this undermined health outcomes for those individuals and raised the chances of 
antibacterial resistance among the public at large. From an economic perspective, 
failure to complete the course of medication undermines cost-effectiveness of 
treatment and is wasteful of a major part of the health system. Doctors had many 
opinions about why so many people failed to complete the prescribed course of drugs. 
(The most common theory was that patients did not “value” the drugs because they 
were free or only of notional cost, and that raising the out-of-pocket price would help 
people value the drugs more. This is not a recommendation of this paper.) However, no 
one really knows. The important policy point is that an apparently widespread 
reluctance to complete drug courses is clearly a major leakage point for better health 
outcomes, and potentially a gross source of inefficiency. Operational research to 
understand the situation, and then respond on the basis of evidence, would therefore 
be a good strategic investment to improve the efficiency and effectiveness of the health 
system. 
4.59 This paper has also identified other areas where operational research would 
strengthen the evidence base for policy making. Clearly, serious studies that increase 
understanding of the socioeconomic reasons for NCD risks are a major priority in Samoa, 
and could potentially enhance regional and global public benefit as well. There would 
be value in understanding better the socioeconomic characteristics of public versus 
private provision (paragraph 2.4). As discussed in paragraph 3.10, it would also be 
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beneficial to verify that the apparently low levels of out-of-pocket expenditure are not 
simply a result of poorer Samoans failing to seek health care. There is policy benefit in 
understanding the economic and financial costs to the future health system of an ageing 
population (paragraph 4.1). There is benefit in understanding the role and impact of user 
fees, should they eventually be trialled (paragraphs 4.35–4.38). Finally, there would be 
public and policy benefit in better understanding why women tend not to make ANC 
visits in the first trimester; why immunization rates against measles is relatively low; and 
what factors are contributing to the level of STIs and certain NCDs, and whether 
conditional cash transfers are cost-effective and affordable interventions (paragraphs 
4.5–5.1). 
Section 5: Conclusion and recommendations 
5.1 Samoa is currently facing two important public policy challenges in the health 
sector. One challenge is to stem, and then reverse, the rapid rise of NCDs. The second 
challenge is to put the country on a health-financing path that is effective, efficient, and 
financially affordable and sustainable. The two challenges are clearly interconnected. 
5.2 However, Samoa also has several strategic building blocks in place that will 
enable it to respond. 
5.3 First, and importantly, it has a government that is clearly committed to improving 
the health (and education) of its people. This is clearly evidenced by its financial 
commitment to the health sector to date. The government is also keen to move the 
health sector to a more outcomes-focused approach. The government wishes its 
expenditures to be pro-poor where possible. The newly elected government is now at 
the beginning of its term, so it has the “political space” to bring forward necessary 
reforms that might — initially at least — be unpopular. 
5.4 Second, government is supported by a competent bureaucracy and active 
development partners. MOH and NHS have clear roles and clarity of purpose (policy and 
regulation, and service delivery, respectively). MOH has a well-developed (although now 
somewhat dated) system of National Health Accounts that has the potential to serve as 
an evidence base for better public expenditure management and resource allocation. 
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5.5 Third, there is some potentially “low hanging fruit” that could be harvested to 
achieve better health outcomes at reduced financial cost to Samoa. The chief 
opportunity exists in making better use of existing resources already in the health 
system, but not used to maximum effect. Improving technical and allocative efficiency 
of the existing system has the potential to make a large difference and is technically 
feasible. Specific recommendations include reorienting public expenditure from 
curative to primary and secondary prevention; increasing investments in maintenance; 
proactively reducing future recurrent costs from large infrastructure projects; exploring 
contracting out and private/public partnerships; leveraging the power of public 
expenditure to drive incentives on the demand side and supply side of health care; 
understanding better the true cost of services and underlying cost drivers; and investing 
in operational research to build up the evidence base for policy making. 
5.6 Samoa also has other opportunities to mobilize additional revenue. Increasing 
taxation on tobacco is an option, and maintaining the tax in real terms against inflation, 
given the inevitable rise of (preventable) tobacco-related NCDs and the simultaneous 
need to generate revenue in Samoa. Some potential exists to generate more investment 
from the supportive group of external development partners, but this is limited. 
Development partners will likely respond favorably to Samoa’s own willingness to 
undertake additional reform and resource-mobilization efforts. There is arguably some 
potential for cost recovery, which at 0.08% of expenditure is currently quite low. 
However, this should only be considered if there is sound evidence cost sharing will lead 
to significant revenues without detrimental impact on access, equity, and financial 
protection. 
5.7 The paper concludes that social health insurance and other forms of formal 
insurance are useful options for the longer term, but are premature at this stage. That 
is because of the formidable technical and managerial challenges associated with 
introducing such schemes in Samoa at present. Further, there are arguably higher — and 
more feasible — gains to be had by improving efficiencies with the resources already in 
the health system. 
5.8 The paper also concludes that there is only limited capacity for additional 
financing directly from government over the longer term, given that health is now the 
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second-largest item in the budget and absorbs approximately 16% of government 
expenditure. The paper argues strongly against deficit financing at the macroeconomic 
level as a source of additional revenue for the health sector. 
Section 6: Next steps 
6.1 This paper is intended to provide an overview of the health-financing situation 
in Samoa, and to identify options for government to consider. Eight options have been 
examined. Some, but not all, are shown to be viable or appropriate in Samoa’s current 
circumstances. 
6.2 Government may wish to discuss these options with key stakeholders, including 
the Ministry of Health, the Ministry of Finance, the National Health Service, private 
sector health professionals, and development partners. Government can then decide 
which of the options discussed in this paper best suit Samoa’s needs and interests. 
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Annex 1: Financial cost to Government of Samoa of funding the National 
Kidney Foundation (NKF) 
Key Messages 
Kidney disease is one important aspect of the large and increasing problem of 
noncommunicable diseases (NCDs) in Samoa. The government of Samoa funds virtually 
all the NKF operations. The NKF itself focuses on treatment (mainly hemodialysis). 
Prevention and retardation of kidney disease absorbs less than 5% of the total 
appropriation. The estimated average total cost of dialysis was SAT 92,110 ($ 38,686) 
per patient per year in Samoa in 2010–11. The average total cost of dialysis per 
treatment was SAT 590 ($247). Those on dialysis need three treatments per week for 
the rest of their lives. Outcomes need to be scrutinized objectively given the cost of SAT 
92,110 per patient per year. Unfortunately, 31% of patients have died less than a year 
after commencing dialysis. Almost two-thirds have died two years after commencing it. 
Much of the reason for these very expensive but poor health outcomes is that patients 
are diagnosed and commence treatment too late for dialysis to extend life significantly. 
This in turn suggests that reallocating resources to secondary prevention and kidney 
disease retardation would have important health benefits for a larger number of 
Samoans and, over time, help to improve the low cost-effectiveness of treatment and 
reduce costs to government. Focusing screening and prevention for diabetes and 
potential kidney disease on pre-pregnant young women would help to interrupt the 
transmission of NCDs to the next generation of Samoans. 
Background and purpose of the paper 
1. Kidney disease is one important aspect of the large and increasing problem of 
noncommunicable diseases in Samoa. Almost three-quarters (73 percent) of all patients 
at the National Kidney Foundation (NKF) have diabetes and/or hypertension as a 
primary diagnosis for serious kidney disease.36 Given risk factors in Samoa, it is inevitable 
that demand for treatment of kidney treatment will continue to grow. Latest estimates 
find that 86% of Samoan adults are overweight, of these, 46% are obese; these are key 
                                                        
36 Report to the General Manager NKF April 2012. 
Chapter 3 
166  
risk factors for diabetes and hypertension.37 Treatment of kidney disease is expensive: 
reports from neighbouring American Samoa suggest treating kidney disease was 
approximately $43,000 per patient.38 Samoa needs to ensure that its expenditure on 
preventing and treating NCDs, including through the NKF, is affordable, effective, 
efficient, equitable, and financially sustainable. This paper provides some preliminary 
analysis of costs at the NKF to contribute to that effort. 
2. The specific purpose of this paper is to estimate the costs of treating 
hemodialysis (“dialysis”) patients at the NKF and make some initial observations about 
affordability and identification of “good buys” for the government. The perspective 
taken is therefore that of the government, rather than society as a whole. (While 
patients bear some direct and indirect costs, these are small. See discussion below). 
Expenditure at the NKF 
3. Table A1 below shows the total government budget appropriation to the NKF 
since its establishment in 2005, and the share of NKF expenditure as a percentage of 
total government expenditure through the Ministry of Health.  
Table A1: Government appropriations to NKF in Samoan tala (current prices) and 
share of NKF as percentage total appropriations to Ministry of Health 
Item 2007/8 2008/9 2009/10 2010/11 2011/12 
Total 
appropriation 
to NKF 
4,611,502 5,343,479 4,376,000 4,521,389 4,966,862 
Total 
appropriation 
to MOH 
60,344,075 70,074,380 58,985,691 65,131,805 69,064,202 
NKF as % of 
total 
appropriation 
to Ministry of 
Health 
7.6 7.6 7.4 6.9 7.2 
Source: Government of Samoa approved estimates for 2007/8 through to 2011/12. 
4. Table A2 below provides the breakdown of costs for the NKF by main output.  
                                                        
37 Village Health Fair Progress Report 2012. 
38 Pacific Islands News Association 2011. 
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Table A2: NKF: Breakdown of costs by main output, in Samoa tala (current prices) 
Output 2010/11 Domestic 
funding in 
2011/12 
Per cent of the 
appropriation 
going to defined 
outputs 1-4 
Per cent of total 
Government 
appropriation in 
2011/1239 
1. Policy Advice to the 
Minister 
585,158 458,331 15 9.2 
2. Medical Services of 
which: 
1,905,598 2,002,983 65.8 40.3 
Personnel 763,312 761,918 - - 
Operating expenses 258,030 316,480 - - 
Capital Costs 128,709 296,854 - - 
Overheads 755,547 627,731 - - 
3. Prevention, Early 
Detection and Education 
of which: 
161,655 233,034 7.6 4.7 
Personnel 61,506 120,917 - - 
Operating expenses 37,030 63,830 - - 
Capital costs 5,000 - - - 
Overheads 58,119 48,287   
4. Maintenance Services 
of which: 
224,076 347,113 11.4 6.9 
Personnel 87,256 110,616 - - 
Operating expenses 60,330 81,080 - - 
Capital costs 18,371 58,843 - - 
Overheads 58,119 96,574 - - 
   100%  
(Sub total of outputs 1-4 
delivered by NKF) 
(2,876,487) (3,041,460) - - 
Transactions on behalf of 
the State of which: 
1,946,982 2,168,742 - 43.6 
Overseas medical 
supplies 
1,390,695 1,540,695 - - 
Water rates 20,000 20,000 - - 
Electricity 150,000 200,000 - - 
Ambulatory supplies 150,000 150,000 - - 
VAGST 236,287 258,047 - - 
 
Government Grant 4,521,389 4,966,862 - - 
Cost recovery  84,3400 - - 
Source: Government of Samoa Approved Estimates 2011–12. 
5. Three things are noticeable from Table A2. 
6. First, government directly bears virtually all of the cost of the NKF. Multilateral 
and bilateral development partners do not provide funding to the NKF, although are 
                                                        
39 Sum to 104% because these are as a percentage of Government appropriations only and do not 
include cost recovery or charitable donations. 
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active and substantial supporters to other parts of the government’s health program. 
Samoan nationals pay only a notional fee of SAT 10 per treatment, and overseas visitors 
pay SAT 500 per treatment. Total cost recovery was SAT 84,340 or just 1.6% of the 
government appropriation for the year; not sufficient to cover even the electricity 
charges at the NKF. There are no third party contributions via insurance. 
7. Second, NKF believes government is nevertheless saving money compared to the 
previous alternative. More specifically, NKF officials state government spent SAT 6 
million on six patients prior to the establishment of the NKF because they were 
transferred to New Zealand for treatment (simple average of around SAT 1 million per 
patient including airfares). Now the NKF is treating 50 patients for SAT 4.9 million (simple 
average of SAT 98,000 per patient), suggesting a saving of SAT 902,000 per patient 
($380,000 per patient) and assuming no difference in quality of treatment and outcome. 
8. Third, it is clear from table 2 that the greatest share of expenditure goes to 
treatment of kidney disease rather than prevention. Virtually two-thirds (65.8 percent) 
of the budget for the four designated outputs goes to “medical treatment” (output 2). 
In contrast, prevention and early detection (output 3) attracts the lowest share — 7.6% 
of the SAT 3,041,460 going to direct outputs. These priorities do not change when the 
total budget to the NKF is examined. The additional payments made by NKF to other 
government authorities, including SAT 1.5 million for overseas medical supplies — 
virtually all of which goes to treatment rather than prevention — reduces prevention 
to 4.7% of the total budget. (Of course, other parts of the Samoan health system also do 
spend money on overall prevention of NCDs, including the Ministry of Health, and the 
National Health Service. The point being made here is that treatment, rather than 
prevention, of kidney disease per se is the focus of the NKF). 
Estimate of cost of treatment per patient 
9. Table A3 estimates the financial cost to government of treating an individual 
patient on dialysis. Several simplifying assumptions and adjustments are applied to 
make this estimate. More specifically, the Value Added Goods and Services Tax (VAGST) 
was excluded as this is an internal transfer payment from NKF to government, and not 
the cost of using a resource. One- off, short-term (often one week) dialysis treatment 
for overseas patients was excluded. The expenditure on items for Samoans, not 
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obviously either “treatment” or “prevention,” were recalculated to reflect the notional 
share of 4.7% total appropriation going to prevention. For example, total expenditure of 
SAT 458,331 for policy advice to the minister and board (output 1) was reduced by 4.7% 
(SAT 21,495) on the simplifying assumption that 4.7% of that output would be on 
prevention, mirroring the share “prevention” receives overall. The same process of 
apportioning the notional 4.7% expenditure to prevention was applied to maintenance 
(output 4), and payments to other government departments (for example, overseas 
medical supplies, electricity, water, ambulatory peritoneal dialysis supplies). This 
process reduced the total government appropriation assigned directly to “treatment” to 
SAT 4,605,535 ($1,934,324). Table A3 then estimates the average cost per patient, 
assuming each patient receives three dialysis treatments per week for every week of the 
year.  
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Table A3: Estimated cost to Government of treating a patient in 2010-11 
Component Tala Cumulative total 
in Tala 
USD equivalent 
Total appropriation to NKF 4,966,862  2,086,082 
Less VAGST (a transfer payment) 236,287 4,730,575 - 
Less pro-rata of 4.69% going to prevention 
applied to: 
Minister and Board (output one) 21,495 - - 
Maintenance (output four) 16,279 - - 
Medicine 72,258 - - 
Water 938 - - 
Electricity 7035 - - 
Peritoneal supplies 7035 - - 
 
Total estimated cost for dialysis treatment  4,605,535 1,934,324 
Cost per patient 
Total average cost per patient per year  
(Total of SAT 4,605,535 for dialysis divided by 
50 patients per year) 
92,110 - 38,686 
Total average cost per patient per week 1771  743 
Total average cost per treatment per patient 
(3 treatments per week) 
590  247 
Source: NKF Annual Report 2010-11 
10. The end result is that the average total cost of dialysis was SAT 92,110 ($38,686) 
per patient per year in Samoa in 2010–11. The average total cost of dialysis per 
treatment was SAT 590 ($247). Those on dialysis need three treatments per week for 
the rest of their lives. 
11. It should be noted that this is a particularly conservative estimate with important 
limitations. It is conservative because no allowance has been made for the capital cost 
of the land on which the NKF sits or for the buildings. The important limitations to this 
exercise include the fact that simple average costs have been estimated, whereas 
marginal costs (how costs change by small increments of increased services) is of more 
relevance. Nor is there any estimation made of scale economies (lower average costs as 
coverage expands) or productivity improvements over time. This is also a snapshot in 
time: wage increases of staff or exchange rate–driven cost of imported medicines and 
equipment would quickly alter the estimates. Given that the unit of analysis is  cost to 
government, direct (transportation costs) and indirect (opportunities foregone to earn 
an income by accompanying care givers) costs were excluded, even though they are real. 
Similarly, no attempt has been made to quantify “pain and suffering” of patients. 
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Policy implications 
12. An estimated average cost of dialysis of SAT 92,110 ($38,686) per patient per 
year raises several important implications. 
13. First, is this expenditure effective and the best use of money? To those being 
treated, and their families, the answer would be yes. How much they would be “willing 
to pay” for the treatment is an important concept in economics as it sheds light on the 
perceived benefits of a service. However, this is difficult to measure and raises ethical 
concerns. Presumably, however, patients value the treatment much more than the SAT 
10 they pay per treatment (SAT 30 per week). 
14. However, from the government’s perspective, the effectiveness of the 
expenditure is questionable. About 31% of patients on dialysis have died in less than a 
year after commencing dialysis. A further 17% of patients have died at the one-year 
point after commencing dialysis. A further 16% have died at the end of two years. Thus, 
nearly two- thirds (64%) of patients have died within two years. Expenditure of an 
average SAT 92,110 ($US38,686) is about 12 times the GNI per capita of Samoa of about 
$US 3220 per capita, and therefore not “cost-effective” under usual benchmarks where, 
for example, WHO suggests, as a rule of thumb, that anything over 3 times GNI per capita 
is unlikely to be “cost-effective”. Officials at NKF believe a key explanation for the 
relatively poor outcomes in terms of extending life are that patients are diagnosed, 
referred, and commence treatment for kidney disease too late. 
15. This, in turn, suggests that focusing more resources on secondary prevention to 
prevent or at least postpone onset of severe kidney disease and dialysis would be a good 
investment in both public health and public finance. If government focused more on 
screening, early referral, and early adherence to “retardation” schemes, then health 
outcomes for a larger number of Samoans would be improved and savings would occur. 
The net savings to government would also be very large: even if secondary prevention 
through provision of medicines and testing cost $1,000 per patient per year,  
government would still save an estimated $37,686 per patient per year in averted costs 
of dialysis. 
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16. A similarly high impact “good buy” would be to focus screening, prevention, and, 
where necessary, diabetes and kidney disease retardation medicine on younger women 
before they are pregnant. Investing in the health of young women is not just desirable 
and justified in its own right (maternal health and gender are prominent parts of the 
Millennium Development Goals). Rather, investing in young women’s health can help to 
interrupt the transmission of metabolic disorders in utero to her offspring, which may 
predispose her child to obesity and NCDs (Elisaia et al. 2009). 
17. The high cost of dialysis also raises the question of the financial affordability and 
sustainability of the current focus on treatment. As Table A1 shows, appropriations to 
the NKF are relatively stable in absolute and relative terms, absorbing about 7% of the 
total appropriation to the Ministry of Health and its sector over recent years. By itself, 
this is not a major problem at least in terms of financial sustainability (although it could 
be argued the money would be better spent on other high priority programs). However, 
Samoa faces a large and growing pipeline of diabetes and heart-related illnesses as the 
population ages and becomes more urbanized. The Village Health Fair found that 86% 
of adult Samoans are overweight or obese: almost half (46%) of those surveyed were 
clinically obese (BMI 30–39) and 14% were morbidly obese (BMI 40+). This implies a 
large increase in the need for treatment over time. Paradoxically, the better Samoa is at 
screening for diabetes, hypertension, and kidney disease, the more demand will be put 
on the health system more generally and the NKF more specifically. This can only 
increase financial pressures on an already tight fiscal situation and outlook. Cost 
recovery of SAT 10 per treatment — totalling just SAT 84,340 or 1.6% of the budget — 
shows that current arrangements are not financially sustainable. 
18. Economic analysis is also about equity. NKF statistics show that dialysis patients 
are reasonably distributed across different age groups and not significantly skewed to 
the very old. The largest age group on dialysis is the 61 to 70 year old (25%), followed by 
the 41 to 50 year old (22%), and then the 51 to 60 year old (14%). Over-71-year-old and 
under 40-year-old make up the balance. (Details on gender were not available at the 
time of this analysis). NKF does not keep statistics on the socioeconomic background of 
patients on dialysis or whether they are urban or rural dwellers. It is therefore not 
possible to assess if the high expenditure is pro-poor or pro-rich. 
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Some selected studies from overseas on dialysis and other options 
19. One major study in the United States found that dialysis for hospitalized adults 
had very limited health benefits in terms of prolonging life, and was not cost-effective. 
More specifically the study found that the median survival time for hospitalized patients 
undergoing dialysis in various hospitals in the United States was just 32 days. Only 27% 
were alive after six months. But costs were high: the estimated average cost was 
$128,200 per quality-adjusted life year saved. For patients with an initially poor 
prognosis, the cost was $274,000 per quality-adjusted life year saved. Even for patients 
with a good prognosis, the estimated cost was $61,900 per quality-adjusted life year 
saved, all of which “far exceeded the $50,000 per quality- adjusted life year, a commonly 
cited threshold for cost-effective care” (Hamel et al. 1997). 
20. On the other hand, there are affordable, cost-effective, and even cost-saving 
interventions at the level of primary and secondary prevention for diabetes. For 
example, preconception care for women with diabetes leads to healthier mothers and 
babies. The Center for Disease Control and Prevention in the United States estimate that 
every $1 invested in such care can reduce health costs by up to $5.19 by preventing 
costly complications (2008). 
21. Furthermore, one major recent study (Li et al. 2010) found strong evidence to 
classify the following interventions as either cost-saving or very cost-effective compared 
to other interventions to treat diabetes across the United States: 
Cost saving: (1) ACE inhibitor (ACEI) therapy for intensive hypertension 
control compared with standard hypertension control; (2) ACEI or 
angiotensin receptor blocker (ARB) therapy to prevent end-stage renal 
disease (ESRD) compared with no ACEI or ARB treatment; (3) early 
irbesartan therapy (at the microalbuminuria stage) to prevent ESRD 
compared with later treatment (at the macroalbuminuria stage); (4) 
comprehensive foot care to prevent ulcers compared with usual care; (5) 
multicomponent interventions for diabetic risk factor control and early 
detection of complications compared with conventional insulin therapy 
for persons with type 1 diabetes; and (6) multicomponent interventions 
for diabetic risk factor control and early detection of complications 
compared with standard glycemic control for persons with type 2 
diabetes. 
Very cost-effective: (1) intensive lifestyle interventions to prevent type 2 
diabetes among persons with impaired glucose tolerance compared with 
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standard lifestyle recommendations; (2) universal opportunistic 
screening for undiagnosed type 2 diabetes in African Americans between 
45 and 54 years old; (3) intensive glycemic control as implemented in the 
United Kingdom Prospective Diabetes Study in persons with newly 
diagnosed type 2 diabetes compared with conventional glycemic control; 
(4) statin therapy for secondary prevention of cardiovascular disease 
compared with no statin therapy; (5) counselling and treatment for 
smoking cessation compared with no counselling and treatment; (6) 
annual screening for diabetic retinopathy and ensuing treatment in 
persons with type 1 diabetes compared with no screening; (7) annual 
screening for diabetic retinopathy and ensuing treatment in persons with 
type 2 diabetes compared with no screening; and (8) immediate 
vitrectomy to treat diabetic retinopathy compared with deferred 
vitrectomy. 
Conclusion 
22. In conclusion, NKF are staffed by skilled and dedicated professionals. Dialysis 
services are valued by those relatively few people (about 50 per year) on dialysis. But 
this is a particularly expensive form of treatment at approximately SAT 92,110 ($38,686) 
per patient per year. The health outcomes, measured in terms of extended life, are poor 
with two-thirds dying within two years of commencement of dialysis. Giving greater 
emphasis to secondary prevention (screening, retardation medicine) would improve the 
cost-effectiveness of the program. Screening and retardation interventions that 
prevented or postponed the requirement for dialysis treatment would be a major and 
strategic public health benefit and save the government millions of tala.  
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Introductory note: Relationship between Chapter 3 and Chapter 4.  
Chapter 4 builds on the preceding chapter by analysing the costs and affordability of 
pharmaceutical drug treatments for type 2 diabetes and hypertension to the 
Government of Vanuatu. Like Chapter 3, Chapter 4 helps to address the specific research 
gap in the Pacific in Chapter 1: lack of published information on the actual costs of 
treating important NCDs in the Pacific and analysis of the affordability and sustainability 
of existing public expenditure. Chapter 4 provides further additional evidence showing 
why primary and secondary prevention of high burden / high cost diseases – including 
especially type 2 diabetes and hypertension – is a prudent and feasible way of improving 
allocative efficiency for the Pacific. 
In consultation with my co-authors, I deliberately targeted and submitted this article to 
the journal Pacific Health Dialog. That is because we specifically wished to reach front-
line primary health care workers in the Pacific Region. I chose that journal because, as 
the Pacific Health Dialog journal web page states: “Pacific Health Journal - the Journal 
of Community Health and Clinical Medicine for the Pacific Region is the only Medline 
listed medical and public health journal published specifically for Pacific island 
countries.”1 
This article is also available from the Pacific Health Dialog website at 
http://pacifichealthdialog.org.fj/.
                                                        
1 Available at http://pacifichealthdialog.org.fj/ 
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Abstract 
Non-communicable diseases (NCDs), including diabetes and hypertension, pose 
increasingly significant health, policy and financing challenges in Vanuatu, a lower 
middle income Pacific Island country. Pharmaceutical costs to Government are 
becoming unsustainable. 
We show how pharmaceutical cost to Government rise in large, step-wise, patterns as 
diabetes or hypertension progressively becomes more severe. For diabetes, 
pharmaceutical costs to Government increased more than four-fold from $5.59 per 
patient per year (pppy) to $24.55 pppy in Vanuatu in late 2012 as a person moves from 
regular testing of blood glucose levels to first stage oral medication. Pharmaceutical 
costs increased again to $367 pppy when insulin and other associated drugs are 
required. For hypertension, pharmaceutical costs to Government increased more than 
twelve times as the patient advances from first line drugs to additional drug therapy 
($1.38 pppy to $17.58 pppy), eventually rising to $75 pppy if additional drugs are 
required. 
Progression of diabetes and hypertension to more advanced stages squeezes an already 
tight Government health budget. One patient requiring insulin absorbs the equivalent 
drug allocation of 76.4 other citizens. Only 1.31% of the total population could be 
treated with insulin, or 5.3% treated with the full regime of anti-hypertensive drugs, 
before the total Government drug budget for the country was fully spent. 
Primary and secondary prevention of diabetes and hypertension is therefore a 
particularly important policy priority. Every person who adopted a healthy lifestyle and 
was able to avoid diabetes or keep it under control would avert direct drug costs to 
Government of up to $367 per person per year. Those able to avoid or control 
hypertension through adopting healthy lifestyles would avert costs to Government for 
drugs of up to $75 per person per year: the equivalent of what the Government currently 
spends on average on 18 other citizens.  
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Introduction: Diabetes and hypertension as a development issue 
Non-communicable diseases8 (NCDs), including diabetes9 and hypertension,10 are 
increasingly being recognised as a development issue (2-5). The World Health 
Organization (6) estimates that two thirds of global deaths in 2008 were caused by NCDs, 
more than all other causes combined. Around 80% of these deaths occurred in low and 
middle-income countries (6). NCDs also account for half of all global disability (7). The 
UN Secretary General’s report to the UN General Assembly High Level Meeting on 
Prevention and Control of NCDs of September 2011 concluded that: 
“Non-communicable diseases affect the developing world and lower-income 
populations hardest. Strong evidence links poverty, lack of education and 
other social determinants to such diseases and their risk factors. A vicious cycle 
is created by the epidemic, whereby non- communicable diseases and their 
risk factors worsen poverty, while poverty results in rising rates of such 
diseases. The prevention of non-communicable diseases would reduce 
poverty, particularly since the majority of expenditures for treatment in low- 
and middle-income countries are paid privately or from out-of-pocket health-
care systems. At the same time, because of the magnitude of the illness, the 
disabilities and premature deaths they cause and the long-term care required, 
non-communicable diseases reduce productivity and increase health-care 
costs, thereby weakening national economic development.” 
 
The World Bank noted at the same UN High Level Meeting on NCDs that “what makes 
the NCD challenge particularly daunting for many developing countries is that, 
compared to their higher- income counterparts, they will face higher levels of NCDs at 
earlier stages of economic development, with fewer resources, and with less time to 
respond effectively” (8). Recent studies estimate that almost three quarters of people 
with hypertension – around 639 million – live in developing countries, and that a number 
of the risk factors for hypertension seem to be more common in developing countries 
                                                        
8 The World Health Organization (WHO) states that “Noncommunicable diseases (NCDs), also 
known as chronic diseases, are not passed from person to person. They are of long duration and 
generally slow progression. The four main types of NCDs are cardiovascular diseases (like heart 
attacks and strokes), cancers, chronic respiratory diseases (such as chronic pulmonary disease and 
asthma) and diabetes.” 1. WHO. WHO Noncommunicable Diseases Fact Sheet. 2011.  
9 WHO definition of diabetes is available at 
http://www.who.int/mediacentre/factsheets/fs312/en/index.html 
10 There are different definitions of hypertension, and disagreements about appropriate cut-off 
levels. This paper defines hypertension as blood pressure of 140/90 mm Hg or higher.  
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than in developed regions, including tobacco use, rapid urbanisation, and possibly 
genetic factors (9). 
Of particular concern are the high rates of premature (that is, under 60 years of age) 
deaths from NCDs in the Pacific, as this indicates loss of potentially productive social and 
economic years. Figures 1 and 2 below show the relatively high rates of premature 
deaths from NCDs for males and females in the Pacific compared to other lower-middle 
income countries. 
 
Figure 1: Proportion of male premature NCD deaths, 2008 
Source: WHO (2011) Noncommunicable Diseases Country Profile.  
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Figure 2: Proportion of female premature NCD deaths 2008 
Source: WHO (2011) Noncommunicable Diseases Country Profile. 
Diabetes and hypertension impose large – but often preventable – health, financial, and 
economic burdens on individuals, health sectors, and governments (10-12). WHO 
estimates that 346 million people worldwide have diabetes; that 80% of diabetes deaths 
occur in low and middle-income countries; and projects that diabetes deaths will double 
between 2005 and 2030 (13). The International Diabetes Federation argues that 
diabetes caused at least $46511 billion in health care expenditure globally in 2011, 11 % 
of total health care expenditure of adults (14). Diabetes is a particular challenge in 
developing countries where an estimated 80% of people with diabetes live (15). 
Hypertension is also a significant and growing problem: almost three quarters (639 
million) people with hypertension now live in developing countries, but with limited 
access to essential health services (9). Diabetes and hypertension impose broader 
economic costs too. The prevalence of diabetes for people of working age (less than 60) 
is higher in lower and middle-income countries than it is in high income countries (14). 
                                                        
11 Current United States dollars used throughout this article unless otherwise stated. 
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This suggests that, other things being equal, fewer people are available full time in the 
work force to generate revenues for services to the very young and the elderly: the 
dependency ratio worsens.12 Cardiovascular diseases and hypertension can result in 
disabling strokes, and diabetes in loss of limbs and vision, further reducing the potential 
for economically productive lives. 
Diabetes and hypertension are significant challenges in the South Pacific (16-21). A 
recent study involving pooled data of 2.7 million people globally found that those in 
Oceania had the highest fasting plasma glucose (6.1 mmol/L for men and women) of any 
region in the world (22). Over one third of the adult population has raised blood pressure 
in eight out of the ten Pacific Island countries, and three quarters of the population are 
overweight in seven out of ten countries, for which data is available (23). The average 
weight of a woman in Tonga has increased by 21.1 Kg in the last 30 years to reach 95 Kg. 
For men, the increase is 17.4 Kg to reach 95.7Kg (24). Increased food availability, rapidly 
changing diets, physical inactivity and possibly genetic factors help explain the rise in 
obesity and overweight prevalence. 
Vanuatu faces several health challenges. Vanuatu is a relatively small (population 
249,528) lower- middle income (GNI per capita of $US 2750)13 country ranked 125 out 
of 187 countries in the United Nations Human Development Index for 2011. Vanuatu 
faces a double burden of disease: NCDs now contribute to 70% of all deaths, while 
maternal, newborn and nutritional disorders contribute a further 25% (23). NCDs now 
contribute over half (56%) of years of life lost, whilst communicable diseases still 
contribute over one third (35%) (23). Latest reports from UNICEF state that nearly 7% of 
all children in Vanuatu are severely stunted and 20% moderately stunted (25). 
Diabetes and hypertension are growing health challenges in Vanuatu. Diabetes is the 
sixth known cause of death in 2011 and the third highest NCD reported: 294 new cases 
of diabetes were reported in 2011 (26). There is no formal diabetes register in Vanuatu 
                                                        
12 This requires further study in the Pacific, where levels of unemployment and under-
employment can be quite high to begin with. The study by Falconer for example found that 40% 
of patients with diabetes in Vanuatu were not employed. 
13 Vanuatu has an estimated Gross National Income of 4,330 ‘International Dollars’: a notional 
figure that reflects the costs of goods and services, and therefore the Purchasing Power Parity 
(PPP) of income in that country 
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at present. However, based on usage data from the Vanuatu Central Medical Store, 
approximately 62 people are currently being treated with insulin. This is likely to be an 
underestimate because of the often asymptomatic nature of early stage diabetes and 
consequent under-diagnosis. Limited capacity for vigorous, nation-wide, screening for 
early detection of diabetes is also a major cause for underestimation. Hypertension is 
also a challenge. A recent WHO supported NCD STEPS survey1414 found that 
approximately 30.8% of males and 26.7% of females of the 4671 surveyed adults had 
raised blood pressure. Around 95% of males and females of that sample were found to 
have raised blood pressure but were not currently on medication. 
Of particular concern is the prevalence of risk factors for diabetes in Vanuatu, potentially 
feeding a pipeline of significantly increased and widespread incidence of the diseases. 
WHO estimates that rates of mean fasting blood glucose for women rose from 4.6 
mmol/l in 1980 to 5.3 mmol/l in 2008, and from 5.2 to 5.4 for males over the same 
period (23). The NCD STEPS survey found that almost one in five adults had impaired 
fasting blood glucose, a risk factor for Type 2 diabetes. More than one fifth (22%) of 
adults of working age (25 – 64 years) have three or more risk factors for acquiring any 
NCD. Only around 10% of adult men (7.5% - 11.9%) and 5% of adult women (3.6%-8.5%) 
did not demonstrate signs of any of the major NCD risk factors (27). 
Demographic pressures will add to these risks, and the cost burdens to Government. 
Vanuatu currently has a youthful age structure, with a median age of 20.5 years. 
However, 35% of the population are also aged between 25 and 59 years (28). Ageing of 
the population will therefore see an increase in heart, vascular and diabetes related 
deaths and disability in future years unless strong preventive measures are taken. 
Importantly, the current relatively youthful demographic structure does not necessarily 
translate into a capacity to then finance public health care costs: only 23,584 people 
contributed to the National Provident Fund in 2010, which the Ministry of Finance see 
as a proxy for the size of the formal workforce. Even if the size of the formal economy 
increased, there is no income tax in Vanuatu to generate revenue for Government, 
including an increasingly over- stretched public health system. 
                                                        
14 The survey involved a multi stage cluster sampling that then surveyed 4671 adults aged 25-64 
between July and October 2011. 
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Method 
It is important to understand the pharmaceutical costs of treating diabetes and 
hypertension for four reasons. First, the Government of Vanuatu bears virtually all the 
costs of pharmaceuticals and other health services as there are negligible co-payments 
or insurance reimbursements. Second, and as a result, the pharmaceutical budget is an 
important part of public expenditure. Total expenditure on the pharmaceuticals line 
item in the budget was $1.37 million (Vt 123.5 million) in 2012, making it the fourth 
largest item of expenditure within the budget for health that Government appropriated 
from its own resources. That budget line item included budgets for vaccines, laboratory 
consumables, dental and X rays. After allowing for these items, the Government’s 
Central Medical Store has, in effect, a budget of $998,000 (Vt 90 million) for drugs and 
dressings. With a population of around 249, 528 this gives a notional allocation for drugs 
from Government’s own resources of $4 per person per year (Vt 360). Third, 
Government expenditure on pharmaceuticals has, along with salaries and allowances, 
been a source of budget over-runs, requiring supplementary budgets and requests for 
substantial emergency funding from development partners. Fourth, the rise of diabetes 
and hypertension will put unsustainable pressure on a public health system that 
currently allocates around $64 (Vt 5849) per person per year from government 
appropriations to health care. Despite its importance to policy makers and framers of 
budgets, however, little is known about the actual costs of treating diabetes and 
hypertensive patients in Vanuatu. Falconer’s study is informative but is now becoming 
a little dated, drawing on surveys in 2006, and did not extend to costs of hypertension 
(29). 
Against that background, we sought to estimate the pharmaceutical cost to Government 
of treating Type 2 diabetes, and hypertensive, patients in Vanuatu during late 2012. The 
objective of the study was to estimate how the financial cost to the Government’s 
pharmaceutical budget increased as the disease progressed, and then place those 
estimates in the context of Government health expenditure and overall affordability. 
The unit of analysis was the direct pharmaceutical drug cost to Government as it is the 
substantial source of drug expenditure. Data limitations did not allow the analysis to 
extend to other direct medical costs, including doctors’ and nurses’ time, other medical 
equipment used including syringes or dressings, diagnostic tests including X rays, patient 
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referrals, surgery or other related treatment arising from medical complications of 
diabetes or high blood pressure, or administrative overheads. Data and time limitations 
did not permit analysis of direct (out of pocket) or indirect (foregone income) costs to 
individuals or their carers. 
The method, data sources, approach and assumptions were as follows. We used 
Vanuatu Government Standard Treatment Guidelines for treating a patient with Type 2 
diabetes or hypertension including recommended generic brand and dosage of drug 
throughout the progression of the disease. We recognise that for many patients, 
diabetes and hypertension coexist as comorbidities or “bad companions” to each 
other15 (11). However, for ease of exposition we first show how pharmaceutical cost 
rises for diabetes as the disease worsens, and then separately show  how costs increase 
for hypertension. We used current prices in October 2012 from the Government owned 
Central Medical Stores as the source of pricing and cost to Government for drugs. 
Table 1 below summarises the actual unit costs of the main drugs used in treating 
diabetes and hypertension, the dosage used at various stages in the disease in Vanuatu, 
and the average annual cost at each stage of treatment. 
Results 
In the case of diabetes, pharmaceutical costs to Government are initially low, but then 
rise in a step wise fashion. As seen from Table 1, glucose testing strips cost the 
Government $5.59 per patient per year at the initial testing stage. If advice on lifestyle 
and diet changes are not successful, oral medication in the form of Metformin tablets 
are prescribed. The cost to Government of one 500 mg Metformin tablet to help control 
blood sugar levels is $0.01 (Vt 1.17) per tablet. As blood glucose testing strips are still 
used on a monthly basis, total direct pharmaceutical costs rise to $24.55 per patient per 
year. If the diet and Metformin are insufficient to control the diabetes, a second oral 
medicine is added, Glibenclamide. Dosage commences at 5mg daily but can rise to a 
maximum of 10mg twice a day. Adding in the additional costs of $8.10 (Vt 730) per 
patient per year for Glibenclamide increases the total drug cost to the Government of 
                                                        
15 Ferrannini and Cushman estimate that, globally, high blood pressure is reported in over two 
thirds of patients with Type 2 diabetes and in patients with diabetes, hypertension produces and 
increased risk of cardiovascular disease 
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$32.65 (VT 2942) per patient per year. At this stage blood glucose testing may also 
increase with associated costs dependent on frequency of testing. 
If the disease progresses further and insulin is required the costs rise dramatically. The 
drug cost of insulin alone adds a further $262 (Vt 23,655) per patient per year at a 
conservative dose of 40 Units daily. Dosage of 1 g Metformin twice daily would continue 
provided renal function remains adequate. Glibenclamide would be discontinued, but 
the frequency of testing for blood sugar levels would increase from monthly to weekly 
tests at a health facility. (Ideally, blood sugar levels would be tested daily, but the vast 
majority of patients in Vanuatu cannot afford a glucometer and the testing strips and so 
rely entirely on public health facilities). In total, this would bring the net cost of drugs to 
$305.78 per patient per year: a more than twelve-fold increase from the oral medication 
stage using metformin. Experience in Vanuatu and elsewhere suggests that when a 
patient’s diabetes has progressed to the point of requiring insulin, there are usually 
other risk factors present, including high cholesterol and high blood pressure, or the 
diabetes has triggered medical complications affecting target organs which require 
additional drug treatment. Most commonly, aspirin, simvastatin16 and enalapril are 
added, incurring an additional $61.17 (Vt 5511) to treatment costs each year. This brings 
the total pharmaceutical drug cost to Government to $366.95 (Vt 33,059) per patient 
per year: a 15-fold increase in costs from oral medication using Metformin. The increase 
in direct pharmaceutical costs to Government as the disease progresses is displayed in 
Figure 3 below.  
                                                        
16 Statins have been approved for restricted use recently but the Government is still awaiting 
supplies. 
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Figure 3: Progression of average pharmaceutical costs per patient per year for 
Type 2 diabetes in 2012 
Source: Government of Vanuatu Ministry of Health. 
A similar exercise was also done to estimate the pharmaceutical costs of treating 
hypertension in Vanuatu. The increase in cost of drugs to the Government as the 
hypertension progresses is displayed in Figure 4 below. 
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Figure 4: Progression of average pharmaceutical costs per patient per year for 
hypertension in 2012 
Source: Government of Vanuatu Ministry of Health. 
Discussion 
The first point to note is that drug costs to Government escalate significantly if diabetes 
and / or hypertension progress to more advanced stages. Costs do not move gradually, 
or smoothly. Instead, as Figures 3 and 4 shows, drug costs move in large, step wise, 
fashion as the disease progresses and more expensive / intensive pharmaceutical 
products are required. Costs increase more than four-fold as a patient moves from the 
stage of close monitoring, lifestyle changes and no- medication to initiating oral 
medication using metformin. Costs increase again if Glibenclamide is added to the 
regime. Costs then increase if the disease further progresses and the patient moves to 
insulin: a more than twelve-fold increase between the oral medication using Metformin 
stage to insulin. There is a sixty five-fold increase in costs between first line testing 
($5.59) and insulin with additional drugs ($366.95). Similarly for hypertension: costs 
increase more than twelve times as the patient’s treatment moves from 
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Hydrochlorothiazide to addition of Enalapril ($1.38 per patient per year to $17.58 per 
patient per year), almost doubling to $30.23 with the addition of Atenolol or Nifedipine, 
and then more than doubling again to $75.14 if Simvastatin is added to the regime. 
Second, the steep increase in costs as the diseases progress has the potential to quickly 
exhaust the Government’s pharmaceutical budget at relatively low levels of service 
coverage. As noted above, the notional budget allocation for drugs from the 
Government’s Central Medical Store is the equivalent of $4  per person per year in 
Vanuatu. Provision of additional essential drugs for those with diabetes and 
hypertension is obviously important if the disease progresses. But it does come at a high 
“opportunity cost” in terms of the number of people that could be treated with drugs 
for other diseases in Vanuatu. As Table 2 shows, a diabetes patient who requires oral 
medication involving metformin tablets to stabilise blood sugar levels absorbs the 
equivalent of 6.14 other person’s notional drug allocation for the year. If the diabetes 
then progresses to a more advanced stage and an insulin regime is required, this absorbs 
the equivalent of 76.4 other person’s notional drug allocation rising to 91.7 person’s 
notional drug allocation if Simvastatin and other drugs are employed. There are similarly 
high opportunity costs arising from hypertension treatment: adding Atenolol to the drug 
regime for one hypertensive patient is the equivalent of the notional drug allocation of 
another 7.5 persons. 
The third point to note is that even relatively low costs of drugs can become 
unaffordable in a low resource setting such as Vanuatu. The right hand column of Table 
2 shows that, with a notional drug allocation averaging $4 per person per year, only 16% 
of the total population could be supplied with early stage oral medication using 
metformin for diabetes before the total budget for the Government’s Central Medical 
Stores was fully spent. Only 1.31 % of the population could be treated with insulin before 
the total nation-wide pharmaceutical budget was fully spent, or 1.09% if additional 
drugs such as simvastatin were added. Similarly for hypertension: only 13.26% of the 
population could receive the combination of Hydrochlorothiazide + Enalapril + Atenolol 
before the total pharmaceutical budget for the year was spent. This is not sufficient to 
cover all those in need, especially when the latest NCD STEPS survey found that 
prevalence of hypertension is high. 
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Vanuatu faces important health financing challenges. It has a health system heavily 
dependent on government financing and provision, but with low absolute levels of 
domestically generated health expenditure of around $64 per person per year in 2012. 
This paper shows that just two NCDs – diabetes and hypertension – impose large and 
ultimately unsustainable pressures on the Government’s pharmaceutical budget. This is 
especially the case if the prevalence of those diseases increases over time and / or those 
diseases progress to more advanced stages and cause severe medical conditions 
requiring more expensive medications. The high level of current risk factors – 30% of the 
adult population in the recent NCD STEPS survey have raised blood pressure but 95% of 
those are not on medication – is a potentially ominous warning of future health and 
financing challenges. The chronic, long term nature of NCDs such as diabetes and 
hypertension carries implications for Vanuatu’s health budget and, ultimately, the 
Government’s longer term fiscal strategies. 
While more funding is needed in the health sector, the prospects for substantial 
increases are limited in the immediate future. This is due to a combination of several 
factors including relatively modest economic growth in Vanuatu; a narrow tax base (and 
no income tax); vulnerability to economic and natural disaster shocks; competing 
Government priorities; and limits to already quite substantial aid funding from 
development partners. Focusing the country’s limited resources on effective primary 
and secondary prevention through health promotion, lifestyle change, screening, early 
detection and treatment and effective clinical management are therefore strategic 
interventions. This would improve health outcomes for large segments of the 
population, whilst simultaneously averting - or at least postponing - additional 
expenditure pressures on an already tightly constrained public budget. 
There are limitations to this study. The estimated costs are restricted solely to drug 
costs. Lack of robust data currently precluded estimates of total counselling, surgery, 
and other treatment and medical overhead costs that Government bears. Nor does the 
study estimate the extent of direct out of pocket expenses incurred by patients. 
(However, these are thought to be quite low given that Government finances and 
provides pharmaceutical products usually without charge, or at nominal cost to the 
patient). Nor, given the absence of data, does the study seek to estimate indirect costs 
to patients (or their employers) that would be incurred through foregone income as a 
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result of illness and absence from work. Nor is there sufficiently robust data at this stage 
on the socio-economic profile of patients to estimate the equity implications and burden 
of hypertension and Type 2 diabetes. On the other hand, this study is the first to have 
estimated the pharmaceutical costs of treating various stages of Type 2 diabetes and 
hypertension in Vanuatu and examined this in the context of broader sustainability of 
health financing. The study has been particularly conservative in its estimating process, 
capturing the drug costs of treatment to the Government’s Central Medical Store as this 
data was robust and reliable. 
The research and analysis was undertaken as part of wider work on health financing 
options for Vanuatu undertaken by the Vanuatu Ministry of Health, and supported by 
the World Bank. Financial support from the Australian Agency for International 
Development (AusAID) enabled this broader work to be undertaken but AusAID had no 
role in the analysis or writing of this article. The authors declare no conflict of interest. 
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Table 1: Pharmaceutical costs of treating diabetes and hypertension in Vanuatu in October 2012 
Disease stage Pharmaceutical product used Unit price in $US 
(Vatu in brackets) 
Dosage used in Vanuatu Additional cost to 
Government of 
treating one patient 
in one year 
Cumulative cost to 
Government of treating 
one patient per 
annum 
DIABETES      
First line testing Blood glucose testing strips $0.47 (Vt 42) per strip One test per month $5.59 (Vt 504) $5.59 (Vt504) 
Oral medication stage Metformin 500 mg $0.01 (Vt 1.17) per 
tablet 
4 tablets per day $18.96 (Vt 1708) $24.55 (Vt 2212) 
Oral medication stage 2 Glibenclamide 5mg (0.5Vt) per tablet 4 tablets per day $8.10 (Vt 730) $32.65 (Vt 2942) 
Insulin stage with Metformin 
and weekly blood glucose 
testing 
Biphasic Insulin $13.82 (Vt 1245) 
per vial of 1000 units. 
40 units per day.* 
Metformin dosage 
remains the same but 
blood glucose testing 
increased to once a week 
but Glibenclamide 
discontinued. 
$262 (Vt 23,655) for 
insulin 
$305.78 (Vt 27,548) 
Insulin stage with additional 
drugs 
150 mg Aspirin and 20 mg 
Simvastatin and 20mg Enalapril 
0.4 Vt /tab Aspirin. 
10.7Vt/tab 
Simvastatin 
and 1Vt/5mg tab 
Enalapril 
One per day of Aspirin 
and Simvastatin. Four per 
day of Enalapril 
$61.17 (Vt 5511) $366.95 (Vt 33,059) 
HYPERTENSION      
                                                        
* We assume there would be some inevitable wastage and spillage as the insulin is withdrawn from the vial. We therefore assume 50 units are actually withdrawn (40 of 
which are delivered to the patient). The cost is therefore 50 units * 365 = Vt 18,250 units, or 18.2 vials. In practice, this  would equate to 19 vials. 19 vials * Vt1245 per vial 
= Vt 23,655 or $262. 
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Disease stage Pharmaceutical product used Unit price in $US 
(Vatu in brackets) 
Dosage used in Vanuatu Additional cost to 
Government of 
treating one patient 
in one year 
Cumulative cost to 
Government of treating 
one patient per 
annum 
First line drug therapy Hydrochlorothiazide 12.5mg-
25mg 
$0.38 for 100 tablets One tablet per day $1.38 (Vt 124) $1.38 (Vt 124) 
Additional drug therapy Enalapril $0.01 (Vt 1 per 5mg 
tablet) 
Two tablets twice a day $16.21 (Vt 1460) $17.58 (Vt 1584) 
Further drug therapy Atenolol† (Vt 3.12 per tablet) 50 mg once daily $12.64 (Vt 1,139) $30.23 (Vt 2723) 
Non- hypertensive drug 
therapy in addition 
Aspirin for blood thinning and 
Simvastatin for cholesterol 
Vt 0.4 per 150 mg 
tablet for Aspirin and 
Vt 10.7 per tablet for 
20 mg Simvastatin 
 
Daily $44.91 (Vt 4046) 
comprising $1.62 (Vt 
146) for Aspirin and 
$43.35 (Vt 3900) for 
Simvastatin 
$75.14 (Vt 6769) 
 
Source: Government of Vanuatu
                                                        
† The alternative treatment in Vanuatu is Nifedipine. The cost is $13.04 per year (Vt 3.22 per 20 mg tablet), taken once a day, which is similar to the $12.64 for Atenolol. 
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Table 2: Number and percentage that can be treated 
Stage of Disease Drug costs 
per annum 
per patient 
Number of other 
people’s notional 
allocation of $4 per 
person used 
Number of people 
that could be treated 
at that level before 
Government’s total 
pharmaceutical 
budget exhausted 
Per cent of 
the total 
population 
that could be 
treated at 
that level 
before 
Government’s 
total 
pharmaceutic
al budget 
exhausted 
Diabetes     
Glucose testing strips $5.59 1.4 persons 178,571 72% 
Oral medication 
(Metformin) 
$24.55 6.14 persons 40,717 16% 
Oral medication 
(Metformin with 
Glibenclamide) 
$32.65 8.1 persons 30,618 12% 
Insulin $305.78 76.4 persons 3,270 1.31% 
Insulin with additional 
drugs 
$366.95 91.73 persons 2,725 1.09% 
Hypertension     
Hydrochlorothiazide $1.38 0.34 persons 724,638 290% 
Adding Enalapril $17.60 4.4 persons 56,818 22% 
Adding Atenolol $30.23 7.5 persons 33,079 13.26% 
Adding Simvastatin 
and Aspirin 
$75.14 18.78 persons 13,308 5.3% 
Source: Government of Vanuatu Ministry of Health 
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Introductory note: Chapter 5 
Chapter 5 addresses another specific research gap in the Pacific: the relative absence of 
published analysis of the implications of ageing on the health systems of the Pacific.  
The focus in this chapter is the implications of ageing per se, and not necessarily NCDs, 
although the two are clearly related. There is substantial evidence to show that globally, 
increased life expectancy, even in low income countries, is associated with an increased  
incidence of NCDs, especially cardiovascular disease, stroke, and cancer, as well as an 
increased risk of dementia and mental health problems (32-36). 
The world-wide link between ageing and increased incidence of NCDs has particular 
resonance in the Pacific. That is because, as this chapter shows with respect to the PICs:  
“with some of the highest rates of obesity and diabetes in the world, an ageing 
population will—unless urgent action is taken—put additional pressure on all aspects of 
the health system: leadership and governance; health financing; health workforce, 
service delivery; drugs and equipment; and information systems”.1   
Consistent with the findings of preceding chapters of this thesis, Chapter 5 also shows 
this is a particularly challenging public health and public financing challenge for the 
Pacific because of the existing high reliance on public expenditure for health care. 
Furthermore, and also consistent with the findings of preceding chapters of this thesis, 
Chapter 5 explains from the analysis of ageing presented the importance of, among 
other things, primary and secondary prevention of high burden / high cost diseases such 
as Type 2 diabetes. That is particularly important because, once acquired, Type 2 
diabetes usually requires treatment for the remaining years of a person’s life and often 
involves co-morbidities including potential loss of eyesight and amputations. 
This article can also be obtained from the Health Systems & Reform journal website at 
http://www.tandfonline.com/doi/abs/10.1080/23288604.2017.1342179 
                                                        
1 Text taken from the Abstract of Chapter 5. 
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Introductory note: Chapter 6 
Chapter 6 completes the trajectory of previous chapters by exploring the policy question 
of how governments can improve budget planning, priority setting and resource 
allocation in the health sector. Chapter 6 responds to the third specific research gap that 
I identified in Chapter 1: little guidance in the international literature on how Ministries 
of Health can better frame and argue their health financing proposals to Ministries of 
Finance and / or development partners. 
As explained in the chapter itself, I wrote this article after chairing a meeting in June 
2015 in Geneva entitled From “shopping lists” to Investment Plans: Supporting countries 
to develop and finance sound Investment Plans for Women’s, Children’s and Adolescents’ 
health. The meeting was sponsored by UNICEF, UNFPA, World Bank and the WHO.  
The theme of improving women’s, children’s and adolescents’ health through better 
public investment was the theme of the international meeting because it is a global 
challenge in low and middle-income countries. This theme also has particular resonance 
for countries in the Pacific given their high Total Fertility Rates and unmet needs for 
modern contraception (as explained in Section 2.1 of chapter 1).  
We make it clear in the article that the ten attributes for improving public investment 
for women’s, children’s and adolescent’s health apply equally and easily to other public 
health challenges facing low and middle-income countries. The analytical framework we 
propose can and should therefore be used by PICs when responding to the NCD crisis 
they face. Having a framework for public health financing based on strong economic 
principles is particularly relevant to the countries of the Pacific given that, as argued 
earlier in the thesis, they face limited health financing options because of the distinctive 
nature of their economies (Chapter 1, 2, and 3 of this thesis); prohibitively expensive 
treatment protocols for certain NCDs including in particular Type 2 diabetes and 
associated kidney disease as well as heart disease (Chapters 3 and 4); and an ageing and 
potentially sick population (Chapter 5). This article is also available from the Bulletin of 
the World Health Organization website at 
http://www.who.int/bulletin/volumes/94/6/15-168419/en/. 
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Chapter 7: Conclusion 
Section 7. Context and significance of the research. 
How countries prioritise and allocate scarce financial and other resources to improving 
health outcomes for their citizens is always a complex and important task. The challenge 
is particularly acute for the fourteen middle-income and small countries of the Pacific 
Islands Forum which face three inter-related public policy challenges in the health sector 
that are particularly distinctive to the Pacific, and that have been under-researched to 
date.  As this thesis shows, those three inter-related challenges are:  
i. Some of the highest rates of NCDs such as type 2 diabetes - and risk factors for 
acquiring such NCDs - in the world, co-existing with an unfinished agenda of 
communicable diseases, high fertility, and under-nutrition; 
ii. Reliance on government expenditure, including aid funding, for expenditure on 
health that are already some of the highest rates in the world.  
iii. Relatively low and / or volatile economic growth that then limits the capacity to 
expand government health expenditure to address population growth and the 
growing burden of expensive to treat NCDs such as type 2 diabetes and kidney 
failure which usually involve treatment for the remaining duration of a person’s 
life.  
7:1. The academic contribution. 
Against that background, this thesis makes four academic contributions based on the 
research methods identified and defended in Section 4 of the Introduction.  
First, it provides a corrective to the existing literature and widely-accepted orthodoxy 
on health financing as it applies to the Pacific. For example, as Chapter 2 and Chapter 3 
shows, four of the five options available under the World Bank fiscal space analysis  – 
now applied in over 50 low and middle-income countries - rarely apply in the Pacific. 
That is so particularly given the low or at least volatile per capita income growth in the 
PICs; already existing high shares of government expenditure on health; already existing 
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high levels of existing aid dependency; and limited capacity for addressing overall health 
financing needs in the Pacific via hypothecated taxes1. The main practical, available 
option for the PICs is therefore improved allocative and technical efficiency. In that 
sense the thesis provides a “corrective” to the existing literature, as it applies to the 
Pacific. The thesis shows that giving significantly higher priority and resources to primary 
and especially secondary prevention of NCDs is a key strategic objective. Addressing the 
high Total Fertility Rate and unmet need for contraception is a similarly strategic 
objective.  
That academic contribution is relevant to all fourteen PICs because they all share to 
varying degrees the particularly distinctive health, and health financing challenges, of 
the Pacific as detailed in Section 1 and 2 of the Introduction. It follows that this 
“corrective” to the orthodox approach to health financing is of less direct relevance, and 
is difficult to generalise, to other low and middle-income countries that do not share 
those distinctive characteristics, even including other small island states outside the 
Pacific. 2   
Second, the thesis helps fill a research gap on the affordability and financial 
sustainability of current approaches to addressing NCDs. I show (Chapter 3) for the first 
time the direct costs of dialysis treatment to the Government of Samoa was $38,686 per 
patient per year in 2010–11, 98.4% of which was borne by government. I show that 
dialysis in the Samoa context is not particularly cost–effective (two thirds of patients 
have died within two years) particularly compared to investing in primary and secondary 
prevention of NCDs. I also show for the first time the pharmaceutical costs of treating 
diabetes and hypertension in Vanuatu, showing that only 1.31% of the total population 
of Vanuatu could be treated with insulin, or 5.3% treated with the full regime of anti-
hypertensive drugs, before the total Government drug budget for the country was fully 
spent (Chapter 4). These specific findings have direct relevance to other PICs which tend 
to have relatively similar disease burdens (especially diabetes), health systems, and 
                                                        
1 Having said that, increased taxes on tobacco, and taxes on food and drink that contributes to 
obesity, are important strategies in the PICs to reduce risk factors for NCDs.  
2 See in particular Figure 1,2,4,5 of the Introduction which shows that the PICs have noticeably different 
characteristics to even ‘’small island states” as defined by the World Bank. As discussed in Section 1:2 of 
the Introduction, the PICs are also significantly more distant from major economic markets than other 
island states including the island countries of the Caribbean. 
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costing structures. The newly generated cost data, and analysis of financial 
sustainability, will have more limited specific relevance given different disease burdens, 
cost structures, and fiscal space characteristics in countries outside the Pacific.  
Third, the thesis researches the implications of ageing on the whole health system. The 
Pacific is often viewed as having a young population and there is literature on, for 
example, the “youth bulge” in the Pacific (1-3). To my knowledge, the article in Chapter 
5 is the first peer-reviewed published research on the implications of ageing on the 
whole of a country’s health system in the Pacific.  
Fourth, there is little guidance in the international literature on how Ministries of Health 
can better frame and argue their health financing proposals to Ministries of Finance and 
/ or development partners. As I noted in Chapter 1, while relevant to all countries, this 
gap is particularly important in the case of the Pacific which face limited health financing 
options given the distinctive nature of their economies (Chapter 1 and 2 of this thesis); 
prohibitively expensive treatment protocols for certain NCDs (Chapters 3 and 4); and an 
ageing and potentially sick population (Chapter 5). Chapter 6 of this thesis addresses 
that gap.  
7:2 The policy contribution, and specific policy recommendations. 
The papers published in this thesis contribute to public policy in three ways. First, it 
expands and deepens the evidence base on the unique challenges of health financing in 
the Pacific, and likely options to respond. The thesis provides a “corrective” to the most 
widely used analytical framework and approaches for assessing fiscal space when 
applied to the Pacific (Chapters 2-5). The research also publishes for the first time the 
actual costs to governments of dialysis in Samoa (Chapter 3); pharmaceutical drugs in 
Vanuatu (Chapter 4); and implications of ageing on the whole health system (Chapter 
5).  
The second policy contribution of the research in this thesis concerns a regional 
agreement in the Pacific to combat NCDs. More specifically, recognition by PIC leaders 
that their countries were facing an “NCD crisis” led to the World Bank commissioning 
me to analyse and write the Non-Communicable Disease Roadmap Report (4). I was the 
sole author of that report. The literature survey and primary analysis of financial costs 
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to government of treating NCDs (Chapters 2-4 of this thesis) directly informed my 
thinking and drafting of that report.  
The NCD Roadmap Report recommended four strategic interventions that all PICs could 
and should adopt: urgently strengthen tobacco control; tax and better regulate food and 
drink products that are directly linked to obesity; improve the efficiency and impact of 
existing health dollar by reallocating scarce health resources to prevention and ‘best 
buys’; and strengthen the evidence base for better investment planning and program 
effectiveness / value for money. The NCD Roadmap Report also included over thirty 
other recommendations, including inter-sectoral interventions, that countries could 
implement depending upon their specific circumstances. 
The Roadmap Report was then tabled in 2014 at the first ever joint meeting of Ministers 
of Health, and Economic and Finance Ministers, from the Pacific Islands Forum. All of 
the specific policy recommendations for addressing NCDs I made in that Report were 
then essentially adopted by the meeting and are entirely consistent with the research 
findings of this thesis. The adoption of those policy recommendations by all relevant PIC 
Ministers at the Pacific Islands Forum would not have occurred in that way had I not 
done extensive literature reviews and research as part of this thesis. 
The third policy contribution of the thesis is that Ministries of Health in low and middle-
income countries–including the Pacific–are often disadvantaged by having a poor 
understanding of how Ministries of Finance, and development partners, assess requests 
for public health financing and priority setting. Chapter 6 of this thesis provides specific 
and practical guidance on how Ministries of Health can strengthen their own 
understanding of and advocacy for public financing for health. I am not aware of other 
peer-reviewed published articles taking that particular, and practical, perspective. 
7:3 Limitations. 
There are significant data limitations in the Pacific. For example, the UN Population 
Division does not prepare projections for countries with less than 100,000 population 
but there are twelve such countries in the Pacific. There are also data limitations at the 
regional level which then makes comparisons difficult. For example, the Pacific 
Community presents latest data on the prevalence of diabetes, overweight adults, and 
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obese adults for 15 PICS (5). However, only one country (Samoa) had data for 2013; 12 
countries had data preceding 2012, with five countries data going back to 2005 or 
longer;3 there is no data for Tokelau and only partial data for Tuvalu; there is often little 
published data on Cook Islands. 
The research focus of this thesis is how PICs can better prioritise and allocate scarce 
financial and other resources within the health sector. It is clear that mental health 
issues, including depression and self-harm, are increasingly important factors globally 
(6, 7), and in the Pacific (8) within the health secotr. While I refer to the importance of 
that challenge in Chapter 5, I did not find enough publicly available data to explore that 
issue further.  
I also recognise, but it is beyond the scope and focus of this thesis, that health outcomes 
are also determined by many factors outside the formal health sector. These factors 
include the availability of water and sanitation, food security, climate change and 
natural disasters, and the all-weather availability of rural roads or inter-island shipping 
to access emergency care (9, 10). Health outcomes are also affected by the social 
determinants of health including education (especially girls’ education), poverty, 
culture, and power structures (11, 12). I also recognise that decisions about allocating 
scarce resources between and within sectors of an economy are always taken within a 
broader political economy context (13, 14, 15, 18-20).  
I also recognise that there are important differences between, and even within, the 
fourteen  countries of the Pacific. It was not always possible to explore those differences 
within the word-length of the articles.  
A final limitation is that multilateral and bilateral aid can play a positive – but also a 
potentially distorting – role in priority setting and resource allocation, especially in the 
Pacific (21-32). I refer to the importance of aid funding in the Pacific in the published 
articles of this thesis. However, had I written another article, I would have analysed the 
role of development partners in terms of priority setting and resource allocation in more 
depth.  
                                                        
3 Fiji and Federated States of Micronesia data is for 2002; Cook Islands and Nauru data is for 2004; 
and Tokelau data is for 2005. 
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7:4 Recommendations for future research. 
As explained in Chapter 1, there is a shortage of up-to-date data and analysis of the 
actual financial costs to Governments in the Pacific of addressing the “NCD crisis” and 
the affordability and cost-effectiveness of various interventions. In addition to my own 
published research, research is being undertaken (33) on the cost-effectiveness of salt 
reduction in the Pacific to reduce risk factors for NCDs. McGrath shows that the 
treatment costs of the Diabetes Foot Clinic in Samoa are nearly eight times lower when 
compared to the costs of admitting a client with diabetic foot sepsis into the nearby 
hospital (34). Such research provides an evidence base for priority setting and allocating 
scarce resources. More research of that nature is recommended.  
Published research is also needed on the affordability and cost-effectiveness of the 
WHO Package of Essential NCD Interventions (PEN) in the Pacific (35). Such research help 
governments to prioritise and allocate their resources on a more transparent and 
rational basis. Furthermore, such published research would have the added advantage 
of being a “regional and global public good”4 because most countries in the Pacific are 
scaling up PEN simultaneously. As a result, there are then opportunities to learn from 
each other if the research is published. Specific research questions could include: 
i. Which PICs are the positive “outriders” in terms of preventing and treating high 
burden / high cost NCDs such as diabetes? What were the financial and human 
resource investments needed?  
ii. How do unit costs to governments change as scale up the intervention 
proceeds? Do unit costs increase (due to inflation in small economies) or 
decrease (due to economies of scale).  
iii. Does cost-effectiveness increase as more remote populations are served 
because the disease burden is higher in remote areas or does cost-
effectiveness decrease because of the additional cost of reaching remote 
areas?  
                                                        
4 That is, available to all stakeholders in the Pacific and beyond. 
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iv. How effective are specific interventions? For example, does a tax on sugary 
drinks – a risk factor for diabetes – actually change consumption, and if so, by 
what amount? 
Further research would also be valuable by examining some of the broader political 
economy, community and social aspects of health service delivery in the PICs. For 
example, what are the constraints and opportunities that affect the extent to which 
scarce health resources are allocated to address gender inequity, particularly in light of 
the relatively high levels of unmet need for family planning and health leadership in 
much of the Pacific? How can political and administrative leaders facilitate – and in some 
countries regain - more community involvement and participation in health promotion 
and service delivery?  
7:5 Concluding comment: The benefits and application of the research. 
A worst-case future scenario involves PIC governments needing to further expand public 
health expenditure to meet growing, ageing, and potentially sicker populations, yet with 
ever decreasing fiscal space to respond. Such a scenario is plausible. Several PICs have 
high Total Fertility Rates that requires expansion of antenatal, maternal, newborn, and 
then infant and child health services (and often publicly funded education services in 
subsequent years). Yet several of those same PICs also have significant increases in the 
incidence and prevalence of chronic, otherwise avoidable, and expensive to treat 
diseases such as diabetes, heart disease, cancers and stroke. That will have the effect of 
putting increased demands – including financial pressure - on the public health system. 
Such an increase could occur given the high level of risk factors for NCDs, and the rapid 
ageing of the population in most PICs (Chapter 5).  
There is a positive alternative. PIC governments can use their dominant position in 
financing health care to proactively reallocate resources to affordable and often more 
cost-effective primary and especially secondary prevention of NCDs. PICs need to 
further prioritise reducing communicable diseases such as sexually transmitted 
infections in most PICs; HIV and AIDS / TB in PNG; and undernutrition in PNG and 
Solomon Islands. Done well, that will allow the pipeline of ageing citizens to live in 
reasonable health compared to the business as usual case, with fewer calls on 
government health budgets. PIC governments can also invest much more proactively in 
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meeting the contraceptive prevalence needs of families and citizens, thereby initiating 
a demographic transition and, with good education and employment policies, the 
potential for a strategic demographic dividend. The starting point for this more positive 
alternative is good public policy informed by sound research. 
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